

Obesity Algorithm[®]

2020

obesitymedicine.org

Obesity Algorithm[®]. © 2020 Obesity Medicine Association



Table of Contents*

Updates to This Version	10	Anti-Obesity Medications.	267
Citations.	11	Functional Foods and Supplements.	314
The Disease of Obesity	12	Metabolic Disease.	329
Classification of Obesity	43	Cardiovascular Disease.	334
Fat Mass Disease	55	Blood Sugar.	356
Adiposopathy (Sick Fat Disease)	64	Blood Pressure.	369
Obesity Paradox.	79	Dyslipidemia.	377
Obesity and Stress.	103	Nonalcoholic Fatty Liver Disease	388
Evaluation and Treatment Overview	111	Cancer.	397
Body Composition.	126	Psychiatric Disease	404
Energy Expenditure	147	Obesity Myths	411
Concomitant Medications.	169	Investigational Anti-obesity Pharmacotherapy.	439
Nutrition Therapy.	180	Early Versus Late Weight Management.	467
Physical Activity.	213	Bariatric Surgery.	471
Motivational Interviewing.	223	Executive Summary	547
Behavioral Therapy.	241	References	552
Technologies for Weight Management.	265	Disclosures	640
		Historic Acknowledgement	642

* Sections and pages not found in the free downloadable slides are found in the eBook.

Purpose

To provide clinicians an overview of principles important to the care of patients with increased and/or dysfunctional body fat, based upon scientific evidence, supported by medical literature, and derived from the clinical experiences of members of the Obesity Medicine Association.

Intent of Use

- The Obesity Algorithm is intended to be a “living document” updated once a year (as needed). It is intended to be an educational tool used to translate the current medical science and the experiences of obesity specialists to better facilitate and improve the clinical care and management of patients with overweight and obesity.
- This algorithm *is not* intended to be interpreted as “rules” and/or directives regarding the medical care of an individual patient.
- While the hope is many clinicians may find this algorithm helpful, the final decision regarding the optimal care of the patient with overweight and obesity is dependent upon the individual clinical presentation and the judgment of the clinician who is tasked with directing a treatment plan that is in the best interest of the patient.
- Throughout this resource is mention of “weight loss” or “reduction in body weight.” In most cases, this is intended to convey a reduction in unhealthful increases in body fat (overweight and obesity), as implicit in an obesity algorithm sponsored by the Obesity Medicine Association.

Disclaimer and Permissions

Disclaimer

- Since the original presentation by the Obesity Medicine Association (OMA) in 2013, the Obesity Algorithm® has undergone yearly updates to include the latest trends in the field of obesity medicine. The OMA Obesity Algorithm was developed to assist health care professionals provide care for patients with overweight and obesity. The Obesity Algorithm is not intended to be a substitute for a medical professional's independent judgment and should not be considered medical advice. The content herein is based on medical literature and the clinical experiences of obesity medicine specialists. In areas regarding inconclusive or insufficient scientific evidence, the authors used their professional judgment.
- The Obesity Algorithm is a working document that is intended to represent the state of obesity medicine at the time of publication. OMA encourages medical professionals to use this information in conjunction with, and not as a replacement for, their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply the principles of the OMA Obesity Algorithm should be made in light of local resources, individual patient circumstances, in partnership with patient agreement, and with the knowledge of federal, state, and local laws.

Permissions

- The Obesity Medicine Association owns the copyright to the Obesity Algorithm but invites you to use the slide set. Access to the Obesity Algorithm content and/or permission for extensive quoting or reproducing excerpts and for the reproduction and use of copyrighted text, images, or entire slides will not be granted until the requestor has signed the copyright consent and permission agreement available at <https://obesitymedicine.org/obesity-algorithm-powerpoint/>. OMA reserves the right to deny a request for permission to use the Obesity Algorithm.

Writing Process

- **Transparency:** This “Writing Process” section describes the processes by which the OMA Obesity Algorithm electronic documents were developed and funded. The Obesity Medicine Association (OMA) Obesity Algorithm is provided in two electronic formats.
 - Downloadable slides: These are free to providers who visit the OMA website. They are intended to be an educational tool to assist Obesity Medicine providers better educate themselves and others. Omitted slide numbers represent content included in the eBook, but not the free downloadable slides.
 - eBook: This more extensive resource is free for OMA members. The OMA Obesity Algorithm eBook is available for a fee for OMA non-members, and intended to be a yearly updated “living textbook” of Obesity Medicine.
- **Managing disclosures, dualities of interest, and funding:**
 - The writing, editing, and publishing of the OMA Obesity Algorithm slides and eBook have never received outside funding for their development.
 - Authors of the OMA Obesity Algorithm slides and eBook have never received payment for their work in developing these documents.
 - Potential dualities of interest of the authors are disclosed in the relative Disclosure sections of each respective Obesity Algorithm document.
 - For sections of the OMA Obesity Algorithm slides and eBook wherein substantive conflicts of interest may exist, members of the writing team having no potential conflicts of interest review these sections, and have final approval of these sections.

Writing Process

- **Group composition:**

- Authors of the OMA Obesity Algorithm slides and eBook represent a diverse range of clinicians, allied health professionals, clinical researchers, and academicians, intended to reflect a multidisciplinary and balanced group of experts in obesity science, evaluation, and treatment.

- **Evidence foundation:**

- The content of the OMA Obesity Algorithm slides and eBook is supported by citations. These citations are derived from literature searches, as well as updates from data reported within the year prior to each annual update.
- Fully referenced citations are listed within the OMA Obesity Algorithm slides and eBook.

- **Review:**

- The OMA Obesity Algorithm slides and eBook undergo repeated reviews and approvals by authors having diverse perspectives of obesity medicine.
- Comments and suggested edits received from OMA members and outside sources are considered with each year's updated revisions.
- Comments and suggested edits originating from those with significant conflicts of interest are vetted by authors without similar conflicts of interest, prior to including the potential edits in revisions.
- The OMA Obesity Algorithm slides and eBook also undergo independent review and approval by the OMA Board of Trustees. The authors then consider all external reviewer comments and respond with a written rationale for modifying or not modifying the documents.

Writing Process

- **Recommendations:**

- These documents are intended to provide an overview of principles important to the care of patients with unhealthful increases in body fat.
- These documents are not intended to be interpreted as “rules” and/or directives regarding the medical care of an individual patient.
- The final decision regarding the optimal care of the patient with overweight and obesity is dependent upon the individual clinical presentation and the judgment of the clinician who is tasked with directing a treatment plan that is in the best interest of the patient.

- **Updating:**

- Both the OMA Obesity Algorithm and eBook are planned for yearly reviews and updates. During each year, the literature is routinely monitored to identify potentially relevant information applicable to forthcoming updates.
- If during the interim of scheduled updates, areas in need of urgent clarification are discovered, or if new evidence suggests the need for urgent modifications, then interim changes to the OMA Obesity Algorithm slides and eBook are made prior to each year’s scheduled update.

Limitations

Prior OMA Obesity Algorithm versions:

- The Obesity Medicine Association (OMA) Obesity Algorithm[®] (first released in 2013) undergoes yearly review with updates to clarify and amend text to reflect the latest research and perspectives in the specialty field of Obesity Medicine.
- Due to ever evolving new science, re-evaluation of older science, and yearly editing to improve clarity, older OMA Obesity Algorithm versions may not reflect up-to-date information.
- No single resource should solely determine patient care. The OMA Obesity Algorithm should be considered an adjunct to the totality of medical resources, as well as an adjunct to the clinical judgment regarding the management of patients with overweight and obesity.
- Upon each new release, it is recommended readers replace outdated OMA Obesity Algorithm versions with the most current version.
- If you find areas that may benefit from clarification or correction, then please contact and notify the Obesity Medicine Association.

Major Updates Included in the 2020 Version

- New Sectional: *“Top 10 takeaway messages”*
- Adiposopathic aging
- Polycystic ovary syndrome
- Ketogenic diet
- Obesity and psychiatry
- Obesity myths
- Anti-obesity agents in development table
- Table of the role of gastrointestinal hormones in energy and nutrient regulation
- Updates to bariatric surgery nutrient replacement
- Links to educational resources
- General updates and text edits
- Updated references

10

OMA Obesity Algorithm eBook, Slides, Authors and Citations

Adult Obesity Algorithm eBook: Detailed overview of Obesity Medicine

Citation: Bays HE, McCarthy W, Christensen S, Tondt J, Karjoo S, Davisson L, Ng J, Golden A, Burrridge K, Conroy R, Wells S, Umashanker D, Afreen S, DeJesus R, Salter D, Shah N, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2020. <https://obesitymedicine.org/obesity-algorithm/> (Accessed = Insert date)

Adult Obesity Algorithm free downloadable slides: General overview of Obesity Medicine (content omitted in the downloadable slides can be found in the eBook)

Citation: Bays HE, McCarthy W, Christensen S, Tondt J, Karjoo S, Davisson L, Ng J, Golden A, Burrridge K, Conroy R, Wells S, Umashanker D, Afreen S, DeJesus R, Salter D, Shah N, Richardson L. Obesity Algorithm Slides, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2020. <https://obesitymedicine.org/obesity-algorithm-powerpoint/> (Accessed = Insert date)

The Obesity Algorithm is listed by the American Board of Obesity Medicine as a suggested resource and study-aid for the obesity medicine certification exam. (<https://www.abom.org/exam-resources-2/>)


The Disease of Obesity

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



The OMA Obesity Algorithm



The Obesity Medicine Association's Definition of Obesity

“Obesity is defined as a chronic, progressive, relapsing, multi-factorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences.”

Top 10 benefits of treating obesity as a disease

1. Healthful nutrition (including negative caloric balance in patients with obesity) and regular physical activity often improves anatomic, physiologic, inflammatory, and metabolic body processes
2. Medically managed weight reduction in patients with obesity often improves glucose and lipid metabolism, reduces blood pressure, and reduces the risk of thrombosis
3. Medically supervised weight management programs for patients with obesity has the potential for statistically significant and clinically meaningful weight loss maintenance
4. Weight loss in patients with obesity may reduce premature all cause mortality
5. Weight loss in patients with obesity may have favorable cardiac hemodynamic effects
6. Weight loss in patients with obesity may improve obstructive sleep apnea and osteoarthritis
7. Weight loss in patients with obesity may reduce the onset of certain cancers, improve response to cancer treatments, and reduce the onset/recurrence of new cancers
8. Weight loss in women with obesity may improve metabolism (polycystic ovary syndrome), as well as improve obesity-related gynecologic and obstetric disorders; weight loss in men may increase testosterone levels when hypogonadism is due to the adiposopathic consequence of obesity
9. Weight loss in patients with obesity may improve quality of life, improve body image, and improve symptoms of some psychiatric disorders (e.g., depression)
10. Weight loss in child-bearing women (and men) with overweight or obesity may help mitigate epigenetically transmitted increased risk of obesity and metabolic disease in future generations

Top 10 Takeaway Messages: Obesity is a Disease

1. The signs, symptoms, and pathophysiology of obesity fulfill the definition of a disease
2. Obesity can substantially be due to inheritance (genetic, epigenetic, and/or environmental inheritance)
3. Obesity may result in cellular and organ anatomic abnormalities
4. Obesity may result in cellular and organ functional abnormalities
5. Obesity may result in pathogenic adipocyte and/or adipose tissue endocrine and immune dysfunctions that contribute to metabolic disease (adiposopathy or “sick fat” disease)
6. Obesity may result in pathogenic physical forces from excessive body fat, promoting stress damage to other body tissues (“fat mass disease”)
7. Even when exacerbated by unhealthful behavior, obesity is no less a disease than other diseases promoted by unhealthful behavior
8. Data from 2015 – 2016 estimate that approximately 40% of US adults have obesity; data from 2015 – 2016 support approximately 18.5% of youths have obesity
9. As with other diseases, obesity is best discussed using “people-first” language
10. Obesity is promoted by genetic predisposition, and shares similar pathophysiologies as aging

Obesity Is a Disease When...

- The patient has excessive body fat, as assessed by reliable measures
- Excessive body fat is caused by genetic or developmental errors, infections, hypothalamic injury, adverse reactions to medications, nutritional/energy imbalance, and/or unfavorable environmental factors
- Excessive body fat results in pathogenic structural or functional abnormalities resulting in increased patient morbidity and mortality
- Multiple pathogenic adipocyte and/or adipose tissue endocrine and immune dysfunctions contribute to metabolic disease (adiposopathy or “sick fat” disease)
- Multiple pathogenic physical forces from excessive body fat cause stress damage to other body tissues (fat mass disease)

The adverse health consequences of increased body fat are not simply “co-morbidities” or “associated risk factors”

Obesity Terminology

“**People-first**” language recognizes the potential hazards of referring to or labeling individuals by their disease. Thus, “**patient who is overweight or has obesity**” or “**patient with overweight or obesity**” are preferred over “obese patient.” This is similar to the standard with other diseases, such as diabetes mellitus, wherein “patient with diabetes” is preferred over “diabetic patient.”


Encouraged Terms

- Weight
- Unhealthy weight
- Overweight
- Body mass index
- Excessive energy stores
- Affected by obesity


Discouraged Terms

- Morbidly obese
- Obese
- Fat
- Heaviness
- Large size

Obesity is a Multifactorial Disease



Overall Management Goals



Classification of Obesity

Top 10 Takeaway Messages: Obesity Classification and Consequence

1. For the general population, body mass index (BMI) ≥ 25 kg/m² is considered overweight; BMI ≥ 30 kg/m² is considered obesity
2. BMI has limitations in assessing adiposity in individuals with increased muscle mass, decrease in muscle mass, men versus women, different races, and postmenopausal status
3. For individuals, accurately determining percent body fat, android fat, and visceral fat is a better assessment of adiposity compared to BMI alone
4. Central obesity is defined as waist circumference ≥ 40 inches (102 cm) for men and ≥ 35 inches (88 cm) for women [≥ 90 cm for Asian men; ≥ 80 cm for Asian women]
5. Waist circumference is well-correlated with the risk of metabolic and cardiovascular disease
6. Fat mass disease results in pathologic mechanical and physical forces leading to adverse clinical outcomes (e.g., sleep apnea, orthopedic problems)
7. Sick fat disease (adiposopathy) results in pathologic endocrine and immune responses that promote the most common metabolic diseases encountered in clinical medical practice (e.g., diabetes mellitus, high blood pressure, dyslipidemia)
8. Anatomic adiposopathic changes with obesity include adipocyte hypertrophy, adipose tissue expansion, increased energy storage in multiple fat depots and increased fat deposition in body organs
9. Functional adiposopathic changes with obesity include adipose hypoxia, increased reactive oxygen species, extracellular matrix abnormalities, intra-organelle dysfunction, neurological changes, and immunopathic/endocrinopathic responses
10. The degree by which adiposopathy results in metabolic disease largely depends on the interactions and crosstalk with other body organs

Obesity Paradox

Top 10 Takeaway Messages: Obesity Paradox

1. An Obesity Paradox exists when increased body weight is found to have an apparent favorable effect on health, which often is less paradoxical when viewed from the perspective of both fat mass ***and*** fat function
2. Many “obesity paradoxes” are reported
3. Fat depots have the potential to be protective and/or pathogenic
4. Obesity increases morbidity and mortality
5. Obesity promotes “fat mass” disease
6. Obesity promotes “sick fat” disease or adiposopathy, which is the most common cause of the most common metabolic conditions encountered in clinical practice (e.g., diabetes mellitus, hypertension, dyslipidemia and thrombosis); thus, obesity indirectly contributes to major cardiovascular disease (CVD) risk factors
7. Obesity may directly increase the risk of CVD (e.g., adiposopathic epicardial effects)
8. Individuals with the highest body weight and lowest body weight have higher mortality
9. The increase in mortality with lower body weight is often due to the confounding effect of concurrent illnesses (e.g., poor nutrition, malabsorptive syndromes, cancer & cardiac cachexia) and cigarette smoking, that not only contribute to low body weight, but also to increased mortality
10. Obesity increases the risk of cancer

Obesity and Stress: Cause and Effect

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Obesity and Stress

1. Shorter-term “fight or flight” stress response increases adrenal sympathomimetic activity
2. Shorter-term adrenergic stress responses may improve cognition, physiologic function, tolerance to pain, and immune function
3. Longer-term “submit and stay” stress may increase hypothalamic corticotropic activity
4. Longer-term hypothalamic stress responses may increase food craving, increase blood pressure, worsen glucose metabolism, promote pain intolerance, and dysregulate immune responses
5. Chronic stress-induced adiposopathic responses may adversely affect the limbic system
6. Dysregulation of the limbic system with chronic stress may affect hunger, food choice, and emotional modulation of food intake
7. Dysregulation of the limbic system with chronic stress may affect reward-seeking behavior
8. Mental stress may affect the cerebrum, which may contribute to prioritization of personal, work, or other behaviors and activities over more healthful behaviors and activities (i.e., healthful nutrition and regular physical activity)
9. Mental stress may impair self-regulation and promote choosing unhealthful (immediately rewarding ultra-processed) foods over more healthful (delayed-gratification unprocessed) foods
10. Obesity and its adverse health complications may increase mental stress, which may contribute to unhealthful behavior, endocrinopathies and immunopathies, which in turn, may further worsen obesity and its complications, resulting in an adiposopathic stress cycle

Evaluation and Treatment Overview:

History, Physical Exam, Laboratory, Diagnostic
Testing, Treatment Priorities

Top 10 Takeaway Messages: Obesity Evaluation

1. Patients with obesity often do not receive standard preventive medical care
2. Useful nutrition monitoring approaches include recording food and beverage diaries
3. Body systems to be evaluated before prescribing a physical activity program include cardiac, pulmonary, and musculoskeletal systems, as well as body metabolic processes (diabetes mellitus, hypertension)
4. Routine laboratory assessment may include measures of glycemia (fasting glucose levels, HbA1c), lipid levels, liver enzymes, electrolytes, creatinine & blood urea nitrogen, thyroid stimulating hormone, complete blood count, urine for albumin, and possibly vitamin D.
5. Individual testing may include evaluation for insulin resistance, insulinoma or nesidioblastosis, hypercortisolism, oligomenorrhea/amenorrhea, hyperandrogenemia & polycystic ovary syndrome in women, and hypogonadism in men.
6. Other diagnostic tests in patients with overweight or obesity might include magnetic-resonance imaging or computed tomography of the pituitary, resting electrocardiogram, cardiac stress testing, echocardiogram, coronary calcium scores, ankle-brachial index, sleep studies, and imaging studies of the liver.
7. Methods to measure body composition include dual-energy x-ray absorptiometry (DXA), bioelectrical impedance, whole body air displacement plethysmography, near-infrared interactance, myotape, calipers, or underwater weighing
8. Prader Willi is the most common non-inherited, non-polygenic syndrome that may promote obesity
9. Melanocortin 4 receptor deficiency (autosomal dominant or recessive) is the most common inherited, non-polygenic syndrome that may promote obesity
10. Medical conditions that may promote fat mass gain include hypothalamic damage, immobility, insulinoma, hypercortisolism, sleep disorders, some cases of untreated hypothyroidism, and adverse effects of concurrent medications

Treatment of Adult Patients with Overweight or Obesity

Medical Management and Coordination

Nutrition

Physical Activity

Behavior Therapy

Pharmacotherapy

Bariatric Surgery

Treatment of Adult Patients with Overweight or Obesity

- Treat adipocyte and adipose tissue dysfunction, which treats sick fat disease (SFD or adiposopathy)
- Treat excessive body fat, which treats fat mass disease (FMD)
- Treating diseases due to increased body fat and its adverse metabolic and biomechanical consequences may improve patient health, quality of life, body weight, and body composition

Body Composition



Podcast
Obesity: A Disease
Episode 5

Top 10 Takeaway Messages: Obesity and Body Composition

1. Lean body mass is total body mass less storage adipose tissue (i.e., water, mineral, protein, glycogen, essential organ fat)
2. In lean individuals, approximately 60% of body weight is water (i.e., water is 75% weight of muscle and body organs). In those with obesity, water weight can be as low as 40% body weight.
3. Ash weight of bone contributes a minor amount to total body weight (~3 to 10 pounds)
4. Percent body fat mass is highly variable, and may range from <5% to > 70%
5. Percent body fat mass is dependent upon both fat and muscle mass
6. Methods to measure body composition vary regarding accuracy, reproducibility, expense, and accessibility
7. Some Dual Energy X-Ray Absorptiometry (DXA) scans can measure percent body fat, android fat (abdominal subcutaneous and visceral fat), lean body mass, and bone mineral density
8. Calipers can estimate percent body fat, are user dependent, are inexpensive, and perhaps more useful for frequent longitudinal assessments once body composition is determined by more accurate measures
9. Bioelectrical impedance is a hydration-dependent body composition assessment procedure; reasonable assessment of android fat may best be achieved via a complementary tape-measured waist circumference
10. Air displacement assessment of percent body fat is clothing and hydration dependent; reasonable assessment of android fat may best be achieved via a complementary tape-measured waist circumference

Energy Expenditure

Top 10 Takeaway Messages: Obesity and Energy Expenditure

1. For most individuals, resting metabolic rate (RMR) represents ~70% of total daily energy expenditure
2. For most individuals without excess body fat, skeletal muscle, liver, brain, heart, and digestive system each account for ~10 - 20% of RMR (~75% of total RMR). Kidney, adipose tissue, and remaining/residual = ~25%.
3. Non-exercise Activity Thermogenesis (NEAT) varies among individuals, can range between 150 – 500 kcal/day (often greater than bouts of physical exercise), and can help account for the perception that some individuals more easily maintain a healthy body weight despite similar caloric intake and dedicated physical exercise
4. Less than 5000 steps per day is considered sedentary; $\geq 10,000$ steps per day is considered active
5. Direct calorimetry estimates energy expenditure via measurement of heat generated by an organism in an enclosed chamber
6. Indirect calorimetry estimates energy expenditure via use of an electronic metabolic “cart,” that measures carbon dioxide production and oxygen consumption. The respiratory quotient (RQ) = CO_2 production / O_2 consumption. The RQ for carbohydrates is 1.0; the RQ for fats is 0.7.
7. Resting energy expenditure can be estimated by calculations (Harris-Benedict & Mifflin St Jeor Equations)
8. Doubly labeled water estimates energy expenditure via oral administration of traceable hydrogen and oxygen isotope, and the estimation of carbon dioxide production, reflecting energy expenditure due to tissue respiration
9. Physical activity expenditure can be estimated by wearable technologies, such as pedometers and accelerometers
10. Energy expenditure may be increased with greater inefficiency in physiologic and behavior processes

Concomitant Medications

Top 10 Takeaway Messages: Obesity and Concomitant Medications

1. Anti-hypertensive medications most associated with body weight gain include some beta-blockers (propranolol, atenolol, and metoprolol) and calcium channel blockers (mainly through edema = nifedipine and amlodipine)
2. Anti-diabetes medications that most promote body weight gain include most insulins, sulfonylureas, thiazolidinediones, and meglitinides
3. Hormone therapies that most promote body weight gain include glucocorticoids and injectable progestins
4. Anti-seizure medications most associated with body weight gain include carbamazepine, gabapentin, valproate, and pregabalin
5. Anti-depressants most associated with body weight gain include some tricyclic antidepressants (amitriptyline, doxepin, imipramine), some selective serotonin reuptake inhibitors (paroxetine), some selective serotonin and norepinephrine reuptake inhibitors (venlafaxine), some irreversible monoamine oxidase inhibitors (isocarboxazid, phenelzine), as well as mirtazapine, brexpiprazole, and trazodone
6. Mood stabilizers most associated with body weight gain include gabapentin, divalproex, lithium, valproate, vigabatrin, cariprazine, carbamazepine
7. Migraine medications most associated with body weight gain include amitriptyline, gabapentin, paroxetine, valproic acid, and some beta blockers
8. Among antipsychotics most associated with body weight gain include clozapine, olanzapine, chlorpromazine, brexpiprazole, iloperidone, lithium, quetiapine, risperidone, sertindole, thioridazine, trifluoperazine, and zotepine.
9. Chemotherapeutic and anti-inflammatory agents most associated with body weight gain include tamoxifen, cyclophosphamide, methotrexate, 5-fluorouracil, aromatase inhibitors, and corticosteroids
10. Other drugs associated with body weight gain include the hypnotic diphenhydramine, some anti-seizure & antidepressants used for treatment of neuropathy, and some highly active antiretroviral therapies (HAART) protease inhibitors when not accompanied by lipodystrophy

Nutrition Therapy for Obesity

Top 10 Takeaway Messages: Obesity and Nutrition

1. Health outcomes are most improved with nutrition therapy when the dietary interventions are evidence-based, quantitative, qualitative, and promote patient adherence
2. Low calorie diet is ~ 1200 to 1800 kcal/day; very low-calorie diet is generally < 800 kcal/day
3. Fat restricted diet is often defined as 10 – 30% of total calories from fat
4. Low carbohydrate diet is generally defined as 50 – 150 grams of carbohydrates per day; very low-carbohydrate diet is < 50 grams of carbohydrates per day
5. The isocaloric substitution of refined carbohydrates with saturated fats does not improve cardiovascular disease risk; the isocaloric substitution of saturated fats with unhealthful ultra-processed carbohydrates does not improve cardiovascular disease risk
6. The Ketogenic Diet is a carbohydrate-restricted intervention that typically discourages unhealthful ultra-processed and refined foods, foods high in glycemic index/load, and foods rich in *trans* fatty acids. Ketosis may reduce appetite.
7. The Mediterranean Diet is not a defined diet, but rather a generalized meal pattern that encourages olive oil, vegetables, fruits, legumes, whole grains, nuts, seeds, seafood, fermented dairy products, poultry, eggs, and red wine; it discourages high amounts of red meats, meat products, and unhealthful ultra-processed carbohydrates
8. The DASH Diet is a diet pattern that encourages vegetables, fruits, whole grains, fat-free or low-fat dairy products, fish, poultry, lean meats, nuts, seeds, legumes, fiber, foods containing calcium, potassium and magnesium; it discourages sodium > 2300 mg per day, total fat > 27% of total daily calories, cholesterol > 150 mg per day for 2100 Calorie eating plan, red and unhealthful ultra-processed meats, sugar-sweetened beverages, and foods with added sugars
9. The Vegetarian Diet encourages vegetables, fruits, whole grains, legumes, seeds, nuts and discourages meats
10. Fasting (alternative day, intermittent, or time-restricted eating) may contribute to overall caloric restriction and weight reduction

Dietary Patterns

Includes many dietary patterns but must be calorically restricted to effectively treat obesity.
Weight loss and metabolic effects vary.

- Mediterranean diet
- Therapeutic lifestyle diet
- DASH (Dietary Approaches to Stop Hypertension)
- Ketogenic (Atkins) diet
- Ornish diet
- Paleo diet
- Vegetarian diet
- Intermittent fasting
- Commercial diet programs

Mediterranean Diet

The Mediterranean Diet is not a defined “diet,” but rather a generalized term to describe several meal pattern variants often found in Greece, Italy, and Spain. The Mediterranean Diet has the most consistent and robust scientific support in reducing atherosclerotic cardiovascular disease risk.

Encouraged

- Olive oil as main source of fat
- Vegetables, fruit, legumes, whole grains, nuts, and seeds
- Moderate intake of red wine
- Moderate consumption of seafood, fermented dairy products (cheese and yogurt), poultry, and eggs

Discouraged

- Limit consumption of high amounts of red meat, meat products, and ultra-processed carbohydrates
- * Saturated fats are often discouraged with the Mediterranean Diet; olive oil is a staple of most definitions of the Mediterranean Diet. However, some Mediterranean cuisine may include lard and butter for cooking, and olive oil for dressing salads and vegetables

Therapeutic Lifestyle Change Diet (TLC)

The TLC Diet is a low-fat meal-plan variant that was recommended by the National Cholesterol Education Program, Adult Treatment Panel. It is the “diet” most often utilized in the conduct of lipid clinical trials.

Encouraged

- Total fat: 25–35% of daily calories
 - Polyunsaturated fat: Up to 10% of total daily calories
 - Monounsaturated fat: Up to 20% of total daily calories
- Carbohydrate: 50% to 60% of total calories
- Soluble fiber: At least 5-10 grams a day, preferably 10-25 grams a day
- 2 grams per day of plant stanols or sterols through foods or dietary supplements

Discouraged

- Limit saturated fat: < 7% of total calories
- Limit cholesterol: < 200 mg a day
- Avoid foods with *trans* fatty acids.

Ketogenic Diet (Keto or Atkins Diet)

The Ketogenic Diet is illustrative of a carbohydrate-restricted nutritional intervention that promotes utilization of fat for energy and generates ketosis, which may reduce appetite.

Encouraged

- **The induction phase** allows no more than 20 grams of carbohydrate per day from non-starchy vegetables and leafy greens; encourages adequate protein, and higher proportion of dietary fat to reduce insulin levels and generate ketosis.
- **The ongoing weight loss phase** allows a wider variety of vegetables, seeds and nuts, and low-glycemic fruits (i.e., strawberries and blueberries).
- **The pre-maintenance phase**, after the goal weight is achieved, allows carbohydrate intake to be slowly increased as long as weight gain does not occur.
- **In the maintenance phase**, 60 to 90 grams of carbohydrates per day is allowed, which may allow legumes, whole grains, and fruits.
- All phases encourage a balance of saturated, monounsaturated, and polyunsaturated fatty acids.

Discouraged

Avoid:

- Ultra-processed and refined foods
- Foods with a high glycemic index / glycemic load
- Foods rich in *trans* fatty acids

In all but the maintenance phase, limit:

- Cereals, breads, and grains
- Dairy products, except cheese
- Starchy vegetables
- Most fruits

Ornish Diet

The Ornish Diet is illustrative of a fat-restricted nutritional intervention.

Encouraged

- Foods are best eaten in their natural form
- Vegetables, fruits, whole grains, and legumes
- One serving of a soy product each day
- Limited amounts of green tea
- Fish oil 3-4 grams each day
- Small meals eaten frequently throughout the day

Discouraged

- Limit dietary fat: < 10% of total daily calories
- Limit dietary cholesterol: ≤ 10 mg per day
- Limit sugar, sodium, and alcohol
- Avoid animal products (red meat, poultry, and fish) and caffeine (except green tea)
- Avoid foods with *trans* fatty acids, including vegetable shortening, stick margarines, and commercially prepared foods, such as frostings; cake, cookie, and biscuit mixes; crackers and microwave popcorn; and deep-fried foods
- Avoid refined carbohydrates and oils

DASH Diet

The “Dietary Approaches to Stop Hypertension” (DASH) is a diet pattern promoted by the U.S. National Heart Lung and Blood Institute, primarily to treat high blood pressure.

Encouraged

- Vegetables, fruits, and whole grains
- Fat-free or low-fat dairy products
- Fish, poultry, and lean meats
- Nuts, seeds, and legumes
- Fiber and the minerals calcium, potassium, and magnesium

Discouraged

- Limit sodium: 1,500-2,300 mg per day
- Limit total fat: ~27% of total daily calories
- Limit saturated fat: <6% of total daily calories
- Limit cholesterol: ≤ 150 mg per day for a 2,100-Calorie eating plan
- Avoid red and processed meats
- Avoid sugar-sweetened beverages
- Avoid foods with added sugars

Paleolithic Diet

Paleolithic nutritional intervention is based upon a diet pattern presumed to exist during the Paleolithic period (lasting 3.4 million years, and ending 6000-2000 BC). It differs from some other diets in that it excludes grains, dairy, and ultra-processed foods.

Encouraged

- Fresh vegetables, fruits, and root vegetables
- Grass-fed lean red meats
- Fish/seafood
- Eggs
- Nuts and seeds
- Healthful oils (olive, walnut, flaxseed, macadamia, avocado, and coconut)

Discouraged

Avoid:

- Cereal grains
- Legumes, including peanuts
- Dairy products
- Potatoes
- Ultra-processed foods
- Refined sugar, refined vegetable oils, and salt

Vegetarian Diet*

A vegetarian nutritional intervention includes a meal plan consisting of foods that come mostly from plants.

Encouraged

- Vegetables
- Fruits
- Whole grains
- Legumes
- Seeds
- Nuts
- May include eggs and milk

Discouraged

- Fowl
- Fish
- Beef
- Pork
- Lamb

* Plant-based nutritional intake is generally associated with weight loss, reduced risk of heart disease (including heart failure), other metabolic diseases, some cancers, and possibly all cause mortality. However, these potential benefits may be negated when more healthful plant-based whole foods (i.e., with natural fiber and nutrients) are replaced by ultra-processed foods, fried foods, and refined carbohydrates.

Vegetarian Diet Variants

Vegan (“Total Vegetarian”): Only plant-based foods (e.g., fruits, vegetables, legumes, grains, seeds, and nuts) with no animal proteins or animal by-products, such as eggs, milk, or honey

Lacto-vegetarian: Plant foods plus some or all dairy products (e.g., cheese)

Lacto-ovo Vegetarian (or Ovo-lactovegetarian): Plant foods, dairy products, and eggs

Semi or Partial Vegetarian: Plant foods and may include chicken or fish, dairy products, and eggs, but not red meat

Pescatarian: Plant foods and seafood

Flexitarian: Mostly plant-based foods (minimally processed), with occasional fish, meat, and animal products in moderation

Fasting (e.g., alternative day, intermittent, time-restricted eating)

- May contribute to overall caloric restriction
- Increasing the frequency of meals may not affect weight loss beyond a reduction in energy intake
- Potential advantages:
 - Reducing “decision fatigue” regarding food selection
 - Quickly reversible
 - May better fit in day-to-day patient scheduling (also Ramadan)
 - May reduce caloric intake with preservation of lean body mass
 - May not reduce resting metabolic rate and total energy expenditure
 - May reduce body weight and improve metabolic parameters (e.g. improve insulin sensitivity, blood pressure, lipids, and inflammatory markers)
- Potential disadvantages
 - Does not necessarily emphasize healthful meal quality
 - May not be appropriate for patients with history of eating disorders (e.g., bulimia)
 - Increases the risk of hypoglycemia among patients with diabetes mellitus who do not appropriately adjust their hypoglycemic anti-diabetes drug treatments (e.g., insulin, sulfonylurea)
 - Unclear if sustainable on a lifetime basis for a lifelong disease (i.e., obesity)
 - Most long-term evidence of efficacy and reported safety in animal studies
 - Prolonged fasting may promote gout, urate nephrolithiasis, postural hypotension, and cardiac dysrhythmias



Podcast
Obesity: A Disease
Episode 6

Physical Activity and Obesity

Top 10 Takeaway Messages: Obesity and Physical Activity

1. Routine physical activity may improve body composition
2. Routine physical activity may improve body processes adversely affected by the disease of obesity (i.e., adiposopathic endocrine and immune abnormalities)
3. Physical activity may improve metabolic, musculoskeletal, cardiovascular, pulmonary, mental, sexual, and cognitive health
4. Dynamic training promotes weight loss and may help prevent weight gain or regain
5. Resistance training may improve body composition, prevent muscle loss during weight loss, and increase resting energy expenditure
6. In addition to physical exercise, increased energy expenditure can be achieved via increased leisure time physical activity and non-exercise activity thermogenesis (NEAT)
7. A common physical exercise prescription (FITTE) includes frequency, intensity, time spent, type, and enjoyment
8. Metabolic equivalent tasks (METs) are used to assess the intensity of physical exercise, with one MET equal to the amount of energy expended for one minute while lying down at rest [equal to 3.5 milliliters of oxygen consumption per kilogram of bodyweight per minute (3.5 ml/kg/min)]
9. Standing = 2 METs; walking 4 miles per hour = 4 METs; running 10 miles per hour = 16 METs
10. Tracking physical activity can be via a variety of activity logs, as well as percent body fat measurements by a reliable technique



Motivational Interviewing

Top 10 Takeaway Messages: Obesity and Motivational Interviewing

1. **Stages of change** that may be evaluated during motivational interviewing include pre-contemplation, contemplation, preparation, action, maintenance, and relapse
2. **General motivational interviewing principles** include empathy, avoid arguments, develop discrepancy, resolve ambivalence, and support self-efficacy
3. **Empathy** involves communication, understanding, collaboration, support, encouragement and listening
4. **Avoiding arguments** involves recognizing types of resistance (arguing, denying, ignoring, interrupting) and then “rolling with resistance” through reflection, shifting focus, reframing, and/or siding with the negative
5. **Developing discrepancy** explores the mismatch between where the patient is today, and where the patient says he/she wants to be in the future
6. **Resolving ambivalence** is amplifying discrepancy and addressing the uncertainty for the desire for change.
7. **Supporting self-efficacy** is affirming favorable results though focusing on patient successes and highlighting patient skills and strengths
8. **The 5A's** of motivational interviewing include Ask, Assess, Advise, Agree, and Arrange or Assist
9. **FRAMES** is a common motivational interviewing acronym = Feedback, Responsibility of the patient, Advice to change, Menu of strategies, Empathy, and Self-Efficacy
10. **OARS** is a common motivational interviewing acronym = Open-ended questions, Affirmation, Reflections, and Summaries

Motivational Interviewing: Stages of Change

Progress



Motivational Interviewing: Principles

Express empathy

Avoid
argumentation

Develop
discrepancy

Resolve
ambivalence

Support self-
efficacy

Motivational Interviewing Techniques: 5A's of Obesity Management

Ask

- Ask for permission to discuss body weight.
- Explore readiness for change.

Assess

- Assess BMI, waist circumference, and obesity stage.
- Explore drivers and complications of excess weight.

Advise

- Advise the patient about the health risks of obesity, the benefits of modest weight loss (i.e., 5-10 percent), the need for long-term strategy, and treatment options.

Agree

- Agree on realistic weight-loss expectations, targets, behavioral changes, and specific details of the treatment plan.

Arrange/Assist

- Assist in identifying and addressing barriers; provide resources; assist in finding and consulting with appropriate providers; arrange regular follow up.

Behavior Therapy

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Obesity and Behavior Therapy

1. Eating behavior is often the result of an imbalance in physiologic forces that strongly resist weight loss and weakly resist weight gain. This is analogous to the imbalanced physiologic response between hypoglycemia (marked symptoms and strong signals to immediately consume food) and hyperglycemia (often no symptoms and often no signal to change eating behavior).
2. Eating behavior is affected by all 5 senses (sight, smell, hearing, taste, and feel)
3. Eating behavior can be affected by mental stress, emotions, habitual time cues, environment, information gap, and reward factors
4. Eating behavior can be affected by eating disorders (e.g., binge-eating disorder, bulimia nervosa, and night-eating syndrome)
5. Physical inactivity behavior may be due to patient musculoskeletal, neurologic, pulmonary, cardiac, and other health disorders
6. Physical inactivity behavior may be related to conveniences, lack of time, disinterest, and environment
7. Behavior related to weight regain may be due to physiologic priority imbalance, neurobiology, and energy expenditure
8. Behavior therapy elements for optimal success include promoting behaviors that are doable, efficacious, measurable, and which engage self-ownership
9. Behavior therapy implementation optimally includes frequent encounters with qualified medical professionals, education, stimulus control, cognitive restructuring, goal setting, self monitoring, behavioral contracting, problem solving, social support, and other contingencies
10. Purchasing or providing access to weight management technologies and social media alone may have limited benefits; however, in motivated patients ready for change, utilization of technologies and social media can help facilitate elements of behavior therapy implementation, such as record keeping, education, and social support/motivation

Eating Disorders and Obesity: Binge-eating Disorder

Diagnosis:

- Frequent episodes of consuming large amounts of food more than once per week for at least three months
 - No self-induced vomiting (purging)
 - No extra exercising
 - Feelings of lack of self control, shame, and guilt
- Occurs in 2-3 percent of U.S. adults
- Often considered the most common eating disorder; may occur in up to 50 percent of patients with severe obesity
- Eating Attitudes Test may assist with diagnosis

Severity based upon episodes per week:

- Mild = 1 – 3; Moderate = 4 – 7; Severe = 8 – 13; Extreme = ≥ 14

Treatment:

- Often requires treatment by a qualified clinician
- Cognitive behavior therapy
- Lisdexamfetamine dimesylate is the only pharmacotherapy with an FDA indication to treat binge-eating disorder
- Although not FDA indicated for this use, clinical trials suggest other pharmacotherapies may be efficacious
 - Some selective serotonin reuptake inhibitors
- 248 – Topiramate

Eating Disorders and Obesity: Bulimia Nervosa

Diagnosis:

- Cycle of recurrent binge eating and compensatory purging, laxative abuse, diuretic abuse, extra exercising, fasting, or strict dieting
- Occurs in approximately 1% of adults (mostly women)
- Russell sign: Calluses and abrasions on dorsum of the hands caused by repeated contact with the teeth during self-induced vomiting
- Laboratory: Hypokalemia due to hypomagnesemia

Treatment:

- Often requires treatment by a qualified clinician
- Fluoxetine is an FDA-approved pharmacotherapy for bulimia nervosa
- Although not FDA-indicated for this use, topiramate and naltrexone may be efficacious

Eating Disorders and Obesity: Night-eating Syndrome

Diagnosis:

- At least 25% of daily food consumption (often greater than 50%) consumed after evening meal
- Recurrent awakenings from sleep that require eating to go back to sleep, often involving carbohydrate-rich snacks
- Little interest in breakfast (morning anorexia)
- Night-eating syndrome may occur in as much as 5% of the U.S. population

Treatment:

- Behavioral therapy regarding nutritional timing and content

Technologies for Weight Management

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Technologies and Social Media

Applications

- Record and assess nutritional and physical activity metrics
- May be assessed and reviewed by clinicians between face-to-face evaluations

Interactive Technology

- Body-weight scales that provide interactive feedback via email or text messaging
- Wearable technologies
 - Tracks active minutes, steps, floors climbed, distance, and caloric consumption
 - Monitors heart rate and sleep patterns
 - Provides daily exercise statistics
 - Wirelessly syncs with smartphones and computers, providing interactive information to user
 - Potential benefits of wearable technology beyond standard behavioral intervention depends on the individual, and thus recommending wearable technologies is best based upon a patient-centered approach

Websites

- Websites can provide educational information regarding:
 - Nutrition
 - Caloric content of foods
 - Physical activity
 - Expected energy expenditure with certain physical activities
 - Meal plans
 - Recipes

Social Media

- Post daily meals and snacks to followers to enhance accountability (Twitter, Facebook, etc.)
- Post physical activity progress to social network group
- Obtain nutritional and physical activity advice from others, including social network support groups specific to weight management (e.g., Twitter, Facebook, blogs, forums)
- Competition or “wagers” regarding fitness metrics and goals

Anti-obesity Medications

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Anti-obesity Medications

1. Phentermine is a sympathomimetic amine with possible adrenergic side effects and contraindications that include use in patients with cardiovascular disease
2. Phentermine hydrochloride (HCl) 8 – 37.5 mg is generally equivalent to 6.4 – 30 mg of phentermine resin
3. Although not consistent with the prescribing information indicated use, phentermine administration for longer than 12 weeks is supported by clinical data and opinion leaders
4. Orlistat is a gastrointestinal lipase inhibitor with possible adverse experiences that include oily rectal discharge and flatus; it is contraindicated in patients with chronic malabsorption syndrome and cholestasis
5. Lorcaserin is a selective serotonin (5-hydroxytryptamine) 2 c receptor agonist with possible adverse experiences that include headache, dizziness, fatigue and dry mouth; precaution is advised when used in combination with serotonergic drugs
6. Liraglutide is a glucagon-like peptide-1 receptor agonist approved at 1.8 mg per day for treatment of type 2 diabetes mellitus, and at 3.0 mg per day for treatment of obesity with possible gastrointestinal side effects; it is contraindicated in patients with personal or family history of medullary thyroid cancer or Type 2 Multiple Endocrine Neoplasia syndrome
7. Naltrexone/bupropion is a combination of an opioid antagonist and antidepressant, with possible gastrointestinal side effects; it is contraindicated in patients with uncontrolled hypertension, chronic opioid use, seizure disorders, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates and antiepileptic drugs
8. Phentermine/topiramate is a combination of a sympathomimetic amine and anti seizure/migraine medication with side effects that include paresthesias, dysgeusia; it is contraindicated in women who may become pregnant (pregnancy tests should be performed monthly during use)
9. Liraglutide, lorcaserin, and phentermine/topiramate can be taken with or without meals
10. Orlistat should be taken three times a day with each meal that contains fat; bupropion/naltrexone should not be taken with high fat meals due to increased absorption

Anti-obesity Medications

Adjunct to nutritional, physical activity, and behavioral therapies.

Objectives:

- Treat disease
 - Adiposopathy or sick fat disease (SFD)
 - Fat mass disease (FMD)
- Facilitate management of eating behavior
- Slow progression of weight gain/regain
- Improve the health, quality of life, and body weight of the patient with overweight or obesity

5-10 percent weight loss may improve both metabolic and fat mass disease.

Anti-Obesity Medication Summary

(All have contraindications for hypersensitivity and pregnancy)

Drug	Description	Main Side Effects	Illustrative Drug Interactions
Phentermine	Sympathomimetic amine approved in 1959. It is a DEA Schedule IV stimulant agent approved for short-term use (12 weeks). Some patients may lose about 5% of body weight.	Side effects include headache, high blood pressure, rapid or irregular heart rate, overstimulation, tremor, and insomnia. Should not use with overactive thyroid or uncontrolled high blood pressure or seizure disorder. Contraindicated in patients with history of cardiovascular disease, within 14 days of monoamine oxidase inhibitors, glaucoma, agitated states, drug abuse	During or within 14 days following monoamine oxidase (MAO) inhibitors, sympathomimetics, alcohol, adrenergic neuron blocking drugs, and possibly some anesthetic agents
Orlistat	Gastrointestinal lipase inhibitor that impairs digestion of dietary fat. Lower doses are approved over-the-counter. Some patients may lose about 5% of body weight.	Side effects include oily discharge with flatus from the rectum, especially after fatty foods. (May help with constipation.) May promote gallstones and kidney stones. May cause malabsorption of fat soluble vitamins (A, D, E, K). Need to take a multivitamin daily. Contraindicated in chronic malabsorption syndrome and cholestasis. Rare cases of severe liver injury and pancreatitis.	Cyclosporine, hormone contraceptives, seizure medications, thyroid hormones, warfarin
Lorcaserin	Selective, serotonin (5-hydroxytryptamine) 2c receptor agonist that is a DEA Schedule IV agent that improves the sense of fullness. Some patients may lose 5 – 10% of body weight.	Lorcaserin is a generally well-tolerated drug, with headache, dizziness, fatigue, nausea, dry mouth, and constipation occurring more frequently compared to placebo. Warnings and Precautions include serotonin syndrome, neuroleptic malignant syndrome-like reactions, heart failure, psychiatric disorders, and priapism.	Serotonergic (SSRI's, SNRI's, MAO inhibitors) or anti-dopaminergic medications, St John's wort, triptans, bupropion, dextromethorphan, CYP 2D6 substrates

Anti-Obesity Medication Summary

(All have contraindications for hypersensitivity and pregnancy)

Drug	Description	Main Side Effects	Some Drug Interactions
Liraglutide	Glucagon-like peptide-1 receptor agonist that is an injectable drug. At lower doses (1.8 mg per day), liraglutide is indicated to lower blood sugar among patients with type 2 diabetes mellitus. Liraglutide 3.0 mg per day is approved for treatment of obesity. Some patients may lose 5 – 10% of body weight, especially with the liraglutide higher dose.	Adverse reactions include nausea, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, and renal insufficiency. Contraindicated with personal or family history or medullary thyroid cancer or Type 2 Multiple Endocrine Neoplasia syndrome. Discontinue with suspected pancreatitis, gall bladder disease, or suicidal behavior and ideation. May promote hypoglycemia, particularly in patients with diabetes mellitus treated with insulin or sulfonylureas.	May slow gastric emptying, which may impact absorption of concomitantly administered oral medication.
Naltrexone / bupropion	Combination of naltrexone (opioid antagonist used for addictions) and bupropion (used for depression and smoking cessation). Some patients may lose 5 - 10% of body weight.	Naltrexone / bupropion can cause nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, diarrhea, and acute closure glaucoma. The bupropion component is an antidepressant, and antidepressants can increase the risk of suicide thinking in children, adolescents, and young adults; monitor for suicidal thoughts and behaviors. Should not be used in patients with uncontrolled high blood pressure, seizure disorders, or drug/alcohol withdrawal.	Opioid pain medications, anti-seizure medications, MAO inhibitors, and possible drug interactions with other drugs.
Phentermine / topiramate	Combination of phentermine (sympathomimetic amine, anti-obesity drug) and topiramate (used to treat seizures and migraine headaches). DEA Schedule IV drug. Some patients may lose 5 – 10% of body weight.	Can cause paresthesia (tingling or numb feelings to extremities), dizziness, dysgeusia (abnormal taste), insomnia, constipation, or dry mouth. Monitor for increased heart rate, suicidal behavior/ideation, mood and sleep disorders, cognitive impairment, metabolic acidosis, elevated creatinine, and low blood sugars in patients on anti-diabetes medications. Discontinue with acute myopia and secondary angle glaucoma. Should not be used with glaucoma or hyperthyroidism. Topiramate can cause birth defects. Phentermine / topiramate should not be started until a pregnancy test is negative, and not continued unless the woman uses contraception; pregnancy tests should be done monthly during use.	Should not be taken during or within 14 days of monoamine oxidase inhibitors. Avoid use with alcohol, due to potentiation of depressant effects. May potentiate hypokalemia when used with non-potassium sparing diuretics.

Functional Foods, Supplements, & Over-the-counter Therapies*

*The Obesity Medicine Association has not endorsed any supplements. This section is intended to provide information the authors believe may be relevant to the clinical management of patients with obesity.

Top 10 Takeaway Messages: Supplements & OTC Therapies

1. Prescription drugs are a therapeutic medicine intended for the diagnosis, cure, mitigation, treatment or prevention of disease. Their approval and marketing is overseen by the US Food and Drug Administration.
2. Over-the-counter (OTC) medications are drugs the FDA considers safe and effective, but do not require a prescription by health professionals. Their approval by the FDA involves the regulatory process involving an OTC drug monograph, and their marketing is overseen by the Federal Trade Commission.
3. Supplements are substances taken in addition to dietary intake (e.g., vitamins, herbs, botanicals, minerals and amino acids). The FDA does not approve supplements, as they are considered a food, and not a drug.
4. Supplements are not permitted to market for the purpose of treating, diagnosing, preventing, or curing diseases.
5. Functional Foods are nutrients with potentially favorable effects beyond basic nutrition (e.g., oatmeal may lower cholesterol).
6. Herbal and dietary supplements are a common cause of hepatotoxicity (e.g., anabolic steroids and green tea extracts), especially multi-ingredient nutritional supplements.
7. Most dietary supplements have limited to no consistent data to support long-term weight loss efficacy and safety, and have the potential for adverse supplement to drug interactions.
8. Some weight loss supplements continue to be marketed, even when banned by the FDA due to adverse effects.
9. Patients should be advised of the limited evidence supporting the efficacy and safety of many supplements and the lack of oversight by government agencies regarding the claims made about such supplements.
10. Human chorionic gonadotropin (HCG) is not effective for weight loss beyond hypocaloric intake. The FDA requires clinicians and facilities that market HCG for weight loss to post a disclaimer that *“There is no substantial evidence that HCG increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or normal distribution of fat, or that it decreases the hunger and discomfort associated with calorie restrictive diets.”*

Position Statement: Recommendations for Dietary Supplements Sold as Medicinal or Curative for Obesity*

Healthcare providers should:

- Be aware of the lack of credible evidence for efficacy and safety of many supplements promoted for the purpose of weight loss.
- Query patients who desire to accomplish weight loss regarding their use of dietary supplements for this purpose.
- Advise patients who desire to accomplish weight loss of the limited evidence supporting the efficacy and safety of many supplements and the lack of oversight by government agencies regarding the claims made about such supplements.
- Be educated on the [Dietary Supplement Health and Education Act \(DSHEA\)](#) and the [roles of FDA and FTC](#) in safety and claims monitoring of supplements promoted for the purpose of weight loss.
- Healthcare providers are strongly discouraged from engaging in entrepreneurial activities in which they directly profit from the prescribing of non-FDA approved weight-loss remedies where both safety and efficacy have not been proven.

* The Obesity Society with co-signatories = Obesity Action Coalition, Obesity Medicine Association, Academy of Nutrition and Dietetics. www.obesity.org/publications/position-and-policies/medicinal-or-curative (accessed October 11, 2019)


Obesity and Metabolic Disease

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Obesity: Both “Fat Mass Disease” and “Sick Fat Disease” are pathogenic



Obesity and Cardiovascular Disease

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Obesity and Cardiovascular Disease (CVD)

1. Obesity adversely affects heart and vascular anatomy and function; CVD is the most common cause of mortality among patients with obesity.
2. Obesity increases the risk of CVD both directly (e.g., via the adiposopathic effects of epicardial fat), and indirectly via the adiposopathic promotion of major CVD risk factors such as diabetes mellitus, high blood pressure, dyslipidemia, and thrombosis.
3. While CVD outcomes trials are ongoing with anti-obesity agents, no drug and dose having an indication to treat obesity has proven to improve CVD outcomes; therefore, patients with obesity should undergo global CVD risk reduction (e.g., healthful nutrition and physical activity, smoking cessation, as well as optimal control of blood sugar, blood pressure, and blood lipids).
4. Obesity may increase pericardial (paracardial and epicardial) fat, intracardial fat, visceral fat, and liver and skeletal muscle fat; visceral and epicardial fat share the same mesodermal embryonic origin, both increase the risk for atherosclerosis, and both are highly correlated with coronary artery calcification.
5. Epicardial fat accumulation may directly contribute to heart failure with preserved ejection fraction (HFpEF), atherosclerotic CVD, dysrhythmias, fatty infiltration of the heart, and increased coronary calcium; HFpEF (diastolic heart failure) is especially common among patients with obesity, women, obstructive sleep apnea, older age, and CVD risk factors.

Top 10 Takeaway Messages: Obesity and Cardiovascular Disease (CVD)

6. Lorcaserin does not decrease the risk of CVD among patients with obesity; but may reduce onset of diabetes mellitus by mechanisms independent of weight loss and reduce the rate of new onset or progressive renal impairment; retrospective data suggests phentermine & topiramate may not increase the risk of major adverse cardiac events; glucagon-like peptide 1 agonists have clinical outcome trial evidence to support CVD benefits in patients with diabetes mellitus (e.g., liraglutide, semaglutide) and are being evaluated in CVD outcomes trials in patients with obesity.
7. Metformin and sodium glucose transporter (SGLT)-2 inhibitors decrease CVD among patients with diabetes mellitus; while they do not have an indication as anti-obesity agents, metformin and SGLT2 inhibitors modestly reduce body weight in patients with and without diabetes mellitus; when accompanied by weight loss, many anti-obesity drugs reduce CVD risk factors (i.e., orlistat, lorcaserin, liraglutide, naltrexone/bupropion, and phentermine/topiramate are not contraindicated in patients with cardiovascular disease).
8. Among patients with obesity, CVD and type 2 diabetes mellitus without congestive cardiomyopathy, initial drug treatments to consider include metformin, liraglutide, and SGLT-2 inhibitors.
9. Among patients with obesity, CVD, type 2 diabetes mellitus with mild congestive cardiomyopathy, initial drug treatments to consider in include metformin and SGLT-2 inhibitors.
10. Among patients with obesity, CVD, and without type 2 diabetes mellitus and without congestive cardiomyopathy, initial treatments to consider include liraglutide and lorcaserin.

Obesity and Elevated Blood Sugar

Top 10 Takeaway Messages: Obesity and Diabetes Mellitus

1. The disease of obesity may promote hyperglycemia and the disease of type 2 diabetes mellitus
2. Diabetes mellitus is a major risk factor for CVD; CVD is the most common cause of morbidity and mortality among patients with obesity and diabetes mellitus
3. Patients with obesity and diabetes should undergo global CVD risk reduction (e.g., healthful nutrition and physical activity, smoking cessation, as well as optimal control of blood glucose, blood pressure, and blood lipids)
4. In a study among patients with overweight or obesity that included patients with diabetes mellitus, lorcaserin did not decrease or increase the risk of CVD
5. Sulfonylureas and many insulins may increase body weight and may increase the risk for CVD
6. Based upon cardiovascular outcome trial data of patients with type 2 diabetes mellitus (consisting mostly of patients with CVD), the anti-diabetes mellitus SGLT2 inhibitors (e.g., empagliflozin and canagliflozin) may reduce major adverse cardiac events (MACE), reduce heart failure, reduce cardiovascular death or heart failure hospitalization, reduce renal disease progression, and in some cases, reduce overall mortality. Body weight and blood pressure may be modestly decreased as well.
7. Liraglutide at the 1.8 mg dose to treat diabetes reduces CVD among patients with diabetes mellitus and reduces body weight and blood pressure.
8. Metformin decreases CVD among patients with diabetes mellitus, and modestly reduces body weight in patients with diabetes mellitus
9. Anti-obesity drugs do not have CVD outcome data to support improved CVD risk reduction; however, when accompanied by weight loss, many anti-obesity drugs reduce blood sugar and other CVD risk factors
10. Both liraglutide and lorcaserin may lower blood sugar through weight dependent and weight independent mechanisms

Obesity and High Blood Pressure

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Obesity and high blood pressure

1. The disease of obesity may promote an increase in blood pressure and the disease of hypertension
2. Hypertension is a major risk factor for CVD; CVD is the most common cause of mortality among patients with obesity and hypertension
3. Patients with obesity and hypertension should undergo global CVD risk reduction (e.g., healthful nutrition and physical activity, smoking cessation, as well as optimal control of blood glucose, blood pressure, and blood lipids)
4. In addition to food intake contributing to positive caloric balance, dietary sodium can also increase blood pressure
5. Obesity and “fat mass disease” can contribute to sleep apnea, kidney and renal vessel compression, perivascular adipose tissue (restricting blood vessel wall expansion) and increased cardiac output – all of which can increase blood pressure
6. Obesity promotes hyperleptinemia and hyperinsulinemia, both of which act upon the central nervous system to increase blood pressure
7. Obesity increases the renin-angiotensin aldosterone system (RAAS) activity in the kidney resulting in increased blood pressure
8. Obesity increases adiposopathic cytokines which increase endothelial dysfunction and increased arteriole vasoconstriction resulting in increased blood pressure
9. Obesity decreases the natriuretic effects of heart left ventricular B-type natriuretic peptide (BNP) resulting in increased blood pressure
10. When accompanied by weight loss, many anti-obesity agents decrease blood pressure; some anti-obesity agents may initially increase blood pressure (i.e., sympathomimetics such as phentermine) with possible longer-term reduction in blood pressure (compared to baseline) after weight loss

Obesity and Dyslipidemia

Top 10 Takeaway Messages: Obesity and dyslipidemia

1. The disease of obesity is an important contributor to dyslipidemia
2. Dyslipidemia is a major risk factor for CVD; CVD is the most common cause of mortality among patients with obesity and dyslipidemia
3. Patients with obesity and dyslipidemia should undergo global CVD risk reduction (e.g., healthful nutrition and physical activity, smoking cessation, as well as optimal control of blood glucose, blood pressure, and blood lipids)
4. In addition to food intake contributing to positive caloric balance, ultra-processed carbohydrates may increase triglycerides (TGs) and reduce high density lipoprotein cholesterol (HDL-C). Saturated fats may increase low density lipoprotein cholesterol levels; however, this may depend on the effect of a carbohydrate restricted diet on body weight, and whether the patient has an underlying genetic hypercholesterolemia syndrome
5. Most of the body's energy is typically stored in the form of triglycerides in adipose tissue; the adipose tissue of patients with obesity may store over 50% of the total body cholesterol

Top 10 Takeaway Messages: Obesity and dyslipidemia

6. Lipoprotein lipase (LPL) is found on the intravascular surface of capillaries within and around body tissues (including adipose tissue), and hydrolyzes the core TG's contained in circulating TG-rich lipoproteins (e.g., very low density lipoproteins/VLDL and chylomicrons), into monoglycerides and fatty acids, thus reducing TG blood levels, and allowing for increased fatty acid transport into adipocytes; LPL is stimulated by physical exercise, insulin, fibrates, and omega-3 fatty acids
7. Hormone sensitive lipase (HSL) is located within adipocytes, and catalyzes the hydrolysis of diacylglycerol to monoacylglycerol, which is a rate limiting step in the release of free fatty acids (FFA) into the circulation. HSL is stimulated by catecholamines and inhibited by insulin. Largely through adipocyte HSL, lipolysis (i.e., adipocyte fat breakdown) is promoted by decreased insulin and increased physical activity (increased catecholamines), while lipolysis is inhibited (i.e., adipocyte fat conservation or gain) by increased insulin and decreased physical activity (decreased catecholamines)
8. The relative adiposopathic lack of uptake of FFA in peripheral subcutaneous adipose tissue (AT) results in energy overflow, with FFA deposition in abdominal subcutaneous, visceral AT, and pericardial AT, as well as FFA deposition in organs such as muscle and liver
9. Increased FFA delivery to the liver from adiposopathy and/or triglyceride-rich lipoproteins may lead to fatty liver and fatty muscle, possible "lipotoxicity" to these organs, increased circulating VLDL (with increased triglyceride levels), increased lipoprotein remnants, reduced HDL-C, and increased proportion of smaller, more dense LDL particles – all representing an adiposopathic dyslipidemia which is atherogenic
10. Weight loss decreases atherogenic apolipoprotein B-containing lipoproteins, and increases high density lipoprotein cholesterol

Obesity and Nonalcoholic Fatty Liver Disease (NAFLD)

Top 10 Takeaway Messages: Obesity & nonalcoholic fatty liver disease (NAFLD)

1. NAFLD includes the spectrum of fatty liver diseases, and is the most common cause of chronic liver disease (~25% of adults)
 - ~45% Hispanics
 - ~33% Caucasians
 - ~24% Blacks
2. More than 2/3 of patients with NAFLD have obesity; NAFLD is a risk factor for cardiovascular disease
3. Hepatosteatosis is fatty liver; hepatosteatitis is fatty liver with inflammation. Nonalcoholic steatohepatitis (NASH) is the presence of $\geq 5\%$ hepatic fat with inflammation and hepatocyte injury with or without fibrosis
4. Up to 30% of patients with NAFLD may have NASH. After 20-year follow-up, the risk of cirrhosis with hepatosteatosis is $\sim 0 - 4\%$. After 9-year follow-up, the risk of cirrhosis with NASH = $\sim 25\%$
5. NAFLD is an important cause of end stage liver disease, hepatocellular carcinoma and by 2020, may be the leading indication for liver transplant
6. While some drugs are suggested to improve NAFLD, no drug has an approved indication to treat NAFLD
7. Simple screening for hepatosteatosis includes otherwise unexplained elevated alanine transaminase (ALT) [and often elevated aspartate transaminase (AST)] in patients with obesity or type 2 diabetes mellitus
8. Among the more reliable and safe imaging tests for fatty liver include transient elastography and magnetic resonance imaging proton density fat fraction (MRI-PDFF) or mMR spectroscopy (MRS)
9. Excessive alcohol consumption is a common cause of fatty liver and cirrhosis. Conversely, common causes of NAFLD include obesity, adiposopathy, type 2 diabetes mellitus, insulin resistance, and some medications
10. Management of NAFLD includes treatment of secondary causes, appropriate nutrition and physical activity, and possibly peroxisome proliferator activated receptor gamma agonists, and glucagon-like protein-1 receptor agonists.

Obesity and Cancer

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Obesity and cancer

1. Obesity is the second most common preventable cause of cancer, and may soon overtake cigarette smoking as the most common preventable cause of cancer
2. Among US adults, the proportion of cancers attributable to excess body weight is ~ 5% for men, and ~10% for women; an increase in body weight may be contributing to an increase in cancer among young adults
3. No drug has an indication to both treat obesity and prevent or treat cancer
4. Adiposopathic consequences of obesity that promote cancer include adipose tissue cytokine production (e.g., tumor necrosis factor, interleukin-6) which may damage cellular DNA, promote gene mutations, enhance angiogenesis, promote cell proliferation and contribute to mitochondrial and endoplasmic reticulum stress, increasing reactive oxygen species (ROS) which may further damage cellular DNA
5. Additional adiposopathic immune processes that promote cancer include cytokine production, which may promote endothelial dysfunction, extracellular matrix abnormalities, and intravasation (rate limiting step of metastasis)
6. Adiposopathic endocrine processes that promote cancer include increased cancer promoting hormones, such as estrogens, leptin, androgens in women, and the growth hormones of insulin and insulin growth factor-1
7. Adiposopathic hypoxia processes that may promote cancer include growth of adipocytes and adipose tissue beyond their vascular supply, increasing immune and angiogenic responses, accelerating the growth and progression of cancer
8. Obesity, adiposopathy, cigarette smoking, and physical inactivity may promote oxidative stress, which is the imbalance in the creation of unstable ROS relative to the body's ability to detoxify these radicals (i.e., "antioxidants")
9. Beyond an increase in fat alone, among foods that may increase the risk of cancer are processed meats and cooking meats at high temperature; among foods that may decrease the risk of cancer are whole foods rich in phytochemicals, fiber, and antioxidants (e.g., citrus fruits, cruciferous and green leafy vegetables, legumes, nuts, whole grains, and some coffees and teas)
10. Among patients with obesity, weight reduction, as well as appropriate nutrition and physical activity may help **398** prevent cancer, enhance chemotherapy for cancer, and reduce recurrent cancer

Obesity and Psychiatric Disease

Top 10 Takeaway Messages: Obesity and Psychiatric Disease

1. Obesity and mood disorders frequently occur together
2. The relationship between obesity and depression is bidirectional. Obesity is a risk factor for mood disorders; mood disorders are a risk factor for obesity.
3. The association between depression and obesity may be stronger among women
4. Obesity and psychiatric diseases may share pathogenic pathways involving the immune and endocrine system, hypothalamic and pituitary axis, and nervous system (e.g., autonomic nervous system, monoamines, synapses, neurogenesis, and neuroinflammation)
5. Psychiatric diseases can sometimes independently contribute to overnutrition and/or consumption of foods rich in carbohydrates and fats
6. Individuals have unique body weight responses to medications used to treat psychiatric disease
7. Study populations support some psychiatric medications may generally increase body weight, while others may promote body weight neutrality or weight loss
8. Weight loss in patients with obesity may improve mood in patients without clinical depression
9. Non-surgical, intentional weight loss in patients with obesity may reduce symptoms of depression
10. Bariatric surgery often improves mental health conditions (e.g., depression and binge eating disorders); however, bariatric surgery is sometimes associated with recurring or new psychiatric disorders, alcohol or substance abuse, or eating disorders

Obesity Myths

Obesity Myths

Common Obesity Myths

1. Obesity is not a disease; it is a lifestyle choice
2. An increase in body weight is always due to an increase in body fat
3. In patients with obesity, increased body fat is the cause of all their health conditions
4. Most people with increased body fat are generally healthy and will remain healthy
5. Increased subcutaneous adipose tissue is healthy; increased visceral adipose tissue is unhealthy
6. Obesity is due to eating too much versus obesity is not related to the caloric content of food
7. In the absence of a genetic or secondary medical cause, obesity is mostly due to a lack of willpower
8. Obesity is caused by eating processed foods
9. Obesity is caused by not eating breakfast versus caused by eating breakfast
10. Obesity is caused by a lack of breastfeeding as a child

Obesity Myths

Common Obesity Myths

11. Obesity is commonly caused by pathogens in the intestine (microbiome)
12. Lean people are “naturally skinny” because they have a higher metabolism
13. Low fat diets are the best way to lose body fat
14. Nutrition medical therapy is more effective when based upon patient preference
15. Increased physical exercise is the most efficient way to lose weight
16. Every pound of muscle that replaces fat burns an additional 50 calories per day
17. Access to exercise equipment, gym memberships, and physical activity trackers will cause weight loss
18. Setting more “realistic” obesity goals will ultimately achieve greater weight loss than more aggressive goals
19. Slow and gradual weight loss is ultimately more effective than large and rapid weight loss
20. Weight loss is difficult; maintaining weight loss is easy once the weight is lost
21. Drugs should not be used to treat obesity, because obesity is due to unhealthy diet and lack of exercise

Obesity Myth: Obesity is not a disease; it is a lifestyle choice

(See section entitled: The Disease of Obesity)

- The signs, symptoms, and pathophysiology of obesity fulfill the standard definition of a disease
- Obesity is often promoted by inheritance (genetic, epigenetic, and/or environmental inheritance)
- Obesity results in cellular and organ anatomic abnormalities
- Obesity results in cellular and organ functional abnormalities
- Obesity may result in pathogenic adipocyte and/or adipose tissue endocrine and immune dysfunctions that contribute to metabolic disease (adiposopathy or “sick fat disease”)
- Obesity may result in pathogenic physical forces from excessive body fat cause stress damage to other body tissues (“fat mass disease”)
- Even when exacerbated by unhealthful behavior, obesity is no less a disease than other diseases often promoted by unhealthful behavior

Investigational Anti-obesity Pharmacotherapy



Podcast:
Obesity: A Disease
Episode 3

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Top 10 Takeaway Messages: Anti-Obesity Drug Development

1. Targets of current anti-obesity drug development are mainly focused on intervention pathways related to the central nervous system, gastrointestinal systems, and adipose tissue
2. Glucagon-like peptide receptor agonists (GLP-1 RA) increase satiety and slow gastric emptying
3. Oxyntomodulin acting agents have dual GLP-1 RA and glucagon RA activity
4. Setmelanotide is a melanocortin-4 receptor agonist
5. GLP-1 RA are being combined with other agents to create twincretins and tri-agonists (e.g., glucagon, glucose-dependent insulinotropic peptide, peptide YY, and amylin)
6. Agents that brown adipocytes have the potential to increase energy expenditure
7. Tesofensine is a triple monoamine reuptake inhibitor (e.g., inhibits dopamine, serotonin, and noradrenaline)
8. Sodium-linked glucose transporters - 2 (SGLT-2) inhibition decreases proximal renal tubule glucose reabsorption; SGLT-1 inhibition decreases gastrointestinal glucose absorption
9. With the exception of anti-obesity agents that are a combination of drugs in a single tablet or capsule, limited data exists for combination anti-obesity drug therapy
10. The development of anti-obesity pharmacotherapy is following the path of drug development of other metabolic diseases

Early versus Late Weight- Management Intervention: Illustrative Consequences

Early Treatment/Prevention

44-year-old woman with overweight/obesity

- Pre-diabetes mellitus
- Pre-hypertension
- Mild dyslipidemia
- Discomfort to weight-bearing joints
- Mild snoring
- Low self-esteem due to increased body weight

Optimal Treatment Strategy

Decide to engage in early, proactive interventions intended to *prevent* onset of adverse health consequences from sick fat disease (diabetes mellitus, dyslipidemia, and hypertension) and fat mass disease (osteoarthritis):

- Optimize nutritional therapy and physical activity
- Initiate behavioral therapy
- Consider anti-obesity medications
- Consider bariatric surgery

Prevent onset of metabolic disease:

- Diabetes mellitus
- Dyslipidemia
- Hypertension

Prevent fat mass diseases:

- Osteoarthritis
- Sleep apnea
- Depression

Delayed Treatment

44-year-old woman with overweight/obesity

- Pre-diabetes mellitus
- Pre-hypertension
- Mild dyslipidemia
- Discomfort to weight-bearing joints
- Mild snoring
- Low self-esteem due to increased body weight

Sub-optimal Treatment Strategy

Simply tell the patient to diet and exercise and otherwise wait for the onset of diabetes mellitus, dyslipidemia, hypertension, osteoarthritis, sleep apnea, and depression. Once adverse health consequences are blatantly apparent:

- Optimize nutritional therapy and physical activity
- Initiate behavioral therapy
- Consider anti-obesity medications
- Consider bariatric surgery

Continued...

Delayed Treatment

If optimal intervention for obesity treatment and prevention is delayed, and the patient develops adverse consequences:

- Follow diabetes mellitus evaluation and treatment guidelines
 - American Diabetes Association Standards of Medical Care in Diabetes
 - American Association of Clinical Endocrinology Comprehensive Diabetes Management Algorithm
- Follow lipid evaluation and treatment recommendations and guidelines
 - AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCN Guideline on the Management of Blood Cholesterol
- Follow blood pressure guidelines
 - Report of the Joint National Committee for Management of High Blood Pressure in Adults
- Follow other disease-specific guidelines
- Utilize diabetes mellitus therapies most likely to improve adipose tissue function
- In patients with fat mass disease, utilize diabetes mellitus therapies having neutral or body weight loss effects, such as metformin, glucagon-like peptide-1 (GLP-1) agonists, sodium glucose cotransporter-2 (SGLT2) inhibitors
- Utilize lipid therapies most likely to reduce atherosclerotic coronary heart disease risk and least likely to increase body weight (e.g., statins)
- Utilize blood pressure therapy most likely to reduce cardiovascular disease risk, which may also provide other health benefits (e.g. diuretics, angiotensin converting enzyme inhibitors, etc.)
- Utilize non-steroidal anti-inflammatory agents to treat osteoarthritis
- Treat sleep apnea
- Utilize anti-depressant medications least likely to promote further weight gain
- Administer additional pharmaceuticals and/or treatment modalities as indicated

Bariatric Surgery

Physiology, Procedures, Micronutrients,
Microbiome, Complications

Top 10 Takeaway Messages: Gastrointestinal (GI) Hormones

1. GI hormones play a critical role in regulation of caloric balance, food digestion, and nutrient utilization via central nervous system signaling, effects on gastrointestinal motility, and enzyme release
2. Common GI hormone action in response to eating include decrease in hunger/appetite and facilitative digestion (delayed gastric emptying, digestive enzyme release, and post-absorptive nutrient metabolism)
3. The jejunum is the second longest segment of the small intestine, and absorbs the greatest amount of simple sugars, fatty acids, proteins, minerals and vitamins
4. The ileum is the longest segment of the small intestine, and absorbs bile salts, bile acids, vitamin B12, some vitamins and some minerals
5. After food intake, most GI hormones decrease appetite/increase satiety.
6. Among the few GI hormones that increase appetite between meals are ghrelin (“hunger hormone”) and neuropeptide Y; positive caloric balance may not always be hunger-related
7. Illustrative GI hormones produced by the stomach include ghrelin and gastrin
8. Illustrative hormones produced by the pancreas include insulin, glucagon, pancreatic polypeptide, amylin, and somatostatin
9. Illustrative GI hormones produced by the small intestine include cholecystikinin, secretin, motilin, and glucose-dependent insulinotropic peptide (GIP; also known as gastric inhibitory peptide)
10. Illustrative GI hormones produced by the ileum and/or large intestine include fibroblast growth factor 19, glucagon-like peptide-1, glucagon-like peptide-2, oxyntomodulin, and peptide YY

Top 10 Takeaway Messages: Bariatric Surgery

1. The two most common bariatric procedures are Roux-en-Y gastric bypass and vertical sleeve gastrectomy (often performed laparoscopically), which provide clinically meaningful improvement in metabolic diseases such as type 2 diabetes mellitus.
2. Gastric bypass involves connecting the jejunum to a proximal gastric pouch, with most of the stomach excised (“bypassed”); the distal duodenum is re-attached to a lower portion of the jejunum
3. Acute complications of gastric bypass include leaks or perforations potentially leading to peritonitis with severe abdominal pain, fever, tachycardia, and leukocytosis; imaging may include soluble contrast (abdominal CT or upper GI study); treatment is immediate surgical exploration.
4. Chronic complications of gastric bypass include gastro-gastric fistula, resulting in an increased capacity to ingest food and suboptimal weight loss or weight regain
5. Dumping syndrome is a complication of gastric bypass resulting in facial flushing, lightheadedness, reactive hypoglycemia, and postprandial diarrhea
6. Internal hernia can occur with gastric bypass, with intermittent postprandial pain and emesis
7. Sleeve gastrectomy involves removing a portion of the stomach, leaving less stomach area
8. Acute complications of sleeve gastrectomy include gastrointestinal obstruction and staple line leaks
9. Chronic complications of sleeve gastrectomy include sleeve dilation, gastrointestinal reflux disease and luminal stenosis/strictures
10. Acute complications that can accompany most any abdominal surgery include infection, cardiac dysrhythmias, atelectasis and pneumonia, deep vein thrombosis, and pulmonary emboli

Potential Bariatric Surgery Patient


Does clinical evidence exist that the increase in body fat is pathogenic?

Did the patient make reasonable attempts to reduce body weight and improve health?

Was the patient evaluated by a physician trained in comprehensive management of overweight and obesity (e.g., certified by the American Board of Obesity Medicine)?

Does the patient demonstrate a commitment to follow post-operative recommendations, maintain necessary lifestyle changes and agree to life-long post-operative medical surveillance?

What are the specific insurance criteria that need to be met (e.g., documentation of prior unsuccessful weight loss attempts)?



Bariatric Surgical Procedures

	Pros	Cons	Expected loss in percent excess body weight* at two years	Optimally suited for patients with:	Other comments
Roux-en-Y Gastric Bypass	Greater improvement in metabolic disease	Increased risk of malabsorptive complications over sleeve	60-75%	Higher BMI, GERD, Type 2 DM	Largest data set, more technically challenging than LAGB, VSG
Vertical Sleeve Gastrectomy	Improves metabolic disease; maintains small intestinal anatomy; micronutrient deficiencies infrequent	No long term data	50-70% (*3-year data)	Metabolic disease	Can be used as the first step of staged approach; most common based on 2014 data
Laparoscopic Adjustable Gastric Banding	Least invasive; removable	25-40% 5 year removal rate internationally	30-50%	Lower BMI; no metabolic disease	Any metabolic benefits achieved are <i>dependent</i> on weight loss
Biliopancreatic Diversion with Duodenal Switch	Greatest amount of weight loss and resolution of metabolic disease	Increased risk macro- and micronutrient deficiencies over bypass	70-80%	Higher BMI, Type 2 DM	Most technically challenging

*Excess body weight (EBW) = (total body weight) - (lean body weight)

Top 10 Takeaway Messages: Bariatric Surgery Nutrient Considerations

1. While biliopancreatic diversion with duodenal switch may result in the greatest amount of weight loss, it is a procedure that has a high rate of multiple post-procedure vitamin and mineral deficiencies.
2. Common vitamin and mineral deficiencies after gastric bypass and sleeve gastrectomy include deficiencies of vitamins B1 (thiamine), B9 (folate), B12 (cyanocobalamin), and D, as well as deficiencies of the minerals iron and calcium (gastric bypass); other vitamin and mineral deficiencies are more rarely reported
3. Lower levels of vitamin D are often found pre-operatively in patients with obesity
4. High-quality multivitamins are routinely recommended after bariatric procedures, with supplements often containing higher amounts of vitamin B12, iron, vitamin C (to assist with iron absorption), vitamin D, and calcium
5. Vitamin B1 (thiamine) deficiency can cause “dry” beriberi (e.g., Wernicke-Korsakoff encephalopathy) and “wet” beriberi (e.g., congestive heart failure)
6. Vitamin B9 (folate) deficiency can cause megaloblastic anemia
7. Vitamin B12 (cyanocobalamin) deficiency can cause megaloblastic anemia and nervous system disorders
8. Vitamin D deficiency can cause osteopenia, secondary hyperparathyroidism, and hypocalcemia
9. Calcium deficiency can cause osteopenia, secondary hyperparathyroidism, and hypocalcemia
10. Iron deficiency can cause microcytic anemia

Bariatric Surgery: Common Micronutrient Deficiencies

	Vitamins							Minerals		
	A	B1	B9	B12	D*	E	K	Ca	Fe	Zn/Cu
RNY		X	X	X	X			X	X	
Sleeve		X	X	X	X				X	
LAGB		X			X					
BPD	X	X	X	X	X	X	X	X	X	X

*Vitamin D deficiency is seen in a significant number of patients with obesity at baseline. However, due to malabsorption, the risk is further increased post-operatively.

Nutritional Principles Following Bariatric Surgery

- Nutritional advice will depend upon type of bariatric procedure
- Initially three to five small meals a day, with decrease in meal number as portion size increases
- Chew small bites of food thoroughly
- Avoid consuming liquids during meals, delay for at least 30 minutes after meals
- Protein: At least 60 grams/day, optimally 1.2 to 1.5 grams/kg/day of lean mass – avoid excessive calorie intake
- Avoid concentrated sweets to minimize dumping (i.e., procedures such as gastric bypass) and to reduce caloric intake
- High-quality multivitamins are routinely recommended after bariatric procedures, irrespective of deficiencies, which are often recommended to be chewable or liquid
- Other routine supplements often include:
 - Vitamin B12 500 µg/d tablet or sublingual, or 1000 µg/mo IM
 - Iron at least 27 mg of elemental iron daily, given with at least 500 mg vitamin C
 - Calcium citrate 1200 mg/d, preferably with vitamin D3

Top 10 Takeaway Messages: Microbiome

1. The microbiome is a collection of micro-organisms; microbiota are the organisms themselves
2. The human organism has ~10 trillion human cells; the human gut is colonized by ~100 trillion cells (bacteria, fungi, and viruses)
3. Among gut bacteria species, over 90% are anaerobic that utilize the substrate of sloughed intestinal cells, plant polysaccharides, starch cellulose, and bile components
4. The phyla Gram positive Firmicutes and gram negative Bacteroidetes make up about 90% of the bacteria in the large intestine; in obesity, Firmicutes is proportionally increased compared to Bacteroidetes
5. Some intestinal bacteria promote increased density of small intestinal villi capillaries and more efficient absorption of nutrients than other bacteria; gram positive Firmicutes may more efficiently extract calories from carbohydrates than Gram negative Bacteroidetes
6. Some intestinal bacteria may also facilitate central nervous system and other body organ signaling that may influence energy balance
7. Intestinal bacteria can also influence bile acid metabolism and gut hormone secretion, both of which can affect energy balance
8. Bariatric surgery may alter the microbiome, and reduce the efficiency of extracting calories from consumed carbohydrates
9. Individuals who are overweight or with obesity may not benefit from microbiota that promote more efficient absorption of nutrients
10. The effects of fecal transplant in humans with obesity differ compared to rodents, with some fecal microbiota transplantation to patients (humans) with obesity not leading to a reduction in body mass index, despite successful and sustained changes in the intestinal microbiome and bile acid profiles similar to the lean donor

Executive Summary

obesitymedicine.org


Obesity Algorithm®. © 2020 Obesity Medicine Association



Assess for the Presence of Obesity, Adiposopathy, Fat Mass Disease

Obesity may be assessed using several criteria (thresholds vary based on gender and ethnic differences):

Body Mass Index (BMI)	18.5-24.9 kg/m ²	25.0-29.9 kg/m ²	≥30 kg/m ²
Percent Body Fat	Male: <25% Female: <32%		Male: >25% Female: >32%
Waist Circumference	Male: <40 in. Female: <35 in.		Male: >40 in. Female: >35 in.
Edmonton Obesity Staging System	Stage 0, 1, 2, 3, 4		



Assess for the Presence of Obesity, Adiposopathy, Fat Mass Disease

Body Mass Index	BMI = (weight in kg)/(height in m) ² OR 703 x (weight in pounds)/(height in inches) ²
Percent Body Fat	Can be assessed by DXA scan, bioelectrical impedance, whole body air-displacement plethysmography, etc.
Waist Circumference	Can be measured by tape measure around the abdomen at the level of the anterior superior iliac crests, parallel to the floor. Tape should be snug against skin without compressing.
Edmonton Obesity Staging System	<p>STAGE 0: No apparent risk factors, no physical symptoms, functional limitations, and/or impairment of well-being</p> <p>STAGE 1: Presence of obesity-related subclinical risk factors, mild physical symptoms, mild psychopathology, mild functional limitations, and/or mild impairment of well-being</p> <p>STAGE 2: Presence of established obesity-related chronic disease, moderate psychopathology, moderate functional limitations, and/or impairment of well-being</p> <p>STAGE 3: Established end-organ damage, significant psychopathology, significant functional limitations, and/or impairment of well-being</p> <p>STAGE 4: Severe (potentially end-stage) disabilities from obesity-related chronic diseases, severe disabling psychopathology, severe functional limitations, and/or severe impairment of well-being</p>

Obesity medicine specialists, certified by the American Board of Obesity Medicine, dedicate a portion or all of their practice to the treatment of obesity. They perform a medical evaluation (history, physical, laboratory, body composition) and provide medical supervision for lifestyle change (nutrition, activity, behavior change), medications, or other nutritional interventions. Obesity is a chronic medical disease and often requires lifelong treatment.

Evaluation and Treatment Summary

Comprehensive Evaluation of the Patient with Overweight/Obesity

History	Weight history, past medical history, family history, social history, screening for weight-promoting medications, food intake, activity, review of systems
Physical Examination	Height, weight, blood pressure, body composition analysis, waist measurement, complete physical examination
Laboratory Tests*	Complete blood count, electrolytes, liver function, kidney function, fasting lipid profile, thyroid tests, hemoglobin A1c, uric acid, vitamin D
Diagnostic Testing*	EKG, echocardiogram, exercise stress test, sleep study, barium swallow or esophagoduodenoscopy

*lab and diagnostic testing should be individualized


Individualized Treatment Plans*

Nutrition	Use calorie restriction, carbohydrate restriction, food journaling, very low-calorie diet programs
Activity	Give exercise prescription, use pedometers, limit TV and computer time, decrease sedentary time, initial goal of 150 minutes per week of moderate-intensity physical activity
Counseling	Eliminate provider bias and stigma, identify self-sabotage, develop strong support, address stress management, sleep optimization, other psychological support as needed
Pharmacotherapy	Use pharmacotherapy as part of a comprehensive program
Referral	Consider referral to an obesity medicine specialist

*If ineffective, consider referral to a metabolic and bariatric surgeon. Optimal pre- and post-operative care includes an obesity medicine specialist.



Current Treatment Options for Obesity



*Potency includes many factors, such as the amount, rate, and sustainability of weight loss, and the long-term resolution of adiposopathy and fat mass disease. Potency varies greatly for each individual (i.e., long-term adherence to a lifestyle program can be as potent as gastric bypass surgery).

References

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Journal References: 1-10

Writing Process

1. Clinical Practice Guidelines We Can Trust 2011 <https://www.ncbi.nlm.nih.gov/pubmed/24983061>

Chronic Disease of Obesity

2. Kyle TK, Dhurandhar EJ, Allison DB: Regarding Obesity as a Disease: Evolving Policies and Their Implications. *Endocrinol Metab Clin North Am* 2016 45:511-520. <https://www.ncbi.nlm.nih.gov/pubmed/27519127>
3. Hurt RT, Edakkanambeth Varayil J, Mundi MS, et al.: Designation of obesity as a disease: lessons learned from alcohol and tobacco. *Curr Gastroenterol Rep* 2014 16:415. <https://www.ncbi.nlm.nih.gov/pubmed/25277042>
4. Kilov D, Kilov G: Philosophical determinants of obesity as a disease. *Obes Rev* 2018 19:41-48. <https://www.ncbi.nlm.nih.gov/pubmed/28960759>
5. Bray GA, Kim KK, Wilding JPH, et al.: Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev* 2017 18:715-723. <https://www.ncbi.nlm.nih.gov/pubmed/28489290>
6. Krishnaswami A, Ashok R, Sidney S, et al.: Real-World Effectiveness of a Medically Supervised Weight Management Program in a Large Integrated Health Care Delivery System: Five-Year Outcomes. *Perm J* 2018 22:17-082. <https://www.ncbi.nlm.nih.gov/pubmed/29401050>
7. Edwards BA, Bristow C, O'Driscoll DM, et al.: Assessing the impact of diet, exercise and the combination of the two as a treatment for OSA: A systematic review and meta-analysis. *Respirology* 2019 24:740-751. <https://www.ncbi.nlm.nih.gov/pubmed/31116901>
8. Danielsen KK, Svendsen M, Maehlum S, et al.: Changes in body composition, cardiovascular disease risk factors, and eating behavior after an intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. *J Obes* 2013 2013:325464. <https://www.ncbi.nlm.nih.gov/pubmed/23710347>
9. Ussery EN, Fulton JE, Galuska DA, et al.: Joint Prevalence of Sitting Time and Leisure-Time Physical Activity Among US Adults, 2015-2016. *JAMA* 2018 320:2036-2038. <https://www.ncbi.nlm.nih.gov/pubmed/30458482>
10. Dansinger ML, Williams PT, Superko HR, et al.: Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors. *Lipids Health Dis* 2019 18:154. <https://www.ncbi.nlm.nih.gov/pubmed/31311555>

Journal References: 11-18

Chronic Disease of Obesity (continued)

11. Ma C, Avenell A, Bolland M, et al.: Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. *BMJ* 2017 359:j4849. <https://www.ncbi.nlm.nih.gov/pubmed/29138133>
12. Fuller NR, Burns J, Sainsbury A, et al.: Examining the association between depression and obesity during a weight management programme. *Clin Obes* 2017 7:354-359. <https://www.ncbi.nlm.nih.gov/pubmed/28801940>
13. Reddy YNV, Anantha-Narayanan M, Obokata M, et al.: Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. *JACC Heart Fail* 2019 7:678-687. <https://www.ncbi.nlm.nih.gov/pubmed/31302042>
14. Colditz GA, Peterson LL: Obesity and Cancer: Evidence, Impact, and Future Directions. *Clin Chem* 2018 64:154-162. <https://www.ncbi.nlm.nih.gov/pubmed/29038151>
15. Fabricatore AN, Wadden TA, Higginbotham AJ, et al.: Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. *Int J Obes (Lond)* 2011 35:1363-1376. <https://www.ncbi.nlm.nih.gov/pubmed/21343903>
16. Dawes AJ, Maggard-Gibbons M, Maher AR, et al.: Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. *JAMA* 2016 315:150-163. <https://www.ncbi.nlm.nih.gov/pubmed/26757464>
17. Moran LJ, Brinkworth GD, Martin S, et al.: Long-Term Effects of a Randomised Controlled Trial Comparing High Protein or High Carbohydrate Weight Loss Diets on Testosterone, SHBG, Erectile and Urinary Function in Overweight and Obese Men. *PLoS One* 2016 11:e0161297. <https://www.ncbi.nlm.nih.gov/pubmed/27584019>
18. Green DD, Engel SG, Mitchell JE: Psychological aspects of bariatric surgery. *Curr Opin Psychiatry* 2014 27:448-452. <https://www.ncbi.nlm.nih.gov/pubmed/25247457>

Journal References: 19-28

Chronic Disease of Obesity (continued)

19. Cardoso L, Rodrigues D, Gomes L, et al.: Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis. *Diabetes Obes Metab* 2017 19:1223-1232. <https://www.ncbi.nlm.nih.gov/pubmed/28244626>
20. Song Z, Baicker K: Effect of a Workplace Wellness Program on Employee Health and Economic Outcomes: A Randomized Clinical Trial. *JAMA* 2019 321:1491-1501. <https://www.ncbi.nlm.nih.gov/pubmed/30990549>
21. Jakicic JM, Davis KK, Rogers RJ, et al.: Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial. *JAMA* 2016 316:1161-1171. <https://www.ncbi.nlm.nih.gov/pubmed/27654602>
22. Sniehotta FF, Evans EH, Sainsbury K, et al.: Behavioural intervention for weight loss maintenance versus standard weight advice in adults with obesity: A randomised controlled trial in the UK (NULevel Trial). *PLoS Med* 2019 16:e1002793. <https://www.ncbi.nlm.nih.gov/pubmed/31063507>
23. Brickwood KJ, Watson G, O'Brien J, et al.: Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. *JMIR Mhealth Uhealth* 2019 7:e11819. <https://www.ncbi.nlm.nih.gov/pubmed/30977740>
24. Chan R, Nguyen M, Smith R, et al.: Effect of Serial Anthropometric Measurements and Motivational Text Messages on Weight Reduction Among Workers: Pilot Randomized Controlled Trial. *JMIR Mhealth Uhealth* 2019 7:e11832. <https://www.ncbi.nlm.nih.gov/pubmed/31017585>
25. Kononova A, Li L, Kamp K, et al.: The Use of Wearable Activity Trackers Among Older Adults: Focus Group Study of Tracker Perceptions, Motivators, and Barriers in the Maintenance Stage of Behavior Change. *JMIR Mhealth Uhealth* 2019 7:e9832. <https://www.ncbi.nlm.nih.gov/pubmed/30950807>
26. Cheatham SW, Stull KR, Fantigrassi M, et al.: The efficacy of wearable activity tracking technology as part of a weight loss program: a systematic review. *J Sports Med Phys Fitness* 2018 58:534-548. <https://www.ncbi.nlm.nih.gov/pubmed/28488834>
27. Nakata Y, Sasai H, Tsujimoto T, et al.: Web-based intervention to promote weight-loss maintenance using an activity monitor: A randomized controlled trial. *Prev Med Rep* 2019 14:100839. <https://www.ncbi.nlm.nih.gov/pubmed/3090668>
28. Jastreboff AM, Kotz CM, Kahan S, et al.: Obesity as a Disease: The Obesity Society 2018 Position Statement. *Obesity (Silver Spring)* 2019 27:7-9. <https://www.ncbi.nlm.nih.gov/pubmed/30569641>

Journal References: 29-37

Chronic Disease of Obesity (continued)

29. Bays H: Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. *Curr Atheroscler Rep* 2014 16:409. <https://www.ncbi.nlm.nih.gov/pubmed/24659222>
30. Hales CM, Carroll MD, Fryar CD, et al.: Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief* 2017 1-8. <https://www.ncbi.nlm.nih.gov/pubmed/29155689>
31. Fryar CD, Kruszon-Moran D, Gu Q, et al.: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999–2000 Through 2015–2016. *National Health Statistics Reports* 2018 Number 122:1 - 16.
32. Araujo J, Cai J, Stevens J: Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. *Metab Syndr Relat Disord* 2019 17:46-52. <https://www.ncbi.nlm.nih.gov/pubmed/30484738>
33. Gurka MJ, Filipp SL, DeBoer MD: Geographical variation in the prevalence of obesity, metabolic syndrome, and diabetes among US adults. *Nutr Diabetes* 2018 8:14. <https://www.ncbi.nlm.nih.gov/pubmed/29549249>
34. Ward ZJ, Bleich SN, Cradock AL, et al.: Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med* 2019 381:2440-2450. <https://www.ncbi.nlm.nih.gov/pubmed/31851800>
35. Puhl R, Peterson JL, Luedicke J: Motivating or stigmatizing? Public perceptions of weight-related language used by health providers. *Int J Obes (Lond)* 2013 37:612-619. <https://www.ncbi.nlm.nih.gov/pubmed/22777543>
36. Ravussin E, Ryan D: Response to "The need for people-first language in our Obesity journal". *Obesity (Silver Spring)* 2015 23:918. <https://www.ncbi.nlm.nih.gov/pubmed/25919920>
37. National Institute of Diabetes and Digestive and Kidney Diseases. Health Information: Talking with patients about weight loss. <https://www.niddk.nih.gov/health-information/health-topics/weight-control/medical/Pages/medical-care-for-patients-with-obesity.aspx> (Accessed August 20, 2016).

Journal References: 38-47

Chronic Disease of Obesity (continued)

38. American Society of Metabolic and Bariatric Surgeons Standards Manual version 2.0. Resources for Optimal Care of the Metabolic and Bariatric Surgery Patient 2016
<https://www.facs.org/~media/files/quality%20programs/bariatric/mbsaqip%20standardsmanual.ashx> (Accessed September 10, 2016).
39. Kushner RF, Kahan S: Introduction: The State of Obesity in 2017. Med Clin North Am 2018 102:1-11.
<https://www.ncbi.nlm.nih.gov/pubmed/29156178>
40. Bays H, Scinta W: Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease. Curr Med Res Opin 2015 31:2059-2069. <https://www.ncbi.nlm.nih.gov/pubmed/26331354>

Genetics

41. Chung WK: An overview of monogenic and syndromic obesities in humans. Pediatr Blood Cancer 2012 58:122-128.
<https://www.ncbi.nlm.nih.gov/pubmed/21994130>
42. Herbst KL: Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin 2012 33:155-172.
<https://www.ncbi.nlm.nih.gov/pubmed/22301856>
43. National Organization for Rare Disorders (NORD). Familial Partial Lipodystrophy
<https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/> Accessed December 3, 2017.
44. Melvin A, Adams C, Flanagan C, et al.: Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. J Clin Endocrinol Metab 2017 102:3616-3620. <https://www.ncbi.nlm.nih.gov/pubmed/28973478>
45. Metreleptin (MYALEPT®) Prescribing Information
http://www.myaleptpro.com/sites/default/files/myalept_pi_sept2015_final.pdf (Accessed November 26, 2018).
46. Youngson NA, Morris MJ: What obesity research tells us about epigenetic mechanisms. Philos Trans R Soc Lond B Biol Sci 2013 368:20110337. <https://www.ncbi.nlm.nih.gov/pubmed/23166398>
47. Curley JP, Mashoodh R, Champagne FA: Epigenetics and the origins of paternal effects. Horm Behav 2011 59:306-314.
<https://www.ncbi.nlm.nih.gov/pubmed/20620140>

Journal References: 48-56

Genetics (continued)

48. Heslehurst N, Vieira R, Akhter Z, et al.: The association between maternal body mass index and child obesity: A systematic review and meta-analysis. PLoS Med 2019 16:e1002817. <https://www.ncbi.nlm.nih.gov/pubmed/31185012>
49. Ling C, Ronn T: Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab 2019 29:1028-1044. <https://www.ncbi.nlm.nih.gov/pubmed/30982733>
50. Soubry A, Schildkraut JM, Murtha A, et al.: Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort. BMC Med 2013 11:29. <https://www.ncbi.nlm.nih.gov/pubmed/23388414>
51. Fruhbeck G, Busetto L, Dicker D, et al.: The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts 2019 12:131-136. <https://www.ncbi.nlm.nih.gov/pubmed/30844811>
52. Bays HE: Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011 57:2461-2473. <https://www.ncbi.nlm.nih.gov/pubmed/21679848>
53. Bays HE: "Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009 122:S26-37. <https://www.ncbi.nlm.nih.gov/pubmed/19110085>
54. Bays HE: Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol 2012 110:4B-12B. <https://www.ncbi.nlm.nih.gov/pubmed/23062567>
55. Salvestrini V, Sell C, Lorenzini A: Obesity May Accelerate the Aging Process. Front Endocrinol (Lausanne) 2019 10:266. <https://www.ncbi.nlm.nih.gov/pubmed/31130916>

Additional references used: [29][40]

Obesity Classification

56. De Lorenzo A, Soldati L, Sarlo F, et al.: New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol 2016 22:681-703. <https://www.ncbi.nlm.nih.gov/pubmed/26811617>

Journal References: 57-67

Obesity Classification (continued)

57. Rahman M, Berenson AB: Accuracy of current body mass index obesity classification for white, black, and Hispanic reproductive-age women. *Obstet Gynecol* 2010 115:982-988. <https://www.ncbi.nlm.nih.gov/pubmed/20410772>
58. Misra A, Shrivastava U: Obesity and dyslipidemia in South Asians. *Nutrients* 2013 5:2708-2733. <https://www.ncbi.nlm.nih.gov/pubmed/23863826>
59. Banack HR, Wactawski-Wende J, Hovey KM, et al.: Is BMI a valid measure of obesity in postmenopausal women? *Menopause* 2017 <https://www.ncbi.nlm.nih.gov/pubmed/29135897>
60. Hsu WC, Araneta MR, Kanaya AM, et al.: BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. *Diabetes Care* 2015 38:150-158. <https://www.ncbi.nlm.nih.gov/pubmed/25538311>
61. American Council on Exercise: What are the guidelines for percentage of body fat loss? <http://www.acefitness.org/acefit/healthy-living-article/60/112/what-are-the-guidelines-for-percentage-of-body-fat> (Accessed August 20, 2016). 2009
62. Calculator.net Army Fat Calculator <https://www.calculator.net/army-body-fat-calculator.html> (Accessed November 26, 2018).
63. Grundy SM, Stone NJ, Bailey AL, et al.: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30423393>
64. Bays H: Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. *Curr Opin Endocrinol Diabetes Obes* 2014 21:345-351. <https://www.ncbi.nlm.nih.gov/pubmed/25106000>
65. Carroll JF, Chiapa AL, Rodriquez M, et al.: Visceral fat, waist circumference, and BMI: impact of race/ethnicity. *Obesity (Silver Spring)* 2008 16:600-607. <https://www.ncbi.nlm.nih.gov/pubmed/18239557>
66. Wang Z, Ma J, Si D: Optimal cut-off values and population means of waist circumference in different populations. *Nutr Res Rev* 2010 23:191-199. <https://www.ncbi.nlm.nih.gov/pubmed/20642876>
67. ICD10Data.com. Overweight and Obesity. <http://www.icd10data.com/ICD10CM/Codes/E00-E89/E65-E68/E66-/E66> (Accessed August 20, 2016).

Journal References: 68-77

Obesity Classification (continued)

68. Chen GC, Arthur R, Iyengar NM, et al.: Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J 2019
<https://www.ncbi.nlm.nih.gov/pubmed/31256194>
69. Deurenberg P, Weststrate JA, Seidell JC: Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991 65:105-114. <https://www.ncbi.nlm.nih.gov/pubmed/2043597>
70. Sun Q, van Dam RM, Spiegelman D, et al.: Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am J Epidemiol 2010 172:1442-1454.
<https://www.ncbi.nlm.nih.gov/pubmed/20952596>
71. Li C, Ford ES, Zhao G, et al.: Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr 2009 90:1457-1465. <https://www.ncbi.nlm.nih.gov/pubmed/19812179>
72. Imboden MT, Welch WA, Swartz AM, et al.: Reference standards for body fat measures using GE dual energy x-ray absorptiometry in Caucasian adults. PLoS One 2017 12:e0175110. <https://www.ncbi.nlm.nih.gov/pubmed/28388669>
73. Stults-Kolehmainen MA, Stanforth PR, Bartholomew JB, et al.: DXA estimates of fat in abdominal, trunk and hip regions varies by ethnicity in men. Nutr Diabetes 2013 3:e64. <https://www.ncbi.nlm.nih.gov/pubmed/23507968>
74. Grundy SM, Neeland IJ, Turer AT, et al.: Waist circumference as measure of abdominal fat compartments. J Obes 2013 2013:454285.
75. Camhi SM, Bray GA, Bouchard C, et al.: The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring) 2011 19:402-408.

Fat Mass Disease

76. Kushner RF, Blatner DJ: Risk assessment of the overweight and obese patient. J Am Diet Assoc 2005 105:S53-62.
<https://www.ncbi.nlm.nih.gov/pubmed/15867897>
77. Kushner RF, Roth JL: Assessment of the obese patient. Endocrinol Metab Clin North Am 2003 32:915-933.
<https://www.ncbi.nlm.nih.gov/pubmed/14711068>

Journal References: 78-88

Fatty Mass Disease (continued)

78. Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. *Obes Res* 2004 12:1197-1211. <https://www.ncbi.nlm.nih.gov/pubmed/15340100>
79. Dekkers IA, Jansen PR, Lamb HJ: Obesity, Brain Volume, and White Matter Microstructure at MRI: A Cross-sectional UK Biobank Study. *Radiology* 2019 292:270. <https://www.ncbi.nlm.nih.gov/pubmed/31219759>
80. Pearl RL, Wadden TA, Hopkins CM, et al.: Association between weight bias internalization and metabolic syndrome among treatment-seeking individuals with obesity. *Obesity (Silver Spring)* 2017 25:317-322. <https://www.ncbi.nlm.nih.gov/pubmed/28124502>
81. Obesity Action Coalition. Weight Bias Guides. <https://www.obesityaction.org/action-through-advocacy/weight-bias/weight-bias-guides/> (Accessed January 5, 2019).
82. Phelan SM, Burgess DJ, Yeazel MW, et al.: Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. *Obes Rev* 2015 16:319-326.
83. Shamsuzzaman AS, Gersh BJ, Somers VK: Obstructive sleep apnea: implications for cardiac and vascular disease. *JAMA* 2003 290:1906-1914. <https://www.ncbi.nlm.nih.gov/pubmed/14532320>
84. Gileles-Hillel A, Kheirandish-Gozal L, Gozal D: Biological plausibility linking sleep apnoea and metabolic dysfunction. *Nat Rev Endocrinol* 2016 12:290-298. <https://www.ncbi.nlm.nih.gov/pubmed/26939978>
85. Nagappa M, Liao P, Wong J, et al.: Validation of the STOP-Bang Questionnaire as a Screening Tool for Obstructive Sleep Apnea among Different Populations: A Systematic Review and Meta-Analysis. *PLoS One* 2015 10:e0143697. <https://www.ncbi.nlm.nih.gov/pubmed/26658438>
86. Broussard JL, Van Cauter E: Disturbances of sleep and circadian rhythms: novel risk factors for obesity. *Curr Opin Endocrinol Diabetes Obes* 2016 23:353-359. <https://www.ncbi.nlm.nih.gov/pubmed/27584008>
87. Poggiogalle E, Jamshed H, Peterson CM: Circadian regulation of glucose, lipid, and energy metabolism in humans. *Metabolism* 2018 84:11-27. <https://www.ncbi.nlm.nih.gov/pubmed/29195759>
88. Tan X, Chapman CD, Cedernaes J, et al.: Association between long sleep duration and increased risk of obesity and type 2 diabetes: A review of possible mechanisms. *Sleep Med Rev* 2018 40:127-134. <https://www.ncbi.nlm.nih.gov/pubmed/29233612>

Journal References: 89-98

Fatty Mass Disease (continued)

89. Nedeltcheva AV, Kilkus JM, Imperial J, et al.: Insufficient sleep undermines dietary efforts to reduce adiposity. *Ann Intern Med* 2010 153:435-441. <https://www.ncbi.nlm.nih.gov/pubmed/20921542>
90. Weaver TE, Calik MW, Farabi SS, et al.: Innovative treatments for adults with obstructive sleep apnea. *Nat Sci Sleep* 2014 6:137-147. <https://www.ncbi.nlm.nih.gov/pubmed/25429246>
91. Awad M, Gouveia C, Zaghi S, et al.: Changing practice: Trends in skeletal surgery for obstructive sleep apnea. *J Craniomaxillofac Surg* 2019 47:1185-1189. <https://www.ncbi.nlm.nih.gov/pubmed/31182256>

Adiposopathy (Sick Fat Disease)

92. Bays HE, Jones PH, Jacobson TA, et al.: Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. *J Clin Lipidol* 2016 10:33-57. <https://www.ncbi.nlm.nih.gov/pubmed/26892120>
93. Kloting N, Bluher M: Adipocyte dysfunction, inflammation and metabolic syndrome. *Rev Endocr Metab Disord* 2014 15:277-287. <https://www.ncbi.nlm.nih.gov/pubmed/25344447>
94. Bluher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. *Best Pract Res Clin Endocrinol Metab* 2013 27:163-177. <https://www.ncbi.nlm.nih.gov/pubmed/23731879>
95. Bays HE, Gonzalez-Campoy JM, Henry RR, et al.: Is adiposopathy (sick fat) an endocrine disease? *Int J Clin Pract* 2008 62:1474-1483. <https://www.ncbi.nlm.nih.gov/pubmed/18681905>
96. Bays HE, Gonzalez-Campoy JM, Bray GA, et al.: Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. *Expert Rev Cardiovasc Ther* 2008 6:343-368. <https://www.ncbi.nlm.nih.gov/pubmed/18327995>
97. Russo L, Lumeng CN: Properties and functions of adipose tissue macrophages in obesity. *Immunology* 2018 155:407-417. <https://www.ncbi.nlm.nih.gov/pubmed/30229891>
98. Chylikova J, Dvorackova J, Tauber Z, et al.: M1/M2 macrophage polarization in human obese adipose tissue. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2018 162:79-82. <https://www.ncbi.nlm.nih.gov/pubmed/29765169>

Journal References: 99-109

Adiposopathy (Sick Fat Disease) - continued

99. Pirola L, Ferraz JC: Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem 2017 8:120-128. <https://www.ncbi.nlm.nih.gov/pubmed/28588755>
100. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A: Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics 2019 15:93. <https://www.ncbi.nlm.nih.gov/pubmed/31197497>
101. Hamer M, Batty GD: Association of body mass index and waist-to-hip ratio with brain structure: UK Biobank study. Neurology 2019 <https://www.ncbi.nlm.nih.gov/pubmed/30626649>
102. Bliddal H, Leeds AR, Christensen R: Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev 2014 15:578-586. <https://www.ncbi.nlm.nih.gov/pubmed/24751192>
103. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab 2004 89:2583-2589. <https://www.ncbi.nlm.nih.gov/pubmed/15181027>
104. Fauser BC, Tarlatzis BC, Rebar RW, et al.: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 97:28-38 e25. <https://www.ncbi.nlm.nih.gov/pubmed/22153789>
105. Lim SS, Norman RJ, Davies MJ, et al.: The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2013 14:95-109. <https://www.ncbi.nlm.nih.gov/pubmed/23114091>
106. Bays HE, Gonzalez-Campoy JM, Schorr AB: What men should know about metabolic syndrome, adiposopathy and 'sick fat'. Int J Clin Pract 2010 64:1735-1739. <https://www.ncbi.nlm.nih.gov/pubmed/21070523>
107. Shin D, Song WO: Prepregnancy body mass index is an independent risk factor for gestational hypertension, gestational diabetes, preterm labor, and small- and large-for-gestational-age infants. J Matern Fetal Neonatal Med 2015 28:1679-1686. <https://www.ncbi.nlm.nih.gov/pubmed/25211384>
108. Rocha AL, Oliveira FR, Azevedo RC, et al.: Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res 2019 8:<https://www.ncbi.nlm.nih.gov/pubmed/31069057>
109. Bozdogan G, Mumusoglu S, Zengin D, et al.: The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016 31:2841-2855. <https://www.ncbi.nlm.nih.gov/pubmed/27664216>

Journal References: 110-121

Adiposopathy (Sick Fat Disease) - continued

110. Bednarska S, Siejka A: The pathogenesis and treatment of polycystic ovary syndrome: What's new? *Adv Clin Exp Med* 2017 26:359-367. <https://www.ncbi.nlm.nih.gov/pubmed/28791858>
111. Mehta J, Kamdar V, Dumesic D: Phenotypic expression of polycystic ovary syndrome in South Asian women. *Obstet Gynecol Surv* 2013 68:228-234. <https://www.ncbi.nlm.nih.gov/pubmed/23945839>
112. Rojas J, Chavez M, Olivar L, et al.: Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. *Int J Reprod Med* 2014 2014:719050. <https://www.ncbi.nlm.nih.gov/pubmed/25763405>
113. Berrino F, Bellati C, Secreto G, et al.: Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. *Cancer Epidemiol Biomarkers Prev* 2001 10:25-33. <https://www.ncbi.nlm.nih.gov/pubmed/11205485>
114. Chetrite GS, Feve B: Preface to special issue on: Adiposopathy in Cancer and (Cardio)Metabolic Diseases: an Endocrine Approach - Part 4. *Horm Mol Biol Clin Invest* 2015 23:1-4. <https://www.ncbi.nlm.nih.gov/pubmed/26353175>
115. Booth A, Magnuson A, Fouts J, et al.: Adipose tissue, obesity and adipokines: role in cancer promotion. *Horm Mol Biol Clin Invest* 2015 21:57-74. <https://www.ncbi.nlm.nih.gov/pubmed/25781552>
116. Hursting SD, Dunlap SM: Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. *Ann N Y Acad Sci* 2012 1271:82-87. <https://www.ncbi.nlm.nih.gov/pubmed/23050968>
117. Whiteman DC, Wilson LF: The fractions of cancer attributable to modifiable factors: A global review. *Cancer Epidemiol* 2016 44:203-221. <https://www.ncbi.nlm.nih.gov/pubmed/27460784>
118. Lauby-Secretan B, Scoccianti C, Loomis D, et al.: Body Fatness and Cancer--Viewpoint of the IARC Working Group. *N Engl J Med* 2016 375:794-798. <https://www.ncbi.nlm.nih.gov/pubmed/27557308>
119. Steele CB, Thomas CC, Henley SJ, et al.: Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014. *MMWR Morb Mortal Wkly Rep* 2017 66:1052-1058. <https://www.ncbi.nlm.nih.gov/pubmed/28981482>
120. Subak LL, Richter HE, Hunskaar S: Obesity and urinary incontinence: epidemiology and clinical research update. *J Urol* 2009 182:S2-7. <https://www.ncbi.nlm.nih.gov/pubmed/19846133>
121. Kudish BI, Iglesia CB, Sokol RJ, et al.: Effect of weight change on natural history of pelvic organ prolapse. *Obstet Gynecol* 2009 113:81-88. <https://www.ncbi.nlm.nih.gov/pubmed/19104363>

Journal References: 122-131

Adiposopathy (Sick Fat Disease) - continued

122. American College of Obstetricians and Gynecologists. Obesity and Pregnancy. Frequently asked Questions. <https://www.acog.org/-/media/For-Patients/faq182.pdf> (Accessed September 10, 2016).
123. American College of Obstetricians Gynecologists: ACOG Committee opinion no. 549: obesity in pregnancy. *Obstet Gynecol* 2013 121:213-217. <https://www.ncbi.nlm.nih.gov/pubmed/23262963>
124. Pasquali R, Patton L, Gambineri A: Obesity and infertility. *Curr Opin Endocrinol Diabetes Obes* 2007 14:482-487. <https://www.ncbi.nlm.nih.gov/pubmed/17982356>
125. Yu Z, Han S, Zhu J, et al.: Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity: a systematic review and meta-analysis. *PLoS One* 2013 8:e61627. <https://www.ncbi.nlm.nih.gov/pubmed/23613888>

Additional references used: [29]

Obesity Paradox

126. Smith KB, Smith MS: Obesity Statistics. *Prim Care* 2016 43:121-135, ix. <https://www.ncbi.nlm.nih.gov/pubmed/26896205>
127. Akin I, Nienaber CA: "Obesity paradox" in coronary artery disease. *World J Cardiol* 2015 7:603-608. <https://www.ncbi.nlm.nih.gov/pubmed/26516414>
128. Yu E, Ley SH, Manson JE, et al.: Weight History and All-Cause and Cause-Specific Mortality in Three Prospective Cohort Studies. *Ann Intern Med* 2017 166:613-620.
129. Caleyachetty R, Thomas GN, Toulis KA, et al.: Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. *J Am Coll Cardiol* 2017 70:1429-1437. <https://www.ncbi.nlm.nih.gov/pubmed/28911506>
130. Chang VW, Langa KM, Weir D, et al.: The obesity paradox and incident cardiovascular disease: A population-based study. *PLoS One* 2017 12:e0188636. <https://www.ncbi.nlm.nih.gov/pubmed/29216243>
131. Bhaskaran K, Dos-Santos-Silva I, Leon DA, et al.: Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. *Lancet Diabetes Endocrinol* 2018 6:944-953. <https://www.ncbi.nlm.nih.gov/pubmed/30389323>

Journal References: 132-141

Obesity Paradox (continued)

132. Khan SS, Ning H, Wilkins JT, et al.: Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. *JAMA Cardiol* 2018 3:280-287. <https://www.ncbi.nlm.nih.gov/pubmed/29490333>
133. Wade KH, Carslake D, Sattar N, et al.: BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. *Obesity (Silver Spring)* 2018 26:1796-1806. <https://www.ncbi.nlm.nih.gov/pubmed/30358150>
134. Iliodromiti S, Celis-Morales CA, Lyall DM, et al.: The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent. *Eur Heart J* 2018 39:1514-1520.
135. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al.: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet* 2016 388:776-786. <https://www.ncbi.nlm.nih.gov/pubmed/27423262>
136. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al.: Body-mass index and mortality among 1.46 million white adults. *N Engl J Med* 2010 363:2211-2219. <https://www.ncbi.nlm.nih.gov/pubmed/21121834>
137. von Haehling S, Lainscak M, Springer J, et al.: Cardiac cachexia: a systematic overview. *Pharmacol Ther* 2009 121:227-252. <https://www.ncbi.nlm.nih.gov/pubmed/19061914>
138. Lavie CJ, De Schutter A, Parto P, et al.: Obesity and Prevalence of Cardiovascular Diseases and Prognosis-The Obesity Paradox Updated. *Prog Cardiovasc Dis* 2016 58:537-547. <https://www.ncbi.nlm.nih.gov/pubmed/26826295>
139. Nouws J, Fitch M, Mata M, et al.: Altered In Vivo Lipid Fluxes and Cell Dynamics in Subcutaneous Adipose Tissues Are Associated With the Unfavorable Pattern of Fat Distribution in Obese Adolescent Girls. *Diabetes* 2019 68:1168-1177. <https://www.ncbi.nlm.nih.gov/pubmed/30936147>
140. Jung CH, Lee WJ, Song KH: Metabolically healthy obesity: a friend or foe? *Korean J Intern Med* 2017 32:611-621. <https://www.ncbi.nlm.nih.gov/pubmed/28602062>
141. Mongraw-Chaffin M, Foster MC, Kalyani RR, et al.: Obesity Severity and Duration Are Associated With Incident Metabolic Syndrome: Evidence Against Metabolically Healthy Obesity From the Multi-Ethnic Study of Atherosclerosis. *J Clin Endocrinol Metab* 2016 101:4117-4124. <https://www.ncbi.nlm.nih.gov/pubmed/27552544>

Journal References: 142-151

Obesity Paradox (continued)

142. Lavie CJ, Laddu D, Arena R, et al.: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018 72:1506-1531. <https://www.ncbi.nlm.nih.gov/pubmed/30236314>
143. Guo F, Garvey WT: Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring) 2016 24:516-525. <https://www.ncbi.nlm.nih.gov/pubmed/26719125>
144. Kuk JL, Rotondi M, Sui X, et al.: Individuals with obesity but no other metabolic risk factors are not at significantly elevated all-cause mortality risk in men and women. Clin Obes 2018 8:305-312. <https://www.ncbi.nlm.nih.gov/pubmed/29998631>
145. Schulze MB: Metabolic health in normal-weight and obese individuals. Diabetologia 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30569272>
146. Gavrilova O, Marcus-Samuels B, Graham D, et al.: Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000 105:271-278. <https://www.ncbi.nlm.nih.gov/pubmed/10675352>
147. Yu XY, Song P, Zou MH: Obesity Paradox and Smoking Gun: A Mystery of Statistical Confounding? Circ Res 2018 122:1642-1644. <https://www.ncbi.nlm.nih.gov/pubmed/29880498>
148. Steele L, Lloyd A, Fotheringham J, et al.: A retrospective cross-sectional study on the association between tobacco smoking and incidence of ST-segment elevation myocardial infarction and cardiovascular risk factors. Postgrad Med J 2015 91:492-496. <https://www.ncbi.nlm.nih.gov/pubmed/26265789>
149. Rallidis LS, Triantafyllis AS, Tsirebolos G, et al.: Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. Atherosclerosis 2016 249:17-21. <https://www.ncbi.nlm.nih.gov/pubmed/27062405>
150. Lavie CJ, Milani RV, Ventura HO: Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009 53:1925-1932. <https://www.ncbi.nlm.nih.gov/pubmed/19460605>
151. Oesch L, Tatlisumak T, Arnold M, et al.: Obesity paradox in stroke - Myth or reality? A systematic review. PLoS One 2017 12:e0171334. <https://www.ncbi.nlm.nih.gov/pubmed/28291782>

Journal References: 152-160

Obesity Paradox (continued)

152. Zhi G, Xin W, Ying W, et al.: "Obesity Paradox" in Acute Respiratory Distress Syndrome: Asystematic Review and Meta-Analysis. PLoS One 2016 11:e0163677. <https://www.ncbi.nlm.nih.gov/pubmed/27684705>
153. Park J, Ahmadi SF, Streja E, et al.: Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014 56:415-425. <https://www.ncbi.nlm.nih.gov/pubmed/24438733>
154. Panwar B, Hanks LJ, Tanner RM, et al.: Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int 2015 87:1216-1222. <https://www.ncbi.nlm.nih.gov/pubmed/25517912>
155. Stenvinkel P, Gillespie IA, Tunks J, et al.: Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. J Am Soc Nephrol 2016 27:1479-1486. <https://www.ncbi.nlm.nih.gov/pubmed/26567245>
156. Niederdeppe J, Roh S, Shapiro MA: Acknowledging individual responsibility while emphasizing social determinants in narratives to promote obesity-reducing public policy: a randomized experiment. PLoS One 2015 10:e0117565. <https://www.ncbi.nlm.nih.gov/pubmed/25706743>

Additional references used: [29][35][52][81][82]

Stress and Obesity

157. Harrell CS, Gillespie CF, Neigh GN: Energetic stress: The reciprocal relationship between energy availability and the stress response. Physiol Behav 2016 166:43-55. <https://www.ncbi.nlm.nih.gov/pubmed/26454211>
158. Yau YH, Potenza MN: Stress and eating behaviors. Minerva Endocrinol 2013 38:255-267. <https://www.ncbi.nlm.nih.gov/pubmed/24126546>
159. Thaler JP, Guyenet SJ, Dorfman MD, et al.: Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes 2013 62:2629-2634. <https://www.ncbi.nlm.nih.gov/pubmed/23881189>
160. Moore CJ, Cunningham SA: Social position, psychological stress, and obesity: a systematic review. J Acad Nutr Diet 2012 112:518-526. <https://www.ncbi.nlm.nih.gov/pubmed/22709702>

Journal References: 161-172

Stress and Obesity (continued)

161. Ouakinin SRS, Barreira DP, Gois CJ: Depression and Obesity: Integrating the Role of Stress, Neuroendocrine Dysfunction and Inflammatory Pathways. *Front Endocrinol (Lausanne)* 2018 9:431. <https://www.ncbi.nlm.nih.gov/pubmed/30108549>
162. Jackson SE, Kirschbaum C, Steptoe A: Hair cortisol and adiposity in a population-based sample of 2,527 men and women aged 54 to 87 years. *Obesity (Silver Spring)* 2017 25:539-544. <https://www.ncbi.nlm.nih.gov/pubmed/28229550>
163. Geer EB, Lalazar Y, Couto LM, et al.: A prospective study of appetite and food craving in 30 patients with Cushing's disease. *Pituitary* 2016 19:117-126. <https://www.ncbi.nlm.nih.gov/pubmed/26496766>
164. Mason AE, Schleicher S, Coccia M, et al.: Chronic Stress and Impulsive Risk-Taking Predict Increases in Visceral Fat over 18 Months. *Obesity (Silver Spring)* 2018 26:869-876. <https://www.ncbi.nlm.nih.gov/pubmed/29566458>
165. Tomiyama AJ: Stress and Obesity. *Annu Rev Psychol* 2019 70:703-718. <https://www.ncbi.nlm.nih.gov/pubmed/29927688>
166. Al-Safi ZA, Polotsky A, Chosich J, et al.: Evidence for disruption of normal circadian cortisol rhythm in women with obesity. *Gynecol Endocrinol* 2018 34:336-340. <https://www.ncbi.nlm.nih.gov/pubmed/29068243>
167. Capuron L, Lasselien J, Castanon N: Role of Adiposity-Driven Inflammation in Depressive Morbidity. *Neuropsychopharmacology* 2017 42:115-128. <https://www.ncbi.nlm.nih.gov/pubmed/27402495>
168. Nishitani N, Sakakibara H: Association of psychological stress response of fatigue with white blood cell count in male daytime workers. *Ind Health* 2014 52:531-534. <https://www.ncbi.nlm.nih.gov/pubmed/24975105>
169. McGregor BA, Murphy KM, Albano DL, et al.: Stress, cortisol, and B lymphocytes: a novel approach to understanding academic stress and immune function. *Stress* 2016 19:185-191. <https://www.ncbi.nlm.nih.gov/pubmed/26644211>
170. Incollingo Rodriguez AC, Epel ES, White ML, et al.: Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: A systematic review. *Psychoneuroendocrinology* 2015 62:301-318. <https://www.ncbi.nlm.nih.gov/pubmed/26356039>
171. Heatherton TF, Wagner DD: Cognitive neuroscience of self-regulation failure. *Trends Cogn Sci* 2011 15:132-139. <https://www.ncbi.nlm.nih.gov/pubmed/21273114>
172. Baumeister RF, Bratslavsky E, Muraven M, et al.: Ego depletion: is the active self a limited resource? *J Pers Soc Psychol* 1998 74:1252-1265. <https://www.ncbi.nlm.nih.gov/pubmed/9599441>

Journal References: 173-179

Assessment and Evaluation

173. Nesbitt S, Palomarez RE: Review: Increasing Awareness and Education on Health Disparities for Health Care Providers. Ethn Dis 2016 26:181-190. <https://www.ncbi.nlm.nih.gov/pubmed/27103768>

Patient Evaluation

174. Rusin M, Arsand E, Hartvigsen G: Functionalities and input methods for recording food intake: a systematic review. Int J Med Inform 2013 82:653-664. <https://www.ncbi.nlm.nih.gov/pubmed/23415822>

175. Jaworowska A, Blackham T, Davies IG, et al.: Nutritional challenges and health implications of takeaway and fast food. Nutr Rev 2013 71:310-318. <https://www.ncbi.nlm.nih.gov/pubmed/23590707>

176. Beechy L, Galpern J, Petrone A, et al.: Assessment tools in obesity - psychological measures, diet, activity, and body composition. Physiol Behav 2012 107:154-171. <https://www.ncbi.nlm.nih.gov/pubmed/22548766>

177. Horn DB, O'Neill JR, Pfeiffer KA, et al.: Predictors of physical activity in the transition after high school among young women. J Phys Act Health 2008 5:275-285. <https://www.ncbi.nlm.nih.gov/pubmed/18382036>

178. Vanhees L, De Sutter J, Gelada SN, et al.: Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012 19:670-686. <https://www.ncbi.nlm.nih.gov/pubmed/22637742>

179. Vanhees L, Geladas N, Hansen D, et al.: Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012 19:1005-1033. <https://www.ncbi.nlm.nih.gov/pubmed/22637741>

Additional references used: [37]

Journal References: 180-190

Physical Exam and Laboratory and Diagnostic Testing

180. Steelman GM, Westman EC: Obesity: Evaluation and Treatment Essentials. New York: Informa Healthcare 2010
181. Bays HE, Toth PP, Kris-Etherton PM, et al.: Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol 2013 7:304-383. <https://www.ncbi.nlm.nih.gov/pubmed/23890517>
182. O'Connor MY, Thoreson CK, Ramsey NL, et al.: The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature. Prog Cardiovasc Dis 2013 56:261-269. <https://www.ncbi.nlm.nih.gov/pubmed/24267433>
183. Kim JJ, Choi YM: Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci 2013 56:137-142. <https://www.ncbi.nlm.nih.gov/pubmed/24327994>
184. Corona G, Rastrelli G, Monami M, et al.: Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013 168:829-843. <https://www.ncbi.nlm.nih.gov/pubmed/23482592>
185. Hochberg I, Hochberg Z: Expanding the definition of hypothalamic obesity. Obes Rev 2010 11:709-721. <https://www.ncbi.nlm.nih.gov/pubmed/20233310>
186. Lim SP, Arasaratnam P, Chow BJ, et al.: Obesity and the challenges of noninvasive imaging for the detection of coronary artery disease. Can J Cardiol 2015 31:223-226. <https://www.ncbi.nlm.nih.gov/pubmed/25661558>
187. Garcia-Labbe D, Ruka E, Bertrand OF, et al.: Obesity and coronary artery disease: evaluation and treatment. Can J Cardiol 2015 31:184-194. <https://www.ncbi.nlm.nih.gov/pubmed/25661553>
188. Ginde SR, Geliebter A, Rubiano F, et al.: Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005 13:1232-1237. <https://www.ncbi.nlm.nih.gov/pubmed/16076993>
189. Beam JR, Szymanski DJ: Validity of 2 skinfold calipers in estimating percent body fat of college-aged men and women. J Strength Cond Res 2010 24:3448-3456. <https://www.ncbi.nlm.nih.gov/pubmed/20040894>
190. Muller MJ, Bosy-Westphal A, Lagerpusch M, et al.: Use of balance methods for assessment of short-term changes in body composition. Obesity (Silver Spring) 2012 20:701-707. <https://www.ncbi.nlm.nih.gov/pubmed/21869755>

Journal References: 191-200

Physical Exam and Laboratory and Diagnostic Testing (continued)

191. Kendler DL, Borges JL, Fielding RA, et al.: The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition. J Clin Densitom 2013 16:496-507. <https://www.ncbi.nlm.nih.gov/pubmed/24090645>
192. Goni L, Cuervo M, Milagro FI, et al.: Future Perspectives of Personalized Weight Loss Interventions Based on Nutrigenetic, Epigenetic, and Metagenomic Data. J Nutr 2016 <https://www.ncbi.nlm.nih.gov/pubmed/26962191>
193. Allison KC, Grilo CM, Masheb RM, et al.: High self-reported rates of neglect and emotional abuse, by persons with binge eating disorder and night eating syndrome. Behav Res Ther 2007 45:2874-2883. <https://www.ncbi.nlm.nih.gov/pubmed/17659255>
194. St-Onge MP: The role of sleep duration in the regulation of energy balance: effects on energy intakes and expenditure. J Clin Sleep Med 2013 9:73-80. <https://www.ncbi.nlm.nih.gov/pubmed/23319909>
195. Pearce EN: Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012 19:408-413. <https://www.ncbi.nlm.nih.gov/pubmed/22931855>
196. Pearce EN: Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012 97:326-333. <https://www.ncbi.nlm.nih.gov/pubmed/22205712>

Body Composition

197. Dulloo AG, Jacquet J, Solinas G, et al.: Body composition phenotypes in pathways to obesity and the metabolic syndrome. Int J Obes (Lond) 2010 34 Suppl 2:S4-17. <https://www.ncbi.nlm.nih.gov/pubmed/21151146>
198. Heymsfield SB, Ebbeling CB, Zheng J, et al.: Multi-component molecular-level body composition reference methods: evolving concepts and future directions. Obes Rev 2015 16:282-294. <https://www.ncbi.nlm.nih.gov/pubmed/25645009>
199. Kendall KL, Fukuda DH, Hyde PN, et al.: Estimating fat-free mass in elite-level male rowers: a four-compartment model validation of laboratory and field methods. J Sports Sci 2017 35:624-633. <https://www.ncbi.nlm.nih.gov/pubmed/27159216>
200. Muller MJ, Braun W, Pourhassan M, et al.: Application of standards and models in body composition analysis. Proc Nutr Soc 2016 75:181-187. <https://www.ncbi.nlm.nih.gov/pubmed/26541411>

Journal References: 201-209

Body Composition (continued)

201. Harvard School of Public Health. Measuring Obesity: From Calipers to CAT Scans, Ten Ways to Tell Whether a Body Is Fat or Lean <https://www.hsph.harvard.edu/obesity-prevention-source/obesity-definition/how-to-measure-body-fatness/> (Accessed August 20, 2016).
202. Williams CA, Bale P: Bias and limits of agreement between hydrodensitometry, bioelectrical impedance and skinfold calipers measures of percentage body fat. Eur J Appl Physiol Occup Physiol 1998 77:271-277. <https://www.ncbi.nlm.nih.gov/pubmed/9535589>
203. Clarys JP, Provyn S, Marfell-Jones MJ: Cadaver studies and their impact on the understanding of human adiposity. Ergonomics 2005 48:1445-1461. <https://www.ncbi.nlm.nih.gov/pubmed/16338712>
204. Choi YJ: Dual-Energy X-Ray Absorptiometry: Beyond Bone Mineral Density Determination. Endocrinol Metab (Seoul) 2016 31:25-30. <https://www.ncbi.nlm.nih.gov/pubmed/26996419>
205. Marra M, Sammarco R, De Lorenzo A, et al.: Assessment of Body Composition in Health and Disease Using Bioelectrical Impedance Analysis (BIA) and Dual Energy X-Ray Absorptiometry (DXA): A Critical Overview. Contrast Media Mol Imaging 2019 2019:3548284. <https://www.ncbi.nlm.nih.gov/pubmed/31275083>
206. Miazgowski T, Kucharski R, Soltysiak M, et al.: Visceral fat reference values derived from healthy European men and women aged 20-30 years using GE Healthcare dual-energy x-ray absorptiometry. PLoS One 2017 12:e0180614. <https://www.ncbi.nlm.nih.gov/pubmed/28683146>
207. Sasai H, Brychta RJ, Wood RP, et al.: Does Visceral Fat Estimated by Dual-Energy X-ray Absorptiometry Independently Predict Cardiometabolic Risks in Adults? J Diabetes Sci Technol 2015 9:917-924. <https://www.ncbi.nlm.nih.gov/pubmed/25802470>
208. Sran MM, Khan KM, Keiver K, et al.: Accuracy of DXA scanning of the thoracic spine: cadaveric studies comparing BMC, areal BMD and geometric estimates of volumetric BMD against ash weight and CT measures of bone volume. Eur Spine J 2005 14:971-976. <https://www.ncbi.nlm.nih.gov/pubmed/15616862>
209. Chirachariyavej T, Limburanasombat S, Tiensuwan M: The relationship between bone and ash weight to body weight and body length of Thai corpses in Bangkok and central part of Thailand after cremation. J Med Assoc Thai 2007 90:1872-1878. <https://www.ncbi.nlm.nih.gov/pubmed/17957933>

Journal References: 210-220

Body Composition (continued)

210. Achamrah N, Colange G, Delay J, et al.: Comparison of body composition assessment by DXA and BIA according to the body mass index: A retrospective study on 3655 measures. PLoS One 2018 13:e0200465. <https://www.ncbi.nlm.nih.gov/pubmed/30001381>
211. Santos DA, Dawson JA, Matias CN, et al.: Reference values for body composition and anthropometric measurements in athletes. PLoS One 2014 9:e97846. <https://www.ncbi.nlm.nih.gov/pubmed/24830292>
212. Chiodini I, Bolland MJ: Calcium supplementation in osteoporosis: useful or harmful? Eur J Endocrinol 2018 178:D13-D25. <https://www.ncbi.nlm.nih.gov/pubmed/29440373>
213. Tai V, Leung W, Grey A, et al.: Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ 2015 351:h4183. <https://www.ncbi.nlm.nih.gov/pubmed/26420598>
214. Hunter GR, Plaisance EP, Fisher G: Weight loss and bone mineral density. Curr Opin Endocrinol Diabetes Obes 2014 21:358-362. <https://www.ncbi.nlm.nih.gov/pubmed/25105997>
215. Warner SE, Shaw JM, Dalsky GP: Bone mineral density of competitive male mountain and road cyclists. Bone 2002 30:281-286. <https://www.ncbi.nlm.nih.gov/pubmed/11792598>
216. Hinton PS, Nigh P, Thyfault J: Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial. Bone 2015 79:203-212. <https://www.ncbi.nlm.nih.gov/pubmed/26092649>
217. Abrahin O, Rodrigues RP, Marcal AC, et al.: Swimming and cycling do not cause positive effects on bone mineral density: a systematic review. Rev Bras Reumatol Engl Ed 2016 56:345-351. <https://www.ncbi.nlm.nih.gov/pubmed/27476628>
218. Dengel DR, Bosch TA, Burruss TP, et al.: Body composition and bone mineral density of national football league players. J Strength Cond Res 2014 28:1-6. <https://www.ncbi.nlm.nih.gov/pubmed/24149760>
219. O'Connor DP, Bray MS, McFarlin BK, et al.: Generalized equations for estimating DXA percent fat of diverse young women and men: the TIGER study. Med Sci Sports Exerc 2010 42:1959-1965. <https://www.ncbi.nlm.nih.gov/pubmed/20305578>
220. Bosch TA, Burruss TP, Weir NL, et al.: Abdominal body composition differences in NFL football players. J Strength Cond Res 2014 28:3313-3319. <https://www.ncbi.nlm.nih.gov/pubmed/25187247>

Journal References: 221-230

Body Composition (continued)

221. Silva DR, Ribeiro AS, Pavao FH, et al.: Validity of the methods to assess body fat in children and adolescents using multi-compartment models as the reference method: a systematic review. Rev Assoc Med Bras (1992) 2013 59:475-486. <https://www.ncbi.nlm.nih.gov/pubmed/24119380>
222. Fields DA, Hunter GR, Goran MI: Validation of the BOD POD with hydrostatic weighing: influence of body clothing. Int J Obes Relat Metab Disord 2000 24:200-205. <https://www.ncbi.nlm.nih.gov/pubmed/10702771>
223. Smith S, Madden AM: Body composition and functional assessment of nutritional status in adults: a narrative review of imaging, impedance, strength and functional techniques. J Hum Nutr Diet 2016 29:714-732. <https://www.ncbi.nlm.nih.gov/pubmed/27137882>
224. Rotella CM, Dicembrini I: Measurement of body composition as a surrogate evaluation of energy balance in obese patients. World J Methodol 2015 5:1-9. <https://www.ncbi.nlm.nih.gov/pubmed/25825693>
225. Bosty-Westphal A, Jensen B, Braun W, et al.: Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. Eur J Clin Nutr 2017 71:1061-1067. <https://www.ncbi.nlm.nih.gov/pubmed/28327564>
226. Day K, Kwok A, Evans A, et al.: Comparison of a Bioelectrical Impedance Device against the Reference Method Dual Energy X-Ray Absorptiometry and Anthropometry for the Evaluation of Body Composition in Adults. Nutrients 2018 10: <https://www.ncbi.nlm.nih.gov/pubmed/30308974>
227. Lee K, Lee S, Kim YJ, et al.: Waist circumference, dual-energy X-ray absorptiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition 2008 24:625-631. <https://www.ncbi.nlm.nih.gov/pubmed/18485667>
228. Alvero-Cruz JR, Garcia-Romero JC, Carrillo de Albornoz-Gil M, et al.: Longitudinal validity of abdominal adiposity assessment by regional bioelectrical impedance. Eur J Clin Nutr 2018 72:1055-1057.
229. Long V, Short M, Smith S, et al.: Testing Bioimpedance to Estimate Body Fat Percentage across Different Hip and Waist Circumferences. J Sports Med (Hindawi Publ Corp) 2019 2019:7624253. <https://www.ncbi.nlm.nih.gov/pubmed/31281848>
230. Lu HK, Chen YY, Yeh C, et al.: Discrepancies between leg-to-leg bioelectrical Impedance analysis and computerized tomography in abdominal visceral fat measurement. Sci Rep 2017 7:9102. <https://www.ncbi.nlm.nih.gov/pubmed/28831095>

Journal References: 231-239

Body Composition (continued)

231. Becroft L, Ooi G, Forsyth A, et al.: Validity of multi-frequency bioelectric impedance methods to measure body composition in obese patients: a systematic review. *Int J Obes (Lond)* 2019 43:1497-1507. <https://www.ncbi.nlm.nih.gov/pubmed/30568268>
232. International Atomic Energy Agency. IAEA Human Health Series No. 12 Introduction To Body Composition Assessment Using The Deuterium Dilution Technique With Analysis Of Saliva Samples By Fourier Transform Infrared Spectrometry (2010) http://www-pub.iaea.org/MTCD/publications/PDF/Pub1450_web.pdf (Accessed August 20, 2016).
233. Heymsfield SB, Adamek M, Gonzalez MC, et al.: Assessing skeletal muscle mass: historical overview and state of the art. *J Cachexia Sarcopenia Muscle* 2014 5:9-18. <https://www.ncbi.nlm.nih.gov/pubmed/24532493>
234. Seabolt LA, Welch EB, Silver HJ: Imaging methods for analyzing body composition in human obesity and cardiometabolic disease. *Ann N Y Acad Sci* 2015 1353:41-59. <https://www.ncbi.nlm.nih.gov/pubmed/26250623>
235. Fosbol MO, Zerahn B: Contemporary methods of body composition measurement. *Clin Physiol Funct Imaging* 2015 35:81-97. <https://www.ncbi.nlm.nih.gov/pubmed/24735332>

Additional references used: [59][72][188][190]

Energy Expenditure

236. Hargrove JL: Does the history of food energy units suggest a solution to "Calorie confusion"? *Nutr J* 2007 6:44. <https://www.ncbi.nlm.nih.gov/pubmed/18086303>
237. Ruggiero C, Ferrucci L: The endeavor of high maintenance homeostasis: resting metabolic rate and the legacy of longevity. *J Gerontol A Biol Sci Med Sci* 2006 61:466-471. <https://www.ncbi.nlm.nih.gov/pubmed/16720742>
238. Konarzewski M, Ksiazek A: Determinants of intra-specific variation in basal metabolic rate. *J Comp Physiol B* 2013 183:27-41. <https://www.ncbi.nlm.nih.gov/pubmed/22847501>
239. Anthanont P, Jensen MD: Does basal metabolic rate predict weight gain? *Am J Clin Nutr* 2016 104:959-963. <https://www.ncbi.nlm.nih.gov/pubmed/27581474>

Journal References: 240-251

Energy Expenditure (continued)

240. Johannsen DL, Marlatt KL, Conley KE, et al.: Metabolic adaptation is not observed after 8 weeks of overfeeding but energy expenditure variability is associated with weight recovery. *Am J Clin Nutr* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31204775>
241. Pettersen AK, Marshall DJ, White CR: Understanding variation in metabolic rate. *J Exp Biol* 2018 221: <https://www.ncbi.nlm.nih.gov/pubmed/29326115>
242. Donahoo WT, Levine JA, Melanson EL: Variability in energy expenditure and its components. *Curr Opin Clin Nutr Metab Care* 2004 7:599-605. <https://www.ncbi.nlm.nih.gov/pubmed/15534426>
243. Barr SB, Wright JC: Postprandial energy expenditure in whole-food and processed-food meals: implications for daily energy expenditure. *Food Nutr Res* 2010 54: <https://www.ncbi.nlm.nih.gov/pubmed/20613890>
244. Chung N, Park MY, Kim J, et al.: Non-exercise activity thermogenesis (NEAT): a component of total daily energy expenditure. *J Exerc Nutrition Biochem* 2018 22:23-30.
245. Barclay CJ: The basis of differences in thermodynamic efficiency among skeletal muscles. *Clin Exp Pharmacol Physiol* 2017 44:1279-1286. <https://www.ncbi.nlm.nih.gov/pubmed/28892557>
246. Rosenbaum M, Heaner M, Goldsmith RL, et al.: Resistance Training Reduces Skeletal Muscle Work Efficiency in Weight-Reduced and Non-Weight-Reduced Subjects. *Obesity (Silver Spring)* 2018 26:1576-1583. <https://www.ncbi.nlm.nih.gov/pubmed/30260099>
247. Hamasaki H, Yanai H, Mishima S, et al.: Correlations of non-exercise activity thermogenesis to metabolic parameters in Japanese patients with type 2 diabetes. *Diabetol Metab Syndr* 2013 5:26. <https://www.ncbi.nlm.nih.gov/pubmed/23711224>
248. Alessio N, Squillaro T, Monda V, et al.: Circulating factors present in the sera of naturally skinny people may influence cell commitment and adipocyte differentiation of mesenchymal stromal cells. *World J Stem Cells* 2019 11:180-195. <https://www.ncbi.nlm.nih.gov/pubmed/30949296>
249. Howell S, Kones R: "Calories in, calories out" and macronutrient intake: the hope, hype, and science of calories. *Am J Physiol Endocrinol Metab* 2017 313:E608-E612. <https://www.ncbi.nlm.nih.gov/pubmed/28765272>
250. Hall KD: What is the required energy deficit per unit weight loss? *Int J Obes (Lond)* 2008 32:573-576. <https://www.ncbi.nlm.nih.gov/pubmed/17848938>
251. Hajna S, Ross NA, Dasgupta K: Steps, moderate-to-vigorous physical activity, and cardiometabolic profiles. *Prev Med* 2017 <https://www.ncbi.nlm.nih.gov/pubmed/29126915>

Journal References: 252-263

Energy Expenditure (continued)

252. Piercy KL, Troiano RP, Ballard RM, et al.: The Physical Activity Guidelines for Americans. *Jama* 2018 320:2020-2028.
253. Flatt JP: Differences in basal energy expenditure and obesity. *Obesity (Silver Spring)* 2007 15:2546-2548.
<https://www.ncbi.nlm.nih.gov/pubmed/18070743>
254. Pourhassan M, Bosity-Westphal A, Schautz B, et al.: Impact of body composition during weight change on resting energy expenditure and homeostasis model assessment index in overweight nonsmoking adults. *Am J Clin Nutr* 2014 99:779-791.
<https://www.ncbi.nlm.nih.gov/pubmed/24500156>
255. Gallagher D, Belmonte D, Deurenberg P, et al.: Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. *Am J Physiol* 1998 275:E249-258. <https://www.ncbi.nlm.nih.gov/pubmed/9688626>
256. Wang Z, Ying Z, Bosity-Westphal A, et al.: Evaluation of specific metabolic rates of major organs and tissues: comparison between men and women. *Am J Hum Biol* 2011 23:333-338. <https://www.ncbi.nlm.nih.gov/pubmed/21484913>
257. Jequier E, Acheson K, Schutz Y: Assessment of energy expenditure and fuel utilization in man. *Annu Rev Nutr* 1987 7:187-208.
<https://www.ncbi.nlm.nih.gov/pubmed/3300732>
258. Psota T, Chen KY: Measuring energy expenditure in clinical populations: rewards and challenges. *Eur J Clin Nutr* 2013 67:436-442.
<https://www.ncbi.nlm.nih.gov/pubmed/23443826>
259. Sabounchi NS, Rahmandad H, Ammerman A: Best-fitting prediction equations for basal metabolic rate: informing obesity interventions in diverse populations. *Int J Obes (Lond)* 2013 37:1364-1370. <https://www.ncbi.nlm.nih.gov/pubmed/23318720>
260. Even PC, Nadkarni NA: Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. *Am J Physiol Regul Integr Comp Physiol* 2012 303:R459-476. <https://www.ncbi.nlm.nih.gov/pubmed/22718809>
261. Ellis AC, Hyatt TC, Hunter GR, et al.: Respiratory quotient predicts fat mass gain in premenopausal women. *Obesity (Silver Spring)* 2010 18:2255-2259. <https://www.ncbi.nlm.nih.gov/pubmed/20448540>
262. Park J, Kazuko IT, Kim E, et al.: Estimating free-living human energy expenditure: Practical aspects of the doubly labeled water method and its applications. *Nutr Res Pract* 2014 8:241-248. <https://www.ncbi.nlm.nih.gov/pubmed/24944767>
263. Byham-Gray L, Parrott JS, Ho WY, et al.: Development of a predictive energy equation for maintenance hemodialysis patients: a pilot study. *J Ren Nutr* 2014 24:32-41. <https://www.ncbi.nlm.nih.gov/pubmed/24355819>

Journal References: 264-272

Energy Expenditure (continued)

264. Evenson KR, Goto MM, Furberg RD: Systematic review of the validity and reliability of consumer-wearable activity trackers. *Int J Behav Nutr Phys Act* 2015 12:159. <https://www.ncbi.nlm.nih.gov/pubmed/26684758>
265. Hall KD, Guo J: Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition. *Gastroenterology* 2017 152:1718-1727 e1713. <https://www.ncbi.nlm.nih.gov/pubmed/28193517>
266. Zheng J, Zheng S, Feng Q, et al.: Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. *Biosci Rep* 2017 37: <https://www.ncbi.nlm.nih.gov/pubmed/28424369>
267. Demine S, Renard P, Arnould T: Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases. *Cells* 2019 8: <https://www.ncbi.nlm.nih.gov/pubmed/31366145>
268. Busiello RA, Savarese S, Lombardi A: Mitochondrial uncoupling proteins and energy metabolism. *Front Physiol* 2015 6:36. <https://www.ncbi.nlm.nih.gov/pubmed/25713540>
269. Flouris AD, Dinas PC, Valente A, et al.: Exercise-induced effects on UCP1 expression in classical brown adipose tissue: a systematic review. *Horm Mol Biol Clin Investig* 2017 31: <https://www.ncbi.nlm.nih.gov/pubmed/28085671>

Additional references used: [167][224]

Concomitant Medications

270. Pillinger T, McCutcheon RA, Vano L, et al.: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020 7:64-77. <https://www.ncbi.nlm.nih.gov/pubmed/31860457>
271. Uguz F, Sahingoz M, Gungor B, et al.: Weight gain and associated factors in patients using newer antidepressant drugs. *Gen Hosp Psychiatry* 2015 37:46-48. <https://www.ncbi.nlm.nih.gov/pubmed/25467076>
272. Valle-Cabrera R, Mendoza-Rodriguez Y, Robaina-Garcia M, et al.: Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial. *J Clin Psychopharmacol* 2018 38:454-459. <https://www.ncbi.nlm.nih.gov/pubmed/30106883>

Journal References: 273-283

Concomitant Medications (continued)

273. Rachdi C, Damak R, Fekih Romdhane F, et al.: Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. *Prim Care Diabetes* 2019 13:57-62. <https://www.ncbi.nlm.nih.gov/pubmed/30287230>
274. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al.: Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. *Schizophr Res* 2008 99:13-22. <https://www.ncbi.nlm.nih.gov/pubmed/18053689>
275. Alonso-Pedrero L, Bes-Rastrollo M, Marti A: Effects of antidepressant and antipsychotic use on weight gain: A systematic review. *Obes Rev* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31524318>
276. Tardy M, Huhn M, Kissling W, et al.: Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev* 2014 CD009268. <https://www.ncbi.nlm.nih.gov/pubmed/25007358>
277. Tek C, Kucukgoncu S, Guloksuz S, et al.: Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. *Early Interv Psychiatry* 2016 10:193-202. <https://www.ncbi.nlm.nih.gov/pubmed/25962699>
278. Leucht S, Cipriani A, Spineli L, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013 382:951-962. <https://www.ncbi.nlm.nih.gov/pubmed/23810019>
279. Apovian CM, Aronne LJ, Bessesen DH, et al.: Pharmacological management of obesity: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2015 100:342-362. <https://www.ncbi.nlm.nih.gov/pubmed/25590212>
280. Bays H: From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. *Curr Med Res Opin* 2009 25:671-681. <https://www.ncbi.nlm.nih.gov/pubmed/19232040>
281. Domecq JP, Prutsky G, Leppin A, et al.: Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2015 100:363-370. <https://www.ncbi.nlm.nih.gov/pubmed/25590213>
282. DiNicolantonio JJ, Fares H, Niazi AK, et al.: beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart* 2015 2:e000230. <https://www.ncbi.nlm.nih.gov/pubmed/25821584>
283. DeFronzo RA, Buse JB, Kim T, et al.: Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. *Diabetologia* 2016 59:1645-1654. <https://www.ncbi.nlm.nih.gov/pubmed/27216492>

Journal References: 284-294

Concomitant Medications (continued)

284. Mahmood K, Naeem M, Rahimnajjad NA: Metformin: the hidden chronicles of a magic drug. *Eur J Intern Med* 2013 24:20-26. <https://www.ncbi.nlm.nih.gov/pubmed/23177353>
285. Johnson NP: Metformin use in women with polycystic ovary syndrome. *Ann Transl Med* 2014 2:56. <https://www.ncbi.nlm.nih.gov/pubmed/25333031>
286. Anisimov VN: Do metformin a real anticarcinogen? A critical reappraisal of experimental data. *Ann Transl Med* 2014 2:60. <https://www.ncbi.nlm.nih.gov/pubmed/25333035>
287. Scinta W, Bayes H, Smith N: Insulin Resistance and Hunger in Childhood Obesity: A Patient and Physician's Perspective. *Adv Ther* 2017 34:2386-2391. <https://www.ncbi.nlm.nih.gov/pubmed/2888444>
288. Apolzan JW, Venditti EM, Edelstein SL, et al.: Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. *Ann Intern Med* 2019 170:682-690. <https://www.ncbi.nlm.nih.gov/pubmed/3100993>
289. Astrup A, Caterson I, Zelissen P, et al.: Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. *Obes Res* 2004 12:1658-1669. <https://www.ncbi.nlm.nih.gov/pubmed/15536230>
290. Ikeda H, Yonemochi N, Ardianto C, et al.: Pregabalin increases food intake through dopaminergic systems in the hypothalamus. *Brain Res* 2018 1701:219-226. <https://www.ncbi.nlm.nih.gov/pubmed/30244110>
291. Bostwick JM: A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. *Mayo Clin Proc* 2010 85:538-550. <https://www.ncbi.nlm.nih.gov/pubmed/20431115>
292. Hasnain M, Vieweg WV: Weight considerations in psychotropic drug prescribing and switching. *Postgrad Med* 2013 125:117-129. <https://www.ncbi.nlm.nih.gov/pubmed/24113670>
293. Hasnain M, Vieweg WV, Hollett B: Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. *Postgrad Med* 2012 124:154-167. <https://www.ncbi.nlm.nih.gov/pubmed/22913904>
294. Baldwin DS, Chrones L, Florea I, et al.: The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. *J Psychopharmacol* 2016 30:242-252. <https://www.ncbi.nlm.nih.gov/pubmed/26864543>

Journal References: 295-303

Concomitant Medications (continued)

295. Newcomer JW, Eriksson H, Zhang P, et al.: Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. *Curr Med Res Opin* 2018 34:2197-2205. <https://www.ncbi.nlm.nih.gov/pubmed/29985680>
296. Parikh NB, Robinson DM, Clayton AH: Clinical role of brexpiprazole in depression and schizophrenia. *Ther Clin Risk Manag* 2017 13:299-306. <https://www.ncbi.nlm.nih.gov/pubmed/28331332>
297. Cutler AJ, Durgam S, Wang Y, et al.: Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. *CNS Spectr* 2018 23:39-50. <https://www.ncbi.nlm.nih.gov/pubmed/28478771>
298. McKnight RF, Adida M, Budge K, et al.: Lithium toxicity profile: a systematic review and meta-analysis. *Lancet* 2012 379:721-728. <https://www.ncbi.nlm.nih.gov/pubmed/22265699>
299. Bak M, Fransen A, Janssen J, et al.: Almost all antipsychotics result in weight gain: a meta-analysis. *PLoS One* 2014 9:e94112. <https://www.ncbi.nlm.nih.gov/pubmed/24763306>
300. Smith ME, Lee JS, Bonham A, et al.: Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery. *Surg Endosc* 2018
301. Christinat A, Di Lascio S, Pagani O: Hormonal therapies in young breast cancer patients: when, what and for how long? *J Thorac Dis* 2013 5 Suppl 1:S36-46. <https://www.ncbi.nlm.nih.gov/pubmed/23819026>
302. Lake JE, Currier JS: Switching antiretroviral therapy to minimize metabolic complications. *HIV Ther* 2010 4:693-711. <https://www.ncbi.nlm.nih.gov/pubmed/22171239>
303. Ighani A, Georgakopoulos JR, Zhou LL, et al.: Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. *J Cutan Med Surg* 2018 22:290-296. <https://www.ncbi.nlm.nih.gov/pubmed/29373924>

Additional references used: [54][78][161]

Journal References: 304-313

Nutrition

304. Eslami O, Shidfar F, Dehnad A: Inverse association of long-term nut consumption with weight gain and risk of overweight/obesity: a systematic review. *Nutr Res* 2019 68:1-8. <https://www.ncbi.nlm.nih.gov/pubmed/31151081>
305. U.S. Department of Agriculture. <https://fnic.nal.usda.gov/how-many-calories-are-one-gram-fat-carbohydrate-or-protein>. Food and Nutrition Information Center (Accessed August 20, 2016).
306. Sacks FM, Lichtenstein AH, Wu JHY, et al.: Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. *Circulation* 2017 136:e1-e23. <https://www.ncbi.nlm.nih.gov/pubmed/28620111>
307. Gepner Y, Shelef I, Schwarzfuchs D, et al.: Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. *Circulation* 2018 137:1143-1157. <https://www.ncbi.nlm.nih.gov/pubmed/29142011>
308. Hyde PN, Sapper TN, Crabtree CD, et al.: Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. *JCI Insight* 2019 4: <https://www.ncbi.nlm.nih.gov/pubmed/31217353>
309. Hernandez-Alonso P, Camacho-Barcia L, Bullo M, et al.: Nuts and Dried Fruits: An Update of Their Beneficial Effects on Type 2 Diabetes. *Nutrients* 2017 9: <https://www.ncbi.nlm.nih.gov/pubmed/28657613>
310. Higgins KA, Mattes RD: A randomized controlled trial contrasting the effects of 4 low-calorie sweeteners and sucrose on body weight in adults with overweight or obesity. *Am J Clin Nutr* 2019 109:1288-1301. <https://www.ncbi.nlm.nih.gov/pubmed/30997499>
311. Borradaile KE, Halpern SD, Wyatt HR, et al.: Relationship between treatment preference and weight loss in the context of a randomized controlled trial. *Obesity (Silver Spring)* 2012 20:1218-1222. <https://www.ncbi.nlm.nih.gov/pubmed/21760633>
312. Yancy WS, Jr., McVay MA, Voils CI: Effect of allowing choice of diet on weight loss--in response. *Ann Intern Med* 2015 163:805-806. <https://www.ncbi.nlm.nih.gov/pubmed/26571246>
313. Leavy JM, Clifton PM, Keogh JB: The Role of Choice in Weight Loss Strategies: A Systematic Review and Meta-Analysis. *Nutrients* 2018 10: <https://www.ncbi.nlm.nih.gov/pubmed/30134595>

Journal References: 314-323

Nutrition (continued)

314. Gonzalez-Campoy JM, St Jeor ST, Castorino K, et al.: Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. *Endocr Pract* 2013 19 Suppl 3:1-82.
<https://www.ncbi.nlm.nih.gov/pubmed/24129260>
315. Clifton PM: Dietary treatment for obesity. *Nat Clin Pract Gastroenterol Hepatol* 2008 5:672-681.
<https://www.ncbi.nlm.nih.gov/pubmed/18852729>
316. Brown T, Avenell A, Edmunds LD, et al.: Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. *Obes Rev* 2009 10:627-638. <https://www.ncbi.nlm.nih.gov/pubmed/19754634>
317. Tsai AG, Wadden TA: Systematic review: an evaluation of major commercial weight loss programs in the United States. *Ann Intern Med* 2005 142:56-66. <https://www.ncbi.nlm.nih.gov/pubmed/15630109>
318. Westman EC, Yancy WS, Jr., Mavropoulos JC, et al.: The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab (Lond)* 2008 5:36.
<https://www.ncbi.nlm.nih.gov/pubmed/19099589>
319. Westman EC, Feinman RD, Mavropoulos JC, et al.: Low-carbohydrate nutrition and metabolism. *Am J Clin Nutr* 2007 86:276-284.
<https://www.ncbi.nlm.nih.gov/pubmed/17684196>
320. Volek JS, Phinney SD, Forsythe CE, et al.: Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. *Lipids* 2009 44:297-309. <https://www.ncbi.nlm.nih.gov/pubmed/19082851>
321. Foster GD, Wyatt HR, Hill JO, et al.: Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. *Ann Intern Med* 2010 153:147-157. <https://www.ncbi.nlm.nih.gov/pubmed/20679559>
322. Tirosh A, Golan R, Harman-Boehm I, et al.: Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. *Diabetes Care* 2013 36:2225-2232. <https://www.ncbi.nlm.nih.gov/pubmed/23690533>
323. Lutas A, Yellen G: The ketogenic diet: metabolic influences on brain excitability and epilepsy. *Trends Neurosci* 2013 36:32-40.
<https://www.ncbi.nlm.nih.gov/pubmed/23228828>

Journal References: 324-333

Nutrition (continued)

324. Ebbeling CB, Feldman HA, Klein GL, et al.: Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. *BMJ* 2018 363:k4583. <https://www.ncbi.nlm.nih.gov/pubmed/30429127>
325. Schwingshackl L, Hoffmann G: Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. *Nutr J* 2013 12:48. <https://www.ncbi.nlm.nih.gov/pubmed/23587198>
326. Meckling KA, O'Sullivan C, Saari D: Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. *J Clin Endocrinol Metab* 2004 89:2717-2723. <https://www.ncbi.nlm.nih.gov/pubmed/15181047>
327. Mulholland Y, Nicokavoura E, Broom J, et al.: Very-low-energy diets and morbidity: a systematic review of longer-term evidence. *Br J Nutr* 2012 108:832-851. <https://www.ncbi.nlm.nih.gov/pubmed/22800763>
328. Johansson K, Sundstrom J, Marcus C, et al.: Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. *Int J Obes (Lond)* 2014 38:279-284. <https://www.ncbi.nlm.nih.gov/pubmed/23736359>
329. Noronha JC, Nishi SK, Braunstein CR, et al.: The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care* 2019 42:767-776. <https://www.ncbi.nlm.nih.gov/pubmed/30923163>
330. Teegala SM, Willett WC, Mozaffarian D: Consumption and health effects of trans fatty acids: a review. *J AOAC Int* 2009 92:1250-1257. <https://www.ncbi.nlm.nih.gov/pubmed/19916363>
331. Nestel P: Trans fatty acids: are its cardiovascular risks fully appreciated? *Clin Ther* 2014 36:315-321. <https://www.ncbi.nlm.nih.gov/pubmed/24636816>
332. Shen W, McIntosh MK: Nutrient Regulation: Conjugated Linoleic Acid's Inflammatory and Browning Properties in Adipose Tissue. *Annu Rev Nutr* 2016 36:183-210. <https://www.ncbi.nlm.nih.gov/pubmed/27431366>
333. Dehghan M, Mente A, Rangarajan S, et al.: Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet* 2018 392:2288-2297. <https://www.ncbi.nlm.nih.gov/pubmed/30217460>

Journal References: 334-344

Nutrition (continued)

334. Lambert EA, Phillips S, Belski R, et al.: Endothelial Function in Healthy Young Individuals Is Associated with Dietary Consumption of Saturated Fat. *Front Physiol* 2017 8:876. <https://www.ncbi.nlm.nih.gov/pubmed/29170641>
335. Dow CA, Stauffer BL, Greiner JJ, et al.: Influence of dietary saturated fat intake on endothelial fibrinolytic capacity in adults. *Am J Cardiol* 2014 114:783-788. <https://www.ncbi.nlm.nih.gov/pubmed/25052545>
336. Hall WL: Dietary saturated and unsaturated fats as determinants of blood pressure and vascular function. *Nutr Res Rev* 2009 22:18-38. <https://www.ncbi.nlm.nih.gov/pubmed/19243668>
337. Tapsell LC: Fermented dairy food and CVD risk. *Br J Nutr* 2015 113 Suppl 2:S131-135. <https://www.ncbi.nlm.nih.gov/pubmed/26148916>
338. Vieira SA, McClements DJ, Decker EA: Challenges of utilizing healthy fats in foods. *Adv Nutr* 2015 6:309S-317S. <https://www.ncbi.nlm.nih.gov/pubmed/25979504>
339. Key TJ, Appleby PN, Bradbury KE, et al.: Consumption of Meat, Fish, Dairy Products, and Eggs and Risk of Ischemic Heart Disease. *Circulation* 2019 139:2835-2845. <https://www.ncbi.nlm.nih.gov/pubmed/31006335>
340. Pollin TI, Quartuccio M: What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation? *Curr Nutr Rep* 2013 2:236-242. <https://www.ncbi.nlm.nih.gov/pubmed/24524012>
341. Jaarin K, Kamisah Y: Repeatedly Heated Vegetable Oils and Lipid Peroxidation <https://www.intechopen.com/books/lipid-peroxidation/repeatedly-heated-vegetable-oils-and-lipid-peroxidation> (Accessed January 6, 2019). *Lipid Peroxidation Chapter 10* 2012
342. Przybylski O, Aladedunye FA: Formation of trans fats during food preparation. *Can J Diet Pract Res* 2012 73:98-101. <https://www.ncbi.nlm.nih.gov/pubmed/22668846>
343. Wang DD, Li Y, Chiuve SE, et al.: Association of Specific Dietary Fats With Total and Cause-Specific Mortality. *JAMA Intern Med* 2016 176:1134-1145. <https://www.ncbi.nlm.nih.gov/pubmed/27379574>
344. Li Y, Hruby A, Bernstein AM, et al.: Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. *J Am Coll Cardiol* 2015 66:1538-1548. <https://www.ncbi.nlm.nih.gov/pubmed/26429077>

Journal References: 345-354

Nutrition (continued)

345. Beulen Y, Martinez-Gonzalez MA, van de Rest O, et al.: Quality of Dietary Fat Intake and Body Weight and Obesity in a Mediterranean Population: Secondary Analyses within the PREDIMED Trial. *Nutrients* 2018 10:
<https://www.ncbi.nlm.nih.gov/pubmed/30572588>
346. Reynolds A, Mann J, Cummings J, et al.: Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *The Lancet* [https://doi.org/10.1016/S0140-6736\(18\)31809-9](https://doi.org/10.1016/S0140-6736(18)31809-9)
347. Clifton PM, Keogh JB: A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. *Nutr Metab Cardiovasc Dis* 2017 27:1060-1080. <https://www.ncbi.nlm.nih.gov/pubmed/29174025>
348. Ferro-Luzzi A, Sette S: The Mediterranean Diet: an attempt to define its present and past composition. *Eur J Clin Nutr* 1989 43 Suppl 2:13-29. <https://www.ncbi.nlm.nih.gov/pubmed/2689161>
349. Fito M, Konstantinidou V: Nutritional Genomics and the Mediterranean Diet's Effects on Human Cardiovascular Health. *Nutrients* 2016 8:218. <https://www.ncbi.nlm.nih.gov/pubmed/27089360>
350. Estruch R, Ros E, Salas-Salvado J, et al.: Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013 368:1279-1290. <https://www.ncbi.nlm.nih.gov/pubmed/23432189>
351. Kris-Etherton P, Eckel RH, Howard BV, et al.: AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. *Circulation* 2001 103:1823-1825. <https://www.ncbi.nlm.nih.gov/pubmed/11282918>
352. Rees K, Takeda A, Martin N, et al.: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2019 3:CD009825. <https://www.ncbi.nlm.nih.gov/pubmed/30864165>
353. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001 285:2486-2497. <https://www.ncbi.nlm.nih.gov/pubmed/11368702>
354. U.S. Department Of Health And Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Your guide to lowering your cholesterol with TLC. NIH Publication No. 06-5235. Bethesda, MD: National Heart, Lung, and Blood Institute; 2005.

Journal References: 355-365

Nutrition (continued)

355. Scrutinio D: The potential of lifestyle changes for improving the clinical outcome of patients with coronary heart disease: mechanisms of benefit and clinical results. *Rev Recent Clin Trials* 2010 5:1-13. <https://www.ncbi.nlm.nih.gov/pubmed/20205683>
356. Gibson AA, Seimon RV, Lee CM, et al.: Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. *Obes Rev* 2015 16:64-76. <https://www.ncbi.nlm.nih.gov/pubmed/25402637>
357. Bueno NB, de Melo IS, de Oliveira SL, et al.: Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr* 2013 110:1178-1187. <https://www.ncbi.nlm.nih.gov/pubmed/23651522>
358. Mansoor N, Vinknes KJ, Veierod MB, et al.: Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr* 2016 115:466-479. <https://www.ncbi.nlm.nih.gov/pubmed/26768850>
359. Murphy EA, Jenkins TJ: A ketogenic diet for reducing obesity and maintaining capacity for physical activity: hype or hope? *Curr Opin Clin Nutr Metab Care* 2019 22:314-319. <https://www.ncbi.nlm.nih.gov/pubmed/31166223>
360. Fuehrlein BS, Rutenberg MS, Silver JN, et al.: Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets. *J Clin Endocrinol Metab* 2004 89:1641-1645. <https://www.ncbi.nlm.nih.gov/pubmed/15070924>
361. Sansone M, Sansone A, Borrione P, et al.: Effects of Ketone Bodies on Endurance Exercise. *Curr Sports Med Rep* 2018 17:444-453. <https://www.ncbi.nlm.nih.gov/pubmed/30531462>
362. Rosenbaum M, Hall KD, Guo J, et al.: Glucose and Lipid Homeostasis and Inflammation in Humans Following an Isocaloric Ketogenic Diet. *Obesity (Silver Spring)* 2019 27:971-981. <https://www.ncbi.nlm.nih.gov/pubmed/31067015>
363. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al.: Ketogenic diet in the treatment of cancer - Where do we stand? *Mol Metab* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31399389>
364. Ornish D, Brown SE, Scherwitz LW, et al.: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990 336:129-133. <https://www.ncbi.nlm.nih.gov/pubmed/1973470>
365. Gardner CD, Kiazand A, Alhassan S, et al.: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. *JAMA* 2007 297:969-977. <https://www.ncbi.nlm.nih.gov/pubmed/17341711>

Journal References: 366-378

Nutrition (continued)

366. Ornish D, Scherwitz LW, Billings JH, et al.: Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998 280:2001-2007. <https://www.ncbi.nlm.nih.gov/pubmed/9863851>
367. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Your guide to lowering your blood pressure with DASH. NIH Publication No. 06-4082. Bethesda, MD: National Heart, Lung, and Blood Institute; 2006.
368. Appel LJ, Sacks FM, Carey VJ, et al.: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005 294:2455-2464. <https://www.ncbi.nlm.nih.gov/pubmed/16287956>
369. Manheimer EW, van Zuuren EJ, Fedorowicz Z, et al.: Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. Am J Clin Nutr 2015 102:922-932. <https://www.ncbi.nlm.nih.gov/pubmed/26269362>
370. Jonsson T, Granfeldt Y, Lindeberg S, et al.: Subjective satiety and other experiences of a Paleolithic diet compared to a diabetes diet in patients with type 2 diabetes. Nutr J 2013 12:105. <https://www.ncbi.nlm.nih.gov/pubmed/23890471>
371. Jonsson T, Granfeldt Y, Ahren B, et al.: Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol 2009 8:35. <https://www.ncbi.nlm.nih.gov/pubmed/19604407>
372. Craig WJ: Health effects of vegan diets. Am J Clin Nutr 2009 89:1627S-1633S. <https://www.ncbi.nlm.nih.gov/pubmed/19279075>
373. Dinu M, Abbate R, Gensini GF, et al.: Vegetarian, vegan diets and multiple health outcomes: a systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr 2016 0. <https://www.ncbi.nlm.nih.gov/pubmed/26853923>
374. Satija A, Bhupathiraju SN, Spiegelman D, et al.: Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol 2017 70:411-422. <https://www.ncbi.nlm.nih.gov/pubmed/28728684>
375. Key TJ, Fraser GE, Thorogood M, et al.: Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 1999 70:516s-524s.
376. Kim H, Caulfield LE, Rebolz CM: Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. J Nutr 2018 148:624-631.
377. Tharrey M, Mariotti F, Mashchak A, et al.: Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol 2018 47:1603-1612.
378. Kahleova H, Levin S, Barnard N: Cardio-Metabolic Benefits of Plant-Based Diets. Nutrients 2017 9(8): 848. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579641/>

Journal References: 379-389

Nutrition (continued)

379. Huang RY, Huang CC, Hu FB, et al.: Vegetarian Diets and Weight Reduction: a Meta-Analysis of Randomized Controlled Trials. *J Gen Intern Med* 2016 31:109-116.
380. Borude S: Which Is a Good Diet-Veg or Non-veg? Faith-Based Vegetarianism for Protection From Obesity-a Myth or Actuality? *Obes Surg* 2019
381. Lara KM, Levitan EB, Gutierrez OM, et al.: Dietary Patterns and Incident Heart Failure in U.S. Adults Without Known Coronary Disease. *J Am Coll Cardiol* 2019 73:2036-2045. <https://www.ncbi.nlm.nih.gov/pubmed/31023426>
382. Gabel K, Hoddy KK, Haggerty N, et al.: Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study. *Nutr Healthy Aging* 2018 4:345-353. <https://www.ncbi.nlm.nih.gov/pubmed/29951594>
383. Antoni R, Johnston KL, Collins AL, et al.: Effects of intermittent fasting on glucose and lipid metabolism. *Proc Nutr Soc* 2017 76:361-368. <https://www.ncbi.nlm.nih.gov/pubmed/28091348>
384. Hutchison AT, Liu B, Wood RE, et al.: Effects of Intermittent Versus Continuous Energy Intakes on Insulin Sensitivity and Metabolic Risk in Women with Overweight. *Obesity (Silver Spring)* 2019 27:50-58. <https://www.ncbi.nlm.nih.gov/pubmed/30569640>
385. Stice E, Davis K, Miller NP, et al.: Fasting increases risk for onset of binge eating and bulimic pathology: a 5-year prospective study. *J Abnorm Psychol* 2008 117:941-946. <https://www.ncbi.nlm.nih.gov/pubmed/19025239>
386. Kerndt PR, Naughton JL, Driscoll CE, et al.: Fasting: the history, pathophysiology and complications. *West J Med* 1982 137:379-399. <https://www.ncbi.nlm.nih.gov/pubmed/6758355>
387. Harris L, Hamilton S, Azevedo LB, et al.: Intermittent fasting interventions for treatment of overweight and obesity in adults: a systematic review and meta-analysis. *JBIC Database System Rev Implement Rep* 2018 16:507-547. <https://www.ncbi.nlm.nih.gov/pubmed/29419624>
388. Lessan N, Ali T: Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. *Nutrients* 2019 11: <https://www.ncbi.nlm.nih.gov/pubmed/31137899>
389. Gabel K, Kroeger CM, Trepanowski JF, et al.: Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance. *Obesity (Silver Spring)* 2019 27:1443-1450. <https://www.ncbi.nlm.nih.gov/pubmed/31328895>

Journal References: 390-399

Nutrition (continued)

390. Golbidi S, Daiber A, Korac B, et al.: Health Benefits of Fasting and Caloric Restriction. *Curr Diab Rep* 2017 17:123.
<https://www.ncbi.nlm.nih.gov/pubmed/29063418>
391. Yildiran H, Mercanligil SM: Does increasing meal frequency improve weight loss and some biochemical parameters in overweight/obese females? *Nutr Hosp* 2019 36:66-72. <https://www.ncbi.nlm.nih.gov/pubmed/30836763>
392. Malinowski B, Zalewska K, Wesierska A, et al.: Intermittent Fasting in Cardiovascular Disorders-An Overview. *Nutrients* 2019 11:
<https://www.ncbi.nlm.nih.gov/pubmed/30897855>

Additional references used: [181][232]

Physical Activity

393. Warburton DE, Nicol CW, Bredin SS: Health benefits of physical activity: the evidence. *CMAJ* 2006 174:801-809.
<https://www.ncbi.nlm.nih.gov/pubmed/16534088>
394. Stanford KI, Middelbeek RJ, Goodyear LJ: Exercise Effects on White Adipose Tissue: Beiging and Metabolic Adaptations. *Diabetes* 2015 64:2361-2368. <https://www.ncbi.nlm.nih.gov/pubmed/26050668>
395. Jeremic N, Chaturvedi P, Tyagi SC: Browning of White Fat: Novel Insight Into Factors, Mechanisms, and Therapeutics. *J Cell Physiol* 2017 232:61-68. <https://www.ncbi.nlm.nih.gov/pubmed/27279601>
396. Jakicic JM, Davis KK: Obesity and physical activity. *Psychiatr Clin North Am* 2011 34:829-840.
<https://www.ncbi.nlm.nih.gov/pubmed/22098807>
397. Gomez-Pinilla F, Hillman C: The influence of exercise on cognitive abilities. *Compr Physiol* 2013 3:403-428.
<https://www.ncbi.nlm.nih.gov/pubmed/23720292>
398. Fletcher GF, Landolfo C, Niebauer J, et al.: Promoting Physical Activity and Exercise: JACC Health Promotion Series. *J Am Coll Cardiol* 2018 72:1622-1639.
399. Rezende LFM, Sa TH, Markozannes G, et al.: Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. *Br J Sports Med* 2018 52:826-833.
<https://www.ncbi.nlm.nih.gov/pubmed/29146752>

Journal References: 400-410

Physical Activity (continued)

400. Luan X, Tian X, Zhang H, et al.: Exercise as a prescription for patients with various diseases. *J Sport Health Sci* 2019 8:422-441.
<https://www.ncbi.nlm.nih.gov/pubmed/31534817>
401. Meriwether RA, Lee JA, Lafleur AS, et al.: Physical activity counseling. *Am Fam Physician* 2008 77:1129-1136.
<https://www.ncbi.nlm.nih.gov/pubmed/18481560>
402. Vincent HK, Raiser SN, Vincent KR: The aging musculoskeletal system and obesity-related considerations with exercise. *Ageing Res Rev* 2012 11:361-373. <https://www.ncbi.nlm.nih.gov/pubmed/22440321>
403. Parr EB, Coffey VG, Hawley JA: 'Sarcobesity': a metabolic conundrum. *Maturitas* 2013 74:109-113.
<https://www.ncbi.nlm.nih.gov/pubmed/23201324>
404. Strasser B: Physical activity in obesity and metabolic syndrome. *Ann N Y Acad Sci* 2013 1281:141-159.
<https://www.ncbi.nlm.nih.gov/pubmed/23167451>
405. Carlson SA, Fulton JE, Schoenborn CA, et al.: Trend and prevalence estimates based on the 2008 Physical Activity Guidelines for Americans. *Am J Prev Med* 2010 39:305-313. <https://www.ncbi.nlm.nih.gov/pubmed/20837280>
406. Garland T, Jr., Schutz H, Chappell MA, et al.: The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. *J Exp Biol* 2011 214:206-229.
<https://www.ncbi.nlm.nih.gov/pubmed/21177942>
407. Ng SW, Popkin BM: Time use and physical activity: a shift away from movement across the globe. *Obes Rev* 2012 13:659-680.
<https://www.ncbi.nlm.nih.gov/pubmed/22694051>
408. Bushman BA: Determining the I (Intensity) for a FITT-VP Aerobic Exercise Prescription. *ACSM's Health & Fitness Journal* 2014 18:4-7.
http://journals.lww.com/acsm-healthfitness/Fulltext/2014/05000/Determining_the_I_Intensity_for_a_FITT_VP.4.aspx
409. Zaleski AL, Taylor BA, Panza GA, et al.: Coming of Age: Considerations in the Prescription of Exercise for Older Adults. *Methodist DeBakey Cardiovasc J* 2016 12:98-104.
410. Lakoski SG, Barlow CE, Farrell SW, et al.: Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center longitudinal study). *Am J Cardiol* 2011 108:34-39.
<https://www.ncbi.nlm.nih.gov/pubmed/21529738>

Journal References: 411-420

Physical Activity (continued)

411. Jette M, Sidney K, Blumchen G: Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990 13:555-565. <https://www.ncbi.nlm.nih.gov/pubmed/2204507>
412. Van Camp CM, Hayes LB: Assessing and increasing physical activity. J Appl Behav Anal 2012 45:871-875. <https://www.ncbi.nlm.nih.gov/pubmed/23322945>
413. Butte NF, Ekelund U, Westerterp KR: Assessing physical activity using wearable monitors: measures of physical activity. Med Sci Sports Exerc 2012 44:S5-12. <https://www.ncbi.nlm.nih.gov/pubmed/22157774>
414. Mercer K, Li M, Giangregorio L, et al.: Behavior Change Techniques Present in Wearable Activity Trackers: A Critical Analysis. JMIR Mhealth Uhealth 2016 4:e40. <https://www.ncbi.nlm.nih.gov/pubmed/27122452>
415. Allen LN, Christie GP: The Emergence of Personalized Health Technology. J Med Internet Res 2016 18:e99. <https://www.ncbi.nlm.nih.gov/pubmed/27165944>

Additional references used: [23][264]

Motivational Interviewing

416. Ries AV, Blackman LT, Page RA, et al.: Goal setting for health behavior change: evidence from an obesity intervention for rural low-income women. Rural Remote Health 2014 14:2682. <https://www.ncbi.nlm.nih.gov/pubmed/24785265>
417. Giannisi F, Pervanidou P, Michalaki E, et al.: Parental readiness to implement life-style behaviour changes in relation to children's excess weight. J Paediatr Child Health 2014 50:476-481. <https://www.ncbi.nlm.nih.gov/pubmed/24612057>
418. Tyler DO, Horner SD: Family-centered collaborative negotiation: a model for facilitating behavior change in primary care. J Am Acad Nurse Pract 2008 20:194-203. <https://www.ncbi.nlm.nih.gov/pubmed/18387016>
419. Miller WR, Rose GS: Toward a theory of motivational interviewing. Am Psychol 2009 64:527-537. <https://www.ncbi.nlm.nih.gov/pubmed/19739882>
420. Teixeira PJ, Silva MN, Mata J, et al.: Motivation, self-determination, and long-term weight control. Int J Behav Nutr Phys Act 2012 9:22. <https://www.ncbi.nlm.nih.gov/pubmed/22385818>

Journal References: 421-430

Motivational Interviewing (continued)

421. Pollak KI, Alexander SC, Tulsy JA, et al.: Physician empathy and listening: associations with patient satisfaction and autonomy. *J Am Board Fam Med* 2011 24:665-672. <https://www.ncbi.nlm.nih.gov/pubmed/22086809>
422. Williams DM, Rhodes RE: The confounded self-efficacy construct: conceptual analysis and recommendations for future research. *Health Psychol Rev* 2016 10:113-128. <https://www.ncbi.nlm.nih.gov/pubmed/25117692>
423. Westra HA, Aviram A: Core skills in motivational interviewing. *Psychotherapy (Chic)* 2013 50:273-278. <https://www.ncbi.nlm.nih.gov/pubmed/24000834>
424. Pollak KI, Coffman CJ, Alexander SC, et al.: Weight's up? Predictors of weight-related communication during primary care visits with overweight adolescents. *Patient Educ Couns* 2014 96:327-332. <https://www.ncbi.nlm.nih.gov/pubmed/25130793>
425. Pantaloni MV, Sledge WH, Bauer SF, et al.: Important medical decisions: Using brief motivational interviewing to enhance patients' autonomous decision-making. *J Psychiatr Pract* 2013 19:98-108. <https://www.ncbi.nlm.nih.gov/pubmed/23507811>
426. Codern-Bove N, Pujol-Ribera E, Pla M, et al.: Motivational interviewing interactions and the primary health care challenges presented by smokers with low motivation to stop smoking: a conversation analysis. *BMC Public Health* 2014 14:1225. <https://www.ncbi.nlm.nih.gov/pubmed/25427643>
427. Williams AA, Wright KS: Engaging families through motivational interviewing. *Pediatr Clin North Am* 2014 61:907-921. <https://www.ncbi.nlm.nih.gov/pubmed/25242705>
428. Resnicow K, McMaster F: Motivational Interviewing: moving from why to how with autonomy support. *Int J Behav Nutr Phys Act* 2012 9:19. <https://www.ncbi.nlm.nih.gov/pubmed/22385702>
429. Miller ST, Oates VJ, Brooks MA, et al.: Preliminary efficacy of group medical nutrition therapy and motivational interviewing among obese African American women with type 2 diabetes: a pilot study. *J Obes* 2014 2014:345941. <https://www.ncbi.nlm.nih.gov/pubmed/25243082>
430. Elwyn G, Dehlendorf C, Epstein RM, et al.: Shared decision making and motivational interviewing: achieving patient-centered care across the spectrum of health care problems. *Ann Fam Med* 2014 12:270-275. <https://www.ncbi.nlm.nih.gov/pubmed/24821899>

Journal References: 431-441

Motivational Interviewing (continued)

431. Carcone AI, Naar-King S, Brogan KE, et al.: Provider communication behaviors that predict motivation to change in black adolescents with obesity. *J Dev Behav Pediatr* 2013 34:599-608. <https://www.ncbi.nlm.nih.gov/pubmed/24131883>
432. Windham ME, Hastings ES, Anding R, et al.: "Teens Talk Healthy Weight": the impact of a motivational digital video disc on parental knowledge of obesity-related diseases in an adolescent clinic. *J Acad Nutr Diet* 2014 14:1611-1618. <https://www.ncbi.nlm.nih.gov/pubmed/24882205>
433. Saelens BE, Lozano P, Scholz K: A randomized clinical trial comparing delivery of behavioral pediatric obesity treatment using standard and enhanced motivational approaches. *J Pediatr Psychol* 2013 38:954-964. <https://www.ncbi.nlm.nih.gov/pubmed/23902797>
434. Kushner RF, Ryan DH: Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. *JAMA* 2014 312:943-952. <https://www.ncbi.nlm.nih.gov/pubmed/25182103>
435. Kisely S, Ligate L, Roy MA, et al.: Applying Motivational Interviewing to the initiation of long-acting injectable atypical antipsychotics. *Australas Psychiatry* 2012 20:138-142. <https://www.ncbi.nlm.nih.gov/pubmed/22467557>
436. Goldberg JH, Kiernan M: Innovative techniques to address retention in a behavioral weight-loss trial. *Health Educ Res* 2005 20:439-447. <https://www.ncbi.nlm.nih.gov/pubmed/15598664>
437. Miller NH: Motivational interviewing as a prelude to coaching in healthcare settings. *J Cardiovasc Nurs* 2010 25:247-251. <https://www.ncbi.nlm.nih.gov/pubmed/20386250>
438. Vallis M, Piccinini-Vallis H, Sharma AM, et al.: Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. *Can Fam Physician* 2013 59:27-31. <https://www.ncbi.nlm.nih.gov/pubmed/23341653>
439. Alexander SC, Cox ME, Boling Turer CL, et al.: Do the five A's work when physicians counsel about weight loss? *Fam Med* 2011 43:179-184. <https://www.ncbi.nlm.nih.gov/pubmed/21380950>
440. Searight R: Realistic approaches to counseling in the office setting. *Am Fam Physician* 2009 79:277-284. <https://www.ncbi.nlm.nih.gov/pubmed/19235494>
441. Foote J, DeLuca A, Magura S, et al.: A group motivational treatment for chemical dependency. *J Subst Abuse Treat* 1999 17:181-192. <https://www.ncbi.nlm.nih.gov/pubmed/10531624>

Journal References: 442-452

Behavioral Therapy

442. Schneeberger M, Gomis R, Claret M: Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance. *J Endocrinol* 2014 220:T25-46. <https://www.ncbi.nlm.nih.gov/pubmed/24222039>
443. Cruwys T, Bevelander KE, Hermans RC: Social modeling of eating: a review of when and why social influence affects food intake and choice. *Appetite* 2015 86:3-18. <https://www.ncbi.nlm.nih.gov/pubmed/25174571>
444. Neymotin F, Nemzer LR: Locus of control and obesity. *Front Endocrinol (Lausanne)* 2014 5:159. <https://www.ncbi.nlm.nih.gov/pubmed/25339940>
445. Kemps E, Tiggemann M: Approach bias for food cues in obese individuals. *Psychol Health* 2015 30:370-380. <https://www.ncbi.nlm.nih.gov/pubmed/25307785>
446. Johnson PM, Kenny PJ: Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. *Nat Neurosci* 2010 13:635-641. <https://www.ncbi.nlm.nih.gov/pubmed/20348917>
447. Adam TC, Epel ES: Stress, eating and the reward system. *Physiol Behav* 2007 91:449-458. <https://www.ncbi.nlm.nih.gov/pubmed/17543357>
448. Monteleone P, Piscitelli F, Scognamiglio P, et al.: Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. *J Clin Endocrinol Metab* 2012 97:E917-924. <https://www.ncbi.nlm.nih.gov/pubmed/22442280>
449. Miller AC, Polgreen LA, Segre EM, et al.: Variations in Marginal Taste Perception by Body Mass Index Classification: A Randomized Controlled Trial. *J Acad Nutr Diet* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31375462>
450. Batra P, Das SK, Salinardi T, et al.: Eating behaviors as predictors of weight loss in a 6 month weight loss intervention. *Obesity (Silver Spring)* 2013 21:2256-2263. <https://www.ncbi.nlm.nih.gov/pubmed/23512619>
451. Amianto F, Ottone L, Abbate Daga G, et al.: Binge-eating disorder diagnosis and treatment: a recap in front of DSM-5. *BMC Psychiatry* 2015 15:70. <https://www.ncbi.nlm.nih.gov/pubmed/25885566>
452. Rikani AA, Choudhry Z, Choudhry AM, et al.: A critique of the literature on etiology of eating disorders. *Ann Neurosci* 2013 20:157-161. <https://www.ncbi.nlm.nih.gov/pubmed/25206042>

Journal References: 453-463

Behavioral Therapy (continued)

453. Brauhardt A, de Zwaan M, Hilbert A: The therapeutic process in psychological treatments for eating disorders: a systematic review. *Int J Eat Disord* 2014 47:565-584. <https://www.ncbi.nlm.nih.gov/pubmed/24796817>
454. Reas DL, Grilo CM: Current and emerging drug treatments for binge eating disorder. *Expert Opin Emerg Drugs* 2014 19:99-142. <https://www.ncbi.nlm.nih.gov/pubmed/24460483>
455. Aigner M, Treasure J, Kaye W, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. *World J Biol Psychiatry* 2011 12:400-443. <https://www.ncbi.nlm.nih.gov/pubmed/21961502>
456. Flament MF, Bissada H, Spettigue W: Evidence-based pharmacotherapy of eating disorders. *Int J Neuropsychopharmacol* 2012 15:189-207. <https://www.ncbi.nlm.nih.gov/pubmed/21414249>
457. Smith KE, Ellison JM, Crosby RD, et al.: The validity of DSM-5 severity specifiers for anorexia nervosa, bulimia nervosa, and binge-eating disorder. *Int J Eat Disord* 2017 50:1109-1113. <https://www.ncbi.nlm.nih.gov/pubmed/28623853>
458. Lisdexamfetamine dimesylate (VYVANSE) Prescribing Information http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf (Accessed August 20, 2016).
459. Allison KC, Lundgren JD, O'Reardon JP, et al.: Proposed diagnostic criteria for night eating syndrome. *Int J Eat Disord* 2010 43:241-247. <https://www.ncbi.nlm.nih.gov/pubmed/19378289>
460. Gallant AR, Lundgren J, Drapeau V: The night-eating syndrome and obesity. *Obes Rev* 2012 13:528-536. <https://www.ncbi.nlm.nih.gov/pubmed/22222118>
461. Milano W, De Rosa M, Milano L, et al.: Night eating syndrome: an overview. *J Pharm Pharmacol* 2012 64:2-10. <https://www.ncbi.nlm.nih.gov/pubmed/22150667>
462. Stunkard AJ, Allison KC, Geliebter A, et al.: Development of criteria for a diagnosis: lessons from the night eating syndrome. *Compr Psychiatry* 2009 50:391-399. <https://www.ncbi.nlm.nih.gov/pubmed/19683608>
463. Gupta H: Barriers to and Facilitators of Long Term Weight Loss Maintenance in Adult UK People: A Thematic Analysis. *Int J Prev Med* 2014 5:1512-1520. <https://www.ncbi.nlm.nih.gov/pubmed/25709786>

Journal References: 464-475

Behavioral Therapy (continued)

464. Peterson JA: Get moving! Physical activity counseling in primary care. *J Am Acad Nurse Pract* 2007 19:349-357.
<https://www.ncbi.nlm.nih.gov/pubmed/17680900>
465. Cornier MA: Is your brain to blame for weight regain? *Physiol Behav* 2011 104:608-612.
<https://www.ncbi.nlm.nih.gov/pubmed/21496461>
466. Sainsbury A, Zhang L: Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit. *Obes Rev* 2012 13:234-257. <https://www.ncbi.nlm.nih.gov/pubmed/22070225>
467. Rosenbaum M, Leibel RL: Adaptive thermogenesis in humans. *Int J Obes (Lond)* 2010 34 Suppl 1:S47-55.
<https://www.ncbi.nlm.nih.gov/pubmed/20935667>
468. Maclean PS, Bergouignan A, Cornier MA, et al.: Biology's response to dieting: the impetus for weight regain. *Am J Physiol Regul Integr Comp Physiol* 2011 301:R581-600. <https://www.ncbi.nlm.nih.gov/pubmed/21677272>
469. Yoo S: Dynamic Energy Balance and Obesity Prevention. *J Obes Metab Syndr* 2018 27:203-212.
<https://www.ncbi.nlm.nih.gov/pubmed/31089565>
470. Howlett N, Trivedi D, Troop NA, et al.: Are physical activity interventions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis. *Transl Behav Med* 2019 9:147-157. <https://www.ncbi.nlm.nih.gov/pubmed/29506209>
471. Lemstra M, Bird Y, Nwankwo C, et al.: Weight loss intervention adherence and factors promoting adherence: a meta-analysis. *Patient Prefer Adherence* 2016 10:1547-1559. <https://www.ncbi.nlm.nih.gov/pubmed/27574404>
472. Richardson LA: Bariatric society is here to help. *J Fam Pract* 2010 59:488. <https://www.ncbi.nlm.nih.gov/pubmed/20824223>
473. Jacob JJ, Isaac R: Behavioral therapy for management of obesity. *Indian J Endocrinol Metab* 2012 16:28-32.
<https://www.ncbi.nlm.nih.gov/pubmed/22276250>
474. Van Dorsten B, Lindley EM: Cognitive and behavioral approaches in the treatment of obesity. *Med Clin North Am* 2011 95:971-988.
<https://www.ncbi.nlm.nih.gov/pubmed/21855703>
475. Karasu SR: Psychotherapy-lite: obesity and the role of the mental health practitioner. *Am J Psychother* 2013 67:3-22.
<https://www.ncbi.nlm.nih.gov/pubmed/23682511>

Journal References: 476-483

Behavioral Therapy (continued)

- 476.Hansen TT, Andersen SV, Astrup A, et al.: Is reducing appetite beneficial for body weight management in the context of overweight and obesity? A systematic review and meta-analysis from clinical trials assessing body weight management after exposure to satiety enhancing and/or hunger reducing products. *Obes Rev* 2019 20:983-997.
<https://www.ncbi.nlm.nih.gov/pubmed/30945414>
- 477.Rutledge T, Groesz LM, Linke SE, et al.: Behavioural weight management for the primary careprovider. *Obes Rev* 2011 12:e290-297.
<https://www.ncbi.nlm.nih.gov/pubmed/21348915>
- 478.Harvey J, Krukowski R, Priest J, et al.: Log Often, Lose More: Electronic Dietary Self-Monitoring for Weight Loss. *Obesity* 2019 27:380-384. <https://doi.org/10.1002/oby.22382>
- 479.Jeffery RW, Bjornson-Benson WM, Rosenthal BS, et al.: Behavioral treatment of obesity with monetary contracting: two-year follow-up. *Addict Behav* 1984 9:311-313. <https://www.ncbi.nlm.nih.gov/pubmed/6496209>
- 480.Brambila-Macias J, Shankar B, Capacci S, et al.: Policy interventions to promote healthy eating: a review of what works, what does not, and what is promising. *Food Nutr Bull* 2011 32:365-375. <https://www.ncbi.nlm.nih.gov/pubmed/22590970>
- 481.Lynch E, Emery-Tiburcio E, Dugan S, et al.: Results of ALIVE: A Faith-Based Pilot Intervention to Improve Diet Among African American Church Members. *Prog Community Health Partnersh* 2019 13:19-30.
<https://www.ncbi.nlm.nih.gov/pubmed/30956244>

Technologies for Weight Management

- 482.Dobkin BH: Wearable motion sensors to continuously measure real-world physical activities. *Curr Opin Neurol* 2013 26:602-608.
<https://www.ncbi.nlm.nih.gov/pubmed/24136126>
- 483.Chou WY, Prestin A, Kunath S: Obesity in social media: a mixed methods analysis. *Transl Behav Med* 2014 4:314-323.
<https://www.ncbi.nlm.nih.gov/pubmed/25264470>

Additional references used: [21][23][25][26][264][414][415]

Journal References: 484-494

Anti-obesity Medications

484. Bray GA: Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 2013 21:893-899.
<https://www.ncbi.nlm.nih.gov/pubmed/23520198>
485. Bays HE, Jones PH, Orringer CE, et al.: National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol 2016 10:S1-43. <https://www.ncbi.nlm.nih.gov/pubmed/26891998>
486. Piscitelli SC, Gallicano KD: Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001 344:984-996.
<https://www.ncbi.nlm.nih.gov/pubmed/11274626>
487. Zhang X, Lerman LO: Obesity and renovascular disease. Am J Physiol Renal Physiol 2015 309:F273-279.
<https://www.ncbi.nlm.nih.gov/pubmed/26041447>
488. Gupta D, Bhatia D, Dave V, et al.: Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. Molecules 2018 23: <https://www.ncbi.nlm.nih.gov/pubmed/30011904>
489. Bays HE, Gadde KM: Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc) 2011 47:903-914. <https://www.ncbi.nlm.nih.gov/pubmed/22348915>
490. Bays H: Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010 8:1777-1801. <https://www.ncbi.nlm.nih.gov/pubmed/20707765>
491. Naltrexone HCL/Bupropion HCL Extended Release Prescribing Information (CONTRAVE).
<http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=c5f9d506-7c0a-4c03-b357-2a926ba14990> (Accessed August 21, 2016).
492. LOMAIRA™ (phentermine hydrochloride USP) tablets, CIV) https://www.lomaira.com/Prescribing_Information.pdf (Accessed December 16, 2018).
493. Bays HE, Cobble M: Individualizing Treatment with Statin Therapy. J Fam Pract 2018 67:S43-S48.
<https://www.ncbi.nlm.nih.gov/pubmed/30137053>
494. Hanley MJ, Abernethy DR, Greenblatt DJ: Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010 49:71-87. <https://www.ncbi.nlm.nih.gov/pubmed/20067334>

Journal References: 495-505

Anti-obesity Medications (continued)

495. Cheymol G: Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000 39:215-231.
<https://www.ncbi.nlm.nih.gov/pubmed/11020136>
496. Jesudason DR, Clifton P: Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician. Int J Obes (Lond) 2012 36:1421-1427. <https://www.ncbi.nlm.nih.gov/pubmed/22184061>
497. Bays HE: Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 2011 9:265-277. <https://www.ncbi.nlm.nih.gov/pubmed/21438803>
498. Food and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. December 3, 2014.
<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm> (Accessed August 21, 2016).
499. Hendricks EJ, Greenway FL, Westman EC, et al.: Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011 19:2351-2360.
<https://www.ncbi.nlm.nih.gov/pubmed/21527891>
500. Fujioka K: Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 2015 17:1021-1032. <https://www.ncbi.nlm.nih.gov/pubmed/26040215>
501. Lorcaserin (BELVIQ) Prescribing Information. http://www.belviq.com/pdf/Belviq_Prescribing_information.pdf (Accessed August 21, 2016).
502. Bays HE: Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev Cardiovasc Ther 2009 7:1429-1445. <https://www.ncbi.nlm.nih.gov/pubmed/19900026>
503. Kose M, Emet S, Akpınar TS, et al.: An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis. Case Rep Gastroenterol 2015 9:152-155. <https://www.ncbi.nlm.nih.gov/pubmed/26078734>
504. Lim S, Rogers LK, Tessler O, et al.: Phentermine: A Systematic Review for Plastic and Reconstructive Surgeons. Ann Plast Surg 2018 81:503-507. <https://www.ncbi.nlm.nih.gov/pubmed/30204622>
505. Liraglutide Prescribing Information for Treatment of Obesity (SAXENDA) <https://www.novo-pi.com/saxenda.pdf> (Accessed March 3, 2019).

Journal References: 506-513

Anti-obesity Medications (continued)

506. Liraglutide Prescribing Information for Treatment of Type 2 Diabetes Mellitus (VICTOZA) <https://www.novo-pi.com/victoza.pdf>
(Accessed March 3, 2019).
507. Phentermine HCL/Topiramate Extended Release Prescribing Information (QSYMIA) <http://www.vivus.com/docs/QsymiaPI.pdf>
(Accessed August 21, 2016).
508. Garvey WT, Mechanick JI, Brett EM, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract* 2016 22 Suppl 3:1-203.
<https://www.ncbi.nlm.nih.gov/pubmed/27219496>
509. Bays H, Rodbard HW, Schorr AB, et al.: Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. *Curr Treat Options Cardiovasc Med* 2007 9:259-271. <https://www.ncbi.nlm.nih.gov/pubmed/17761111>
510. Cercato C, Roizenblatt VA, Leanca CC, et al.: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. *Int J Obes (Lond)* 2009 33:857-865.
<https://www.ncbi.nlm.nih.gov/pubmed/19564877>
511. Le Riche WH, Van Belle G: Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects. *Can Med Assoc J* 1962 87:29-31. <https://www.ncbi.nlm.nih.gov/pubmed/14463177>

Additional references used: [78][122][123]

Phentermine

512. Hendricks EJ: Off-label drugs for weight management. *Diabetes Metab Syndr Obes* 2017 10:223-234.
<https://www.ncbi.nlm.nih.gov/pubmed/28652791>
513. Lewis KH, Fischer H, Ard J, et al.: Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. *Obesity (Silver Spring)* 2019 27:591-602. <https://www.ncbi.nlm.nih.gov/pubmed/30900410>

Additional references used: [279][492][499]

Journal References: 514-518

Orlistat

514. XENICAL® (orlistat) Capsules https://www.xenical.com/pdf/PI_Xenical-brand_FINAL.PDF (Accessed December 16, 2018).
515. Zenical: (orlistat). Drugs.com <https://www.drugs.com/pro/xenical.html> (Accessed October 12, 2019)
516. Kumar RB, Aronne LJ: Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring) 2015 23 Suppl 1:S4-7. <https://www.ncbi.nlm.nih.gov/pubmed/25900871>
Additional references used: [500][503][509]

Lorcaserin

- References used: [497][500][501][502][508][516]

Liraglutide

517. Saunders KH, Umashanker D, Igel LI, et al.: Obesity Pharmacotherapy. Med Clin North Am 2018 102:135-148.
<https://www.ncbi.nlm.nih.gov/pubmed/29156182>
Additional references used: [500][505][506][508][516]

Naltrexone HCL/Bupropion HCL Extended Release

- References used: [491][500][508][516]

Phentermine HCL/Topiramate Extended Release

- References used: [489][490][500][507][508][516]

Biodegradable Hydrogel Capsule Device

518. Plenity Instructions for Use https://www.gelesis.com/wp-content/uploads/DEN180060_Physician_IFU_FDA_FINAL_4.9.2019Gelesis.pdf Accessed September 8, 2019.

Journal References: 519-529

Functional Foods, Supplements, & Over-the-counter Therapies

519. Wharton S, Bonder R, Jeffery A, et al.: The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. *Crit Rev Food Sci Nutr* 2019 1-17. <https://www.ncbi.nlm.nih.gov/pubmed/30896252>
520. Barrea L, Altieri B, Polese B, et al.: Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. *Int J Obes Suppl* 2019 9:32-49. <https://www.ncbi.nlm.nih.gov/pubmed/31391923>
521. Zarin DA, Tse T, Sheehan J: The proposed rule for U.S. clinical trial registration and results submission. *N Engl J Med* 2015 372:174-180. <https://www.ncbi.nlm.nih.gov/pubmed/25539444>
522. Dubben HH, Beck-Bornholdt HP: Systematic review of publication bias in studies on publication bias. *BMJ* 2005 331:433-434. <https://www.ncbi.nlm.nih.gov/pubmed/15937056>
523. Heyman ML, Williams RL: Ensuring global access to quality medicines: role of the US Pharmacopeia. *J Pharm Sci* 2011 100:1280-1287.
524. Navarro VJ, Khan I, Bjornsson E, et al.: Liver injury from herbal and dietary supplements. *Hepatology* 2017 65:363-373. <https://www.ncbi.nlm.nih.gov/pubmed/27677775>
525. Pol K, Christensen R, Bartels EM, et al.: Whole grain and body weight changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr* 2013 98:872-884. <https://www.ncbi.nlm.nih.gov/pubmed/23945718>
526. Seganfredo FB, Blume CA, Moehlecke M, et al.: Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. *Obes Rev* 2017 18:832-851. <https://www.ncbi.nlm.nih.gov/pubmed/28524627>
527. He M, Shi B: Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. *Cell Biosci* 2017 7:54. <https://www.ncbi.nlm.nih.gov/pubmed/29090088>
528. Gibson GR, Hutkins R, Sanders ME, et al.: Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* 2017 14:491-502. <https://www.ncbi.nlm.nih.gov/pubmed/28611480>
529. Harpaz E, Tamir S, Weinstein A, et al.: The effect of caffeine on energy balance. *J Basic Clin Physiol Pharmacol* 2017 28:1-10. <https://www.ncbi.nlm.nih.gov/pubmed/27824614>

Journal References: 530-540

Functional Foods, Supplements, & Over-the-counter Therapies (continued)

- 530.Examine.com. <https://examine.com> Accessed December 4, 2017.
- 531.Janssens PL, Hursel R, Westerterp-Plantenga MS: Nutraceuticals for body-weight management: The role of green tea catechins. *Physiol Behav* 2016 162:83-87. <https://www.ncbi.nlm.nih.gov/pubmed/26836279>
- 532.Onakpoya I, Terry R, Ernst E: The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. *Gastroenterol Res Pract* 2011 2011: <https://www.ncbi.nlm.nih.gov/pubmed/20871849>
- 533.Onakpoya IJ, Posadzki PP, Watson LK, et al.: The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials. *Eur J Nutr* 2012 51:127-134. <https://www.ncbi.nlm.nih.gov/pubmed/21990002>
- 534.Cederroth CR, Nef S: Soy, phytoestrogens and metabolism: A review. *Mol Cell Endocrinol* 2009 304:30-42. <https://www.ncbi.nlm.nih.gov/pubmed/19433245>
- 535.Cope MB, Erdman JW, Jr., Allison DB: The potential role of soyfoods in weight and adiposity reduction: an evidence-based review. *Obes Rev* 2008 9:219-235. <https://www.ncbi.nlm.nih.gov/pubmed/18419671>
- 536.Benjamin S, Prakasan P, Sreedharan S, et al.: Pros and cons of CLA consumption: an insight from clinical evidences. *Nutr Metab (Lond)* 2015 12:4. <https://www.ncbi.nlm.nih.gov/pubmed/25972911>
- 537.Patisaul HB, Jefferson W: The pros and cons of phytoestrogens. *Front Neuroendocrinol* 2010 31:400-419. <https://www.ncbi.nlm.nih.gov/pubmed/20347861>
- 538.Crespillo A, Alonso M, Vida M, et al.: Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. *Br J Pharmacol* 2011 164:1899-1915. <https://www.ncbi.nlm.nih.gov/pubmed/21557739>
- 539.Koba K, Yanagita T: Health benefits of conjugated linoleic acid (CLA). *Obes Res Clin Pract* 2014 8:e525-532. <https://www.ncbi.nlm.nih.gov/pubmed/25434907>
- 540.Schwartz SM, Bansal VP, Hale C, et al.: Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. *Obesity (Silver Spring)* 2008 16:623-629. <https://www.ncbi.nlm.nih.gov/pubmed/18239553>

Journal References: 541-550

Functional Foods, Supplements, & Over-the-counter Therapies (continued)

541. Onakpoya I, Davies L, Posadzki P, et al.: The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. *J Diet Suppl* 2013 10:29-38. <https://www.ncbi.nlm.nih.gov/pubmed/23419021>
542. Jull AB, Ni Mhurchu C, Bennett DA, et al.: Chitosan for overweight or obesity. *Cochrane Database Syst Rev* 2008 CD003892. <https://www.ncbi.nlm.nih.gov/pubmed/18646097>
543. Onakpoya I, Posadzki P, Ernst E: The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. *J Am Coll Nutr* 2014 33:70-78. <https://www.ncbi.nlm.nih.gov/pubmed/24533610>
544. Marquez F, Babio N, Bullo M, et al.: Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. *Crit Rev Food Sci Nutr* 2012 52:585-594. <https://www.ncbi.nlm.nih.gov/pubmed/22530711>
545. Lunsford KE, Bodzin AS, Reino DC, et al.: Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. *World J Gastroenterol* 2016 22:10071-10076. <https://www.ncbi.nlm.nih.gov/pubmed/28018115>
546. Vermorel M, Davicco MJ, Evrard J: Valorization of rapeseed meal. 3. Effects of glucosinolate content on food intake, weight gain, liver weight and plasma thyroid hormone levels in growing rats. *Reprod Nutr Dev* 1987 27:57-66. <https://www.ncbi.nlm.nih.gov/pubmed/3575869>
547. Loftus HL, Astell KJ, Mathai ML, et al.: Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial. *Nutrients* 2015 7:9508-9522. <https://www.ncbi.nlm.nih.gov/pubmed/26593941>
548. Smith C, Krygsman A: Hoodia gordonii: to eat, or not to eat. *J Ethnopharmacol* 2014 155:987-991. <https://www.ncbi.nlm.nih.gov/pubmed/24955559>
549. Roza O, Lovasz N, Zupko I, et al.: Sympathomimetic activity of a Hoodia gordonii product: a possible mechanism of cardiovascular side effects. *Biomed Res Int* 2013 2013:171059. <https://www.ncbi.nlm.nih.gov/pubmed/24307991>
550. Ju J, Li J, Lin Q, et al.: Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. *Phytomedicine* 2018 50:25-34. <https://www.ncbi.nlm.nih.gov/pubmed/30466986>

Journal References: 551-560

Functional Foods, Supplements, & Over-the-counter Therapies (continued)

551. Zalewski BM, Szajewska H: No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial. *J Pediatr* 2019 211:85-91 e81. <https://www.ncbi.nlm.nih.gov/pubmed/31036412>
552. Yen M, Ewald MB: Toxicity of weight loss agents. *J Med Toxicol* 2012 8:145-152. <https://www.ncbi.nlm.nih.gov/pubmed/22351299>
553. Tucker J, Fischer T, Upjohn L, et al.: Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. *JAMA Netw Open* 2018 1:e183337. <https://www.ncbi.nlm.nih.gov/pubmed/30646238>
554. U.S. Food and Drug Administration. HCG Diet Products are Illegal. www.fda.gov/forconsumers/consumerupdates/ucm281333.htm Accessed December 4, 2017.
555. Lijesen GK, Theeuwen I, Assendelft WJ, et al.: The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. *Br J Clin Pharmacol* 1995 40:237-243. <https://www.ncbi.nlm.nih.gov/pubmed/8527285>
556. Obesity Medicine Association. Obesity Medicine Association Applauds American Medical Association's Decision to Adopt New Anti-HCG Policy. <https://obesitymedicine.org/use-of-hcg-for-weight-loss-inappropriate> Accessed December 4, 2017.

Obesity and Metabolic Disease

557. Ayas NT, Taylor CM, Laher I: Cardiovascular consequences of obstructive sleep apnea. *Curr Opin Cardiol* 2016 31:599-605.
558. Reutrakul S, Van Cauter E: Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes. *Metabolism* 2018 84:56-66. <https://www.ncbi.nlm.nih.gov/pubmed/29510179>
559. de Simone G, Mancusi C, Izzo R, et al.: Obesity and hypertensive heart disease: focus on body composition and sex differences. *Diabetol Metab Syndr* 2016 8:79. <https://www.ncbi.nlm.nih.gov/pubmed/27956942>
560. Gu C, Younas H, Jun JC: Sleep apnea: An overlooked cause of lipotoxicity? *Med Hypotheses* 2017 108:161-165.

Journal References: 561-569

Obesity and Metabolic Disease (continued)

561. Pearson T, Wattis JA, King JR, et al.: The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans. Bull Math Biol 2016 78:1189-1217. <https://www.ncbi.nlm.nih.gov/pubmed/27306890>
562. Sarr O, Strohm RJ, MacDonald TL, et al.: Subcutaneous and Visceral Adipose Tissue Secretions from Extremely Obese Men and Women both Acutely Suppress Muscle Insulin Signaling. Int J Mol Sci 2017 18: <https://www.ncbi.nlm.nih.gov/pubmed/28468326>
563. Kitessa SM, Abeywardena MY: Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid Intermediates. Nutrients 2016 8: <https://www.ncbi.nlm.nih.gov/pubmed/27483311>

Additional reference used: [29]

Obesity and Cardiovascular Disease

564. Cavender MA, Norhammar A, Birkeland KI, et al.: SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol 2018 71:2497-2506. <https://www.ncbi.nlm.nih.gov/pubmed/29852973>
565. Kosiborod M, Lam CSP, Kohsaka S, et al.: Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol 2018 71:2628-2639. <https://www.ncbi.nlm.nih.gov/pubmed/29540325>
566. Home P: Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia 2019 <https://www.ncbi.nlm.nih.gov/pubmed/30607467>
567. Coulter AA, Rebello CJ, Greenway FL: Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs 2018 78:1113-1132. <https://www.ncbi.nlm.nih.gov/pubmed/30014268>
568. Bohula EA, Wiviott SD, McGuire DK, et al.: Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med 2018 379:1107-1117. <https://www.ncbi.nlm.nih.gov/pubmed/30145941>
569. Bohula EA, Scirica BM, Inzucchi SE, et al.: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet 2018 392:2269-2279. <https://www.ncbi.nlm.nih.gov/pubmed/30293771>

Journal References: 570-581

Obesity and Cardiovascular Disease (continued)

570. Bays H, Perdomo C, Nikonova E, et al.: Lorcaserin and metabolic disease: weight-loss dependent and independent effects. *Obes Sci Pract* 2018 4:499-505. <https://www.ncbi.nlm.nih.gov/pubmed/30574343>
571. Scirica BM, Bohula EA, Dwyer JP, et al.: Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. *Circulation* 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30586726>
572. Gadde KM, Martin CK, Berthoud HR, et al.: Obesity: Pathophysiology and Management. *J Am Coll Cardiol* 2018 71:69-84. <https://www.ncbi.nlm.nih.gov/pubmed/29301630>
573. Ritchey ME, Harding A, Hunter S, et al.: Cardiovascular Safety During and After Use of Phentermine and Topiramate. *J Clin Endocrinol Metab* 2019 104:513-522. <https://www.ncbi.nlm.nih.gov/pubmed/30247575>
574. Nagy E, Jermendy AL, Merkely B, et al.: Clinical importance of epicardial adipose tissue. *Arch Med Sci* 2017 13:864-874. <https://www.ncbi.nlm.nih.gov/pubmed/28721155>
575. Riaz H, Khan MS, Siddiqi TJ, et al.: Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. *JAMA Netw Open* 2018 1:e183788.
576. Vilahur G, Ben-Aicha S, Badimon L: New insights into the role of adipose tissue in thrombosis. *Cardiovasc Res* 2017 113:1046-1054. <https://www.ncbi.nlm.nih.gov/pubmed/28472252>
577. Karmazyn M, Rajapurohitam V: Leptin as a cardiac pro-hypertrophic factor and its potential role in the development of heart failure. *Curr Pharm Des* 2014 20:646-651. <https://www.ncbi.nlm.nih.gov/pubmed/23688017>
578. Neeland IJ, Poirier P, Despres JP: Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. *Circulation* 2018 137:1391-1406. <https://www.ncbi.nlm.nih.gov/pubmed/29581366>
579. Ei Ei Khaing N, Shyong TE, Lee J, et al.: Epicardial and visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese population. *PLoS One* 2018 13:e0196328.
580. Abazid RM, Kattea MO, Sayed S, et al.: Visceral adipose tissue influences on coronary artery calcification at young and middle-age groups using computed tomography angiography. *Avicenna J Med* 2015 5:83-88.
581. Csige I, Ujvarosy D, Szabo Z, et al.: The Impact of Obesity on the Cardiovascular System. *J Diabetes Res* 2018 2018:3407306. <https://www.ncbi.nlm.nih.gov/pubmed/30525052>

Journal References: 582-591

Obesity and Cardiovascular Disease (continued)

582. Kaushik M, Reddy YM: Distinction of "fat around the heart". J Am Coll Cardiol 2011 58:1640; author reply 1640-1641. <https://www.ncbi.nlm.nih.gov/pubmed/21958896>
583. Prenner SB, Mather PJ: Obesity and heart failure with preserved ejection fraction: A growing problem. Trends Cardiovasc Med 2018 28:322-327. <https://www.ncbi.nlm.nih.gov/pubmed/29305040>
584. Tsujimoto T, Kajio H: Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF. J Am Coll Cardiol 2017 70:2739-2749. <https://www.ncbi.nlm.nih.gov/pubmed/29191321>
585. Packer M: Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. JAMA Cardiol 2018 3:883-887. <https://www.ncbi.nlm.nih.gov/pubmed/30046826>
586. Parikh KS, Sharma K, Fiuzat M, et al.: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC Heart Fail 2018 6:619-632. <https://www.ncbi.nlm.nih.gov/pubmed/30071950>
587. Savji N, Meijers WC, Bartz TM, et al.: The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail 2018 6:701-709. <https://www.ncbi.nlm.nih.gov/pubmed/30007554>
588. Obokata M, Reddy YNV, Pislaru SV, et al.: Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 2017 136:6-19. <https://www.ncbi.nlm.nih.gov/pubmed/28381470>
589. Oikonomou EK, Marwan M, Desai MY, et al.: Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 2018 392:929-939. <https://www.ncbi.nlm.nih.gov/pubmed/30170852>
590. Goeller M, Achenbach S, Marwan M, et al.: Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects. J Cardiovasc Comput Tomogr 2018 12:67-73. <https://www.ncbi.nlm.nih.gov/pubmed/29233634>
591. Wu Y, Zhang A, Hamilton DJ, et al.: Epicardial Fat in the Maintenance of Cardiovascular Health. Methodist DeBakey Cardiovasc J 2017 13:20-24. <https://www.ncbi.nlm.nih.gov/pubmed/28413578>

Journal References: 592-602

Obesity and Cardiovascular Disease (continued)

592. Pandey A, LaMonte M, Klein L, et al.: Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. *J Am Coll Cardiol* 2017 69:1129-1142.
593. Patel VB, Shah S, Verma S, et al.: Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. *Heart Fail Rev* 2017 22:889-902. <https://www.ncbi.nlm.nih.gov/pubmed/28762019>
594. Packer M: Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. *J Am Coll Cardiol* 2018 71:2360-2372. <https://www.ncbi.nlm.nih.gov/pubmed/29773163>
595. Fitzgibbons TP, Czech MP: Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. *J Am Heart Assoc* 2014 3:e000582. <https://www.ncbi.nlm.nih.gov/pubmed/24595191>
596. Javaheri S, Javaheri S, Javaheri A: Sleep apnea, heart failure, and pulmonary hypertension. *Curr Heart Fail Rep* 2013 10:315-320. <https://www.ncbi.nlm.nih.gov/pubmed/24097114>
597. Blokhin IO, Lentz SR: Mechanisms of thrombosis in obesity. *Curr Opin Hematol* 2013 20:437-444. <https://www.ncbi.nlm.nih.gov/pubmed/23817170>
598. Lefranc C, Friederich-Persson M, Palacios-Ramirez R, et al.: Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor. *J Endocrinol* 2018 238:R143-R159. <https://www.ncbi.nlm.nih.gov/pubmed/29875164>
599. Gruzdeva OV, Akbasheva OE, Dyleva YA, et al.: Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. *Bull Exp Biol Med* 2017 163:608-611. <https://www.ncbi.nlm.nih.gov/pubmed/28948552>
600. Uchida Y, Uchida Y, Shimoyama E, et al.: Human pericoronary adipose tissue as storage and possible supply site for oxidized low-density lipoprotein and high-density lipoprotein in coronary artery. *J Cardiol* 2017 69:236-244. <https://www.ncbi.nlm.nih.gov/pubmed/27209423>
601. Subbotin VM: Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis. *Theor Biol Med Model* 2012 9:11. <https://www.ncbi.nlm.nih.gov/pubmed/22490844>
602. Salazar J, Luzardo E, Mejias JC, et al.: Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. *Cardiol Res Pract* 2016 2016:1291537. <https://www.ncbi.nlm.nih.gov/pubmed/27213076>

Journal References 603-610

Obesity and Cardiovascular Disease (continued)

603. Zhu N, Jiang W, Wang Y, et al.: Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction. BMC Cardiovasc Disord 2018 18:104. <https://www.ncbi.nlm.nih.gov/pubmed/29843618>
604. Das SR, Everett BM, Birtcher KK, et al.: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018 72:3200-3223. <https://www.ncbi.nlm.nih.gov/pubmed/30497881>
605. Kramer CK, Ye C, Campbell S, et al.: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. JACC Heart Fail 2018 6:823-830. <https://www.ncbi.nlm.nih.gov/pubmed/30196071>
606. Sanches Machado d'Almeida K, Ronchi Spillere S, Zuchinali P, et al.: Mediterranean Diet and Other Dietary Patterns in Primary Prevention of Heart Failure and Changes in Cardiac Function Markers: A Systematic Review. Nutrients 2018 10: <https://www.ncbi.nlm.nih.gov/pubmed/29320401>
607. Jorsal A, Kistorp C, Holmager P, et al.: Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017 19:69-77. <https://www.ncbi.nlm.nih.gov/pubmed/27790809>
608. Retwinski A, Kosmalski M, Crespo-Leiro M, et al.: The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. Kardiol Pol 2018 76:1336-1343. <https://www.ncbi.nlm.nih.gov/pubmed/29862487>
609. Weir DL, Abrahamowicz M, Beauchamp ME, et al.: Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. Diabetes Obes Metab 2018 20:2653-2660. <https://www.ncbi.nlm.nih.gov/pubmed/29934961>
610. Margulies KB, Hernandez AF, Redfield MM, et al.: Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2016 316:500-508. <https://www.ncbi.nlm.nih.gov/pubmed/27483064>

Journal References: 611-620

Obesity and Cardiovascular Disease (continued)

611. Margulies KB, McNulty SE, Cappola TP: Lack of Benefit for Liraglutide in Heart Failure-Reply. JAMA 2016 316:2429-2430.
<https://www.ncbi.nlm.nih.gov/pubmed/27959992>
612. Vorsanger MH, Subramanyam P, Weintraub HS, et al.: Cardiovascular Effects of the New Weight Loss Agents. J Am Coll Cardiol 2016 68:849-859.
613. Bethel MA, Patel RA, Merrill P, et al.: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018 6:105-113.
614. Sharma A, Cooper LB, Fiuzat M, et al.: Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. JACC Heart Fail 2018 6:813-822.

Additional references used: [29][52][63][138][142][505][506][559]

Obesity and Elevated Blood Sugar

615. Cefalu WT, Kaul S, Gerstein HC, et al.: Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2018 41:14-31. <https://www.ncbi.nlm.nih.gov/pubmed/29263194>
616. Schnell O, Ryden L, Standl E, et al.: Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2017 16:128.
<https://www.ncbi.nlm.nih.gov/pubmed/29020969>
617. Andrikou E, Tsioufis C, Andrikou I, et al.: GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol 2018
<https://www.ncbi.nlm.nih.gov/pubmed/30528435>
618. O'Brien MJ, Karam SL, Wallia A, et al.: Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open 2018 1:e186125.
619. Bays H, Blonde L, Rosenson R: Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006 4:871-895. <https://www.ncbi.nlm.nih.gov/pubmed/17173503>
620. Bays H, Ballantyne C: Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 2006 1:389-420.

Journal References: 621-630

Obesity and Elevated Blood Sugar (continued)

621. Bays H, Abate N, Chandalia M: Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. *Future Cardiol* 2005 1:39-59. <https://www.ncbi.nlm.nih.gov/pubmed/19804060>
622. Bays H: Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. *Expert Rev Cardiovasc Ther* 2005 3:393-404. <https://www.ncbi.nlm.nih.gov/pubmed/15889967>
623. Yu JS, Cui W: Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development* 2016 143:3050-3060. <https://www.ncbi.nlm.nih.gov/pubmed/27578176>
624. Makki K, Froguel P, Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. *ISRN Inflamm* 2013 2013:139239. <https://www.ncbi.nlm.nih.gov/pubmed/24455420>
625. DeMarco VG, Aroor AR, Sowers JR: The pathophysiology of hypertension in patients with obesity. *Nat Rev Endocrinol* 2014 10:364-376. <https://www.ncbi.nlm.nih.gov/pubmed/24732974>
626. Zoller V, Funcke JB, Keuper M, et al.: TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors. *Cell Death Dis* 2016 7:e2412.
627. Fronczyk A, Moleda P, Safranow K, et al.: Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. *Inflammation* 2014 37:349-357. <https://www.ncbi.nlm.nih.gov/pubmed/24197824>
628. D'Souza A M, Neumann UH, Glavas MM, et al.: The glucoregulatory actions of leptin. *Mol Metab* 2017 6:1052-1065. <https://www.ncbi.nlm.nih.gov/pubmed/28951828>
629. Geer EB, Islam J, Buettner C: Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. *Endocrinol Metab Clin North Am* 2014 43:75-102. <https://www.ncbi.nlm.nih.gov/pubmed/24582093>
630. Fisette A, Lapointe M, Cianflone K: Obesity-inducing diet promotes acylation stimulating protein resistance. *Biochem Biophys Res Commun* 2013 437:403-407. <https://www.ncbi.nlm.nih.gov/pubmed/23831465>

Journal References: 631-640

Obesity and Elevated Blood Sugar (continued)

631. Thorp AA, Schlaich MP: Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. J Diabetes Res 2015 2015:341583. <https://www.ncbi.nlm.nih.gov/pubmed/26064978>
632. Stimson RH, Walker BR: The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Horm Mol Biol Clin Investig 2013 15:37-48.
633. Balland E, Chen W, Tiganis T, et al.: Persistent leptin signalling in the arcuate nucleus impairs hypothalamic insulin signalling and glucose homeostasis in obese mice. Neuroendocrinology 2019 <https://www.ncbi.nlm.nih.gov/pubmed/30995667>
634. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004 89:463-478. <https://www.ncbi.nlm.nih.gov/pubmed/14764748>
635. Veret J, Bellini L, Giussani P, et al.: Roles of Sphingolipid Metabolism in Pancreatic beta Cell Dysfunction Induced by Lipotoxicity. J Clin Med 2014 3:646-662. <https://www.ncbi.nlm.nih.gov/pubmed/26237395>
636. Larsen PJ, Tennagels N: On ceramides, other sphingolipids and impaired glucose homeostasis. Mol Metab 2014 3:252-260. <https://www.ncbi.nlm.nih.gov/pubmed/24749054>
637. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al.: Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for beta Cell Recovery. Cell Metab 2018 28:547-556 e543. <https://www.ncbi.nlm.nih.gov/pubmed/30078554>
638. Hernandez AF, Green JB, Janmohamed S, et al.: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018 392:1519-1529. <https://www.ncbi.nlm.nih.gov/pubmed/30291013>
639. Rosenstock J, Perkovic V, Johansen OE, et al.: Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30418475>
640. Wiviott SD, Raz I, Bonaca MP, et al.: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30415602>

Journal References: 641-648

Obesity and Elevated Blood Sugar (continued)

641. Hsu PF, Sung SH, Cheng HM, et al.: Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. J Clin Endocrinol Metab 2018 103:3611-3619. <https://www.ncbi.nlm.nih.gov/pubmed/30113697>
642. Verma S, Poulter NR, Bhatt DL, et al.: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation 2018 138:2884-2894. <https://www.ncbi.nlm.nih.gov/pubmed/30566004>
643. Gerstein HC, Colhoun HM, Dagenais GR, et al.: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 394:121-130. <https://www.ncbi.nlm.nih.gov/pubmed/31189511>
644. Marso SP, Bain SC, Consoli A, et al.: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016 375:1834-1844. <https://www.ncbi.nlm.nih.gov/pubmed/27633186>

Additional references used: [53][54][376][505][506][575]

Obesity and High Blood Pressure

645. Landsberg L, Aronne LJ, Beilin LJ, et al.: Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 2013 21:8-24. <https://www.ncbi.nlm.nih.gov/pubmed/23401272>
646. Kim DH, Kim C, Ding EL, et al.: Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension 2013 62:27-32. <https://www.ncbi.nlm.nih.gov/pubmed/23716587>
647. Nguyen NQ, Debreceni TL, Burgstad CM, et al.: Effects of Posture and Meal Volume on Gastric Emptying, Intestinal Transit, Oral Glucose Tolerance, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass. Obes Surg 2015 25:1392-1400. <https://www.ncbi.nlm.nih.gov/pubmed/25502436>
648. Kawarazaki W, Fujita T: The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens 2016 29:415-423. <https://www.ncbi.nlm.nih.gov/pubmed/26927805>

Journal References: 649-660

Obesity and High Blood Pressure (continued)

649. Lim K, Burke SL, Head GA: Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. *Hypertension* 2013 61:628-634. <https://www.ncbi.nlm.nih.gov/pubmed/23339171>
650. Trahair LG, Horowitz M, Jones KL: Postprandial hypotension: a systematic review. *J Am Med Dir Assoc* 2014 15:394-409. <https://www.ncbi.nlm.nih.gov/pubmed/24630686>
651. von Schnurbein J, Manzoor J, Brandt S, et al.: Leptin Is Not Essential for Obesity-Associated Hypertension. *Obes Facts* 2019 12:460-475. <https://www.ncbi.nlm.nih.gov/pubmed/31357197>
652. Rust P, Ekmekcioglu C: Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension. *Adv Exp Med Biol* 2017 956:61-84. <https://www.ncbi.nlm.nih.gov/pubmed/27757935>
653. DiNicolantonio JJ, Lucan SC: The wrong white crystals: not salt but sugar as aetiological in hypertension and cardiometabolic disease. *Open Heart* 2014 1:e000167.
654. Grillo A, Salvi L, Coruzzi P, et al.: Sodium Intake and Hypertension. *Nutrients* 2019 11:<https://www.ncbi.nlm.nih.gov/pubmed/31438636>
655. Farquhar WB, Edwards DG, Jurkowitz CT, et al.: Dietary sodium and health: more than just blood pressure. *J Am Coll Cardiol* 2015 65:1042-1050. <https://www.ncbi.nlm.nih.gov/pubmed/25766952>
656. Barton M, Baretella O, Meyer MR: Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. *Br J Pharmacol* 2012 165:591-602. <https://www.ncbi.nlm.nih.gov/pubmed/21557734>
657. Buckley LF, Canada JM, Del Buono MG, et al.: Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. *ESC Heart Fail* 2018 5:372-378. <https://www.ncbi.nlm.nih.gov/pubmed/29345112>
658. Engin A: Endothelial Dysfunction in Obesity. *Adv Exp Med Biol* 2017 960:345-379. <https://www.ncbi.nlm.nih.gov/pubmed/28585207>
659. Khalid U, Wruck LM, Quibrera PM, et al.: BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. *Int J Cardiol* 2017 233:61-66. <https://www.ncbi.nlm.nih.gov/pubmed/28185703>
660. Kistorp C, Bliddal H, Goetze JP, et al.: Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. *BMC Obes* 2014 1:24. <https://www.ncbi.nlm.nih.gov/pubmed/26217511>

Additional references used: [29][52][513][620][631]

Journal References: 661-668

Obesity and Dyslipidemia

661. Dansinger M, Williams PT, Superko HR, et al.: Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women. *J Clin Lipidol* 2019 13:308-316. <https://www.ncbi.nlm.nih.gov/pubmed/30665769>
662. Bays H, Kothari SN, Azagury DE, et al.: Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). *Surg Obes Relat Dis* 2016 12:468-495. <https://www.ncbi.nlm.nih.gov/pubmed/27050404>
663. Aguilar D, Fernandez ML: Hypercholesterolemia induces adipose dysfunction in conditions of obesity and nonobesity. *Adv Nutr* 2014 5:497-502. <https://www.ncbi.nlm.nih.gov/pubmed/25469381>
664. Collins JM, Neville MJ, Pinnick KE, et al.: De novo lipogenesis in the differentiating human adipocyte can provide all fatty acids necessary for maturation. *J Lipid Res* 2011 52:1683-1692. <https://www.ncbi.nlm.nih.gov/pubmed/21677304>
665. Chung S, Parks JS: Dietary cholesterol effects on adipose tissue inflammation. *Curr Opin Lipidol* 2016 27:19-25. <https://www.ncbi.nlm.nih.gov/pubmed/26655292>
666. Christou GA, Kiortsis DN: Adiponectin and lipoprotein metabolism. *Obes Rev* 2013 14:939-949. <https://www.ncbi.nlm.nih.gov/pubmed/23957239>
667. Ebbert JO, Jensen MD: Fat depots, free fatty acids, and dyslipidemia. *Nutrients* 2013 5:498-508. <https://www.ncbi.nlm.nih.gov/pubmed/23434905>
668. Klop B, Elte JW, Cabezas MC: Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients* 2013 5:1218-1240. <https://www.ncbi.nlm.nih.gov/pubmed/23584084>

Additional references used: [10][29][54][63][92][181][568]

Journal References: 669-679

Obesity and Non-alcoholic Fatty Liver Disease (NAFLD)

669. Barb D, Portillo-Sanchez P, Cusi K: Pharmacological management of nonalcoholic fatty liver disease. *Metabolism* 2016 65:1183-1195.
<https://www.ncbi.nlm.nih.gov/pubmed/27301803>
670. Choo VL, Vigiou E, Blanco Mejia S, et al.: Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies. *BMJ* 2018 363:k4644. <https://www.ncbi.nlm.nih.gov/pubmed/30463844>
671. Jung UJ, Choi MS: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 2014 15:6184-6223.
<https://www.ncbi.nlm.nih.gov/pubmed/24733068>
672. Calzadilla Bertot L, Adams LA: The Natural Course of Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci* 2016 17:
673. Kanda H, Tateya S, Tamori Y, et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J Clin Invest* 2006 116:1494-1505. <https://www.ncbi.nlm.nih.gov/pubmed/16691291>
674. Duwaerts CC, Maher JJ: Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. *Curr Hepatol Rep* 2014 13:119-129.
<https://www.ncbi.nlm.nih.gov/pubmed/25045618>
675. Saponaro C, Gaggini M, Carli F, et al.: The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. *Nutrients* 2015 7:9453-9474. <https://www.ncbi.nlm.nih.gov/pubmed/26580649>
676. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018 67:328-357.
<https://www.ncbi.nlm.nih.gov/pubmed/28714183>
677. Lee DH: Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. *Clin Mol Hepatol* 2017 23:290-301.
<https://www.ncbi.nlm.nih.gov/pubmed/28994271>
678. Idilman IS, Keskin O, Celik A, et al.: A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. *Acta Radiol* 2016 57:271-278.
<https://www.ncbi.nlm.nih.gov/pubmed/25855666>
679. Leoni S, Tovoli F, Napoli L, et al.: Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World J Gastroenterol* 2018 24:3361-3373.

Journal References: 680-689

Obesity and Non-alcoholic Fatty Liver Disease (NAFLD) (continued)

680. Pandeyarajan V, Gish RG, Alkhoury N, et al.: Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterol Hepatol (N Y) 2019 15:357-365. <https://www.ncbi.nlm.nih.gov/pubmed/31391806>
- 681.de Alwis NM, Anstee QM, Day CP: How to Diagnose Nonalcoholic Fatty Liver Disease. Dig Dis 2016 34 Suppl 1:19-26. <https://www.ncbi.nlm.nih.gov/pubmed/27547937>
- 682.Kneeman JM, Misdraji J, Corey KE: Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012 5:199-207. <https://www.ncbi.nlm.nih.gov/pubmed/22570680>
- 683.Vos MB, Abrams SH, Barlow SE, et al.: NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017 64:319-334. <https://www.ncbi.nlm.nih.gov/pubmed/28107283>
- 684.Harrison SA, Neuschwander-Tetri BA: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004 8:861-879, ix. <https://www.ncbi.nlm.nih.gov/pubmed/15464659>
- 685.Luukkonen PK, Sadevirta S, Zhou Y, et al.: Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care 2018 41:1732-1739. <https://www.ncbi.nlm.nih.gov/pubmed/29844096>
686. van der Windt DJ, Sud V, Zhang H, et al.: The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018 18:89-101.

Obesity and Cancer

- 687.Islami F, Goding Sauer A, Gapstur SM, et al.: Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015. JAMA Oncol 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30589925>
- 688.Sung H, Siegel RL, Torre LA, et al.: Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 2018 <https://www.ncbi.nlm.nih.gov/pubmed/30548482>
- 689.Sung H, Siegel RL, Rosenberg PS, et al.: Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019 <https://www.ncbi.nlm.nih.gov/pubmed/30733056>

Journal References: 690-701

Obesity and Cancer (continued)

690. Spyrou N, Avgerinos KI, Mantzoros CS, et al.: Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies. *Curr Obes Rep* 2018 7:260-275. <https://www.ncbi.nlm.nih.gov/pubmed/30145771>
691. Golemis EA, Scheet P, Beck TN, et al.: Molecular mechanisms of the preventable causes of cancer in the United States. *Genes Dev* 2018 32:868-902. <https://www.ncbi.nlm.nih.gov/pubmed/29945886>
692. Druso JE, Fischbach C: Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer. *Trends Cancer* 2018 4:271-273. <https://www.ncbi.nlm.nih.gov/pubmed/29606310>
693. Wlodarczyk M, Nowicka G: Obesity, DNA Damage, and Development of Obesity-Related Diseases. *Int J Mol Sci* 2019 20:https://www.ncbi.nlm.nih.gov/pubmed/30845725
694. Mackenzie H, Markar SR, Askari A, et al.: Obesity surgery and risk of cancer. *Br J Surg* 2018 105:1650-1657. <https://www.ncbi.nlm.nih.gov/pubmed/30003539>
695. Seiler A, Chen MA, Brown RL, et al.: Obesity, Dietary Factors, Nutrition, and Breast Cancer Risk. *Curr Breast Cancer Rep* 2018 10:14-27.
696. Pan K, Luo J, Aragaki AK, et al.: Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. *Oncotarget* 2019 10:3088-3092. <https://www.ncbi.nlm.nih.gov/pubmed/31139321>
697. Diallo A, Deschasaux M, Latino-Martel P, et al.: Red and processed meat intake and cancer risk: Results from the prospective NutriNet-Sante cohort study. *Int J Cancer* 2018 142:230-237. <https://www.ncbi.nlm.nih.gov/pubmed/28913916>
698. Liou GY, Storz P: Reactive oxygen species in cancer. *Free Radic Res* 2010 44:479-496.
699. Salehi B, Martorell M, Arbiser JL, et al.: Antioxidants: Positive or Negative Actors? *Biomolecules* 2018 8: <https://www.ncbi.nlm.nih.gov/pubmed/30366441>
700. Gorlach A, Dimova EY, Petry A, et al.: Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? *Redox Biol* 2015 6:372-385. <https://www.ncbi.nlm.nih.gov/pubmed/26339717>
701. Davidson KT, Zhu Z, Balabanov D, et al.: Beyond Conventional Medicine - a Look at Blueberry, a Cancer-Fighting Superfruit. *Pathol Oncol Res* 2018 24:733-738.

Journal References: 702-711

Obesity and Cancer (continued)

702. Turati F, Rossi M, Pelucchi C, et al.: Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr 2015 113 Suppl 2:S102-110.

Additional references used: [92][119]

Obesity and Psychiatric Disease

703. Wurtman J, Wurtman R: The Trajectory from Mood to Obesity. Curr Obes Rep 2018 7:1-5. <https://www.ncbi.nlm.nih.gov/pubmed/29218451>

704. Jantaratnotai N, Mosikanon K, Lee Y, et al.: The interface of depression and obesity. Obes Res Clin Pract 2017 11:1-10.

<https://www.ncbi.nlm.nih.gov/pubmed/27498907>

705. Rajan TM, Menon V: Psychiatric disorders and obesity: A review of association studies. J Postgrad Med 2017 63:182-190.

<https://www.ncbi.nlm.nih.gov/pubmed/28695871>

706. Kohn JN, Cabrera Y, Dimitrov S, et al.: Sex-specific roles of cellular inflammation and cardiometabolism in obesity-associated depressive symptomatology. Int J Obes (Lond) 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31089263>

707. Kurhe Y, Mahesh R: Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention. Asian J Psychiatr 2015 17:3-9. <https://www.ncbi.nlm.nih.gov/pubmed/26243683>

708. Kvam S, Kleppe CL, Nordhus IH, et al.: Exercise as a treatment for depression: A meta-analysis. J Affect Disord 2016 202:67-86.

<https://www.ncbi.nlm.nih.gov/pubmed/27253219>

709. Krogh J, Hjorthoj C, Speyer H, et al.: Exercise for patients with major depression: a systematic review with meta-analysis and trial sequential analysis. BMJ Open 2017 7:e014820. <https://www.ncbi.nlm.nih.gov/pubmed/28928174>

710. Crow SJ: Pharmacologic Treatment of Eating Disorders. Psychiatr Clin North Am 2019 42:253-262.

<https://www.ncbi.nlm.nih.gov/pubmed/31046927>

711. Bello NT, Yeomans BL: Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf 2018 17:17-23. <https://www.ncbi.nlm.nih.gov/pubmed/29053927>

Journal References: 712-720

Obesity and Psychiatric Disease (continued)

712. Arnone D: Review of the use of Topiramate for treatment of psychiatric disorders. *Ann Gen Psychiatry* 2005 4:5. <https://www.ncbi.nlm.nih.gov/pubmed/15845141>
713. Brownley KA, Berkman ND, Peat CM, et al.: Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. *Ann Intern Med* 2016 165:409-420. <https://www.ncbi.nlm.nih.gov/pubmed/27367316>
714. Dayabandara M, Hanwella R, Ratnatunga S, et al.: Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. *Neuropsychiatr Dis Treat* 2017 13:2231-2241. <https://www.ncbi.nlm.nih.gov/pubmed/28883731>
715. Solmi M, Murru A, Pacchiarotti I, et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther Clin Risk Manag* 2017 13:757-777. <https://www.ncbi.nlm.nih.gov/pubmed/28721057>
716. Zhuo C, Xu Y, Liu S, et al.: Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis. *Front Pharmacol* 2018 9:1393. <https://www.ncbi.nlm.nih.gov/pubmed/30546312>
717. Mora F, Molina JD, Zubillaga E, et al.: CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs. doi:10.4172/2161-1459.1000176. <https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf>. *Clin Exp Pharmacol Physiol* 2015 5:1-10.
718. Urichuk L, Prior TI, Dursun S, et al.: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. *Curr Drug Metab* 2008 9:410-418. <https://www.ncbi.nlm.nih.gov/pubmed/18537577>

Additional references used: [15][16][18][161][270][461]

Obesity Myths

719. Chaput JP, Ferraro ZM, Prud'homme D, et al.: Widespread misconceptions about obesity. *Can Fam Physician* 2014 60:973-975, 981-974. <https://www.ncbi.nlm.nih.gov/pubmed/25392431>
720. Rico-Campa A, Martinez-Gonzalez MA, Alvarez-Alvarez I, et al.: Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. *BMJ* 2019 365:l1949. <https://www.ncbi.nlm.nih.gov/pubmed/31142450>

Journal References: 721-731

Obesity Myths (continued)

721. Hall KD, Ayuketah A, Brychta R, et al.: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. *Cell Metab* 2019 30:226. <https://www.ncbi.nlm.nih.gov/pubmed/31269427>
722. Srour B, Fezeu LK, Kesse-Guyot E, et al.: Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Sante). *BMJ* 2019 365:l1451. <https://www.ncbi.nlm.nih.gov/pubmed/31142457>
723. Vandevijvere S, Jaacks LM, Monteiro CA, et al.: Global trends in ultraprocessed food and drink product sales and their association with adult body mass index trajectories. *Obes Rev* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31099480>
724. Ludwig DS, Astrup A, Bazzano LA, et al.: Ultra-Processed Food and Obesity: The Pitfalls of Extrapolation from Short Studies. *Cell Metab* 2019 30:3-4. <https://www.ncbi.nlm.nih.gov/pubmed/31230987>
725. Monteiro CA, Cannon G, Moubarac JC, et al.: The UN Decade of Nutrition, the NOVA food classification and the trouble with ultra-processing. *Public Health Nutr* 2018 21:5-17. <https://www.ncbi.nlm.nih.gov/pubmed/28322183>
726. Monteiro CA, Cannon G, Levy RB, et al.: Ultra-processed foods: what they are and how to identify them. *Public Health Nutr* 2019 22:936-941. <https://www.ncbi.nlm.nih.gov/pubmed/30744710>
727. Rong S, Sneltselaar LG, Xu G, et al.: Association of Skipping Breakfast With Cardiovascular and All-Cause Mortality. *J Am Coll Cardiol* 2019 73:2025-2032. <https://www.ncbi.nlm.nih.gov/pubmed/31023424>
728. Ballon A, Neuenschwander M, Schlesinger S: Breakfast Skipping Is Associated with Increased Risk of Type 2 Diabetes among Adults: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *J Nutr* 2019 149:106-113. <https://www.ncbi.nlm.nih.gov/pubmed/30418612>
729. Sievert K, Hussain SM, Page MJ, et al.: Effect of breakfast on weight and energy intake: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2019 364:l42. <https://www.ncbi.nlm.nih.gov/pubmed/30700403>
730. Chowdhury EA, Richardson JD, Gonzalez JT, et al.: Six Weeks of Morning Fasting Causes Little Adaptation of Metabolic or Appetite Responses to Feeding in Adults with Obesity. *Obesity (Silver Spring)* 2019 27:813-821. <https://www.ncbi.nlm.nih.gov/pubmed/30925197>
731. Betts JA, Chowdhury EA, Gonzalez JT, et al.: Is breakfast the most important meal of the day? *Proc Nutr Soc* 2016 75:464-474. <https://www.ncbi.nlm.nih.gov/pubmed/27292940>

Journal References: 732-743

Obesity Myths (continued)

732. Casazza K, Fontaine KR, Astrup A, et al.: Myths, presumptions, and facts about obesity. N Engl J Med 2013 368:446-454.
<https://www.ncbi.nlm.nih.gov/pubmed/23363498>
733. Bjerregaard LG, Pedersen DC, Mortensen EL, et al.: Breastfeeding duration in infancy and adult risks of type 2 diabetes in a high-income country. Matern Child Nutr 2019 e12869. <https://www.ncbi.nlm.nih.gov/pubmed/31267694>
734. Woo JG, Martin LJ: Does Breastfeeding Protect Against Childhood Obesity? Moving Beyond Observational Evidence. Curr Obes Rep 2015 4:207-216. <https://www.ncbi.nlm.nih.gov/pubmed/26627216>
735. Ventura AK: Does Breastfeeding Shape Food Preferences? Links to Obesity. Ann Nutr Metab 2017 70 Suppl 3:8-15.
<https://www.ncbi.nlm.nih.gov/pubmed/28903109>
736. Verduci E, Banderali G, Barberi S, et al.: Epigenetic effects of human breast milk. Nutrients 2014 6:1711-1724.
<https://www.ncbi.nlm.nih.gov/pubmed/24763114>
737. Allegretti JR, Kassam Z, Mullish BH, et al.: Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31301451>
738. Hunter GR, Singh H, Carter SJ, et al.: Sarcopenia and Its Implications for Metabolic Health. J Obes 2019 2019:8031705.
<https://www.ncbi.nlm.nih.gov/pubmed/30956817>
739. Rossi AP, Rubele S, Calugi S, et al.: Weight Cycling as a Risk Factor for Low Muscle Mass and Strength in a Population of Males and Females with Obesity. Obesity (Silver Spring) 2019 27:1068-1075. <https://www.ncbi.nlm.nih.gov/pubmed/31231958>
740. Wang Z, Ying Z, Bosy-Westphal A, et al.: Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am J Clin Nutr 2010 92:1369-1377. <https://www.ncbi.nlm.nih.gov/pubmed/20962155>
741. Bays HE, Gonzalez-Campoy JM: Adiposopathy. . New Opathies: An Emerging Molecular Reclassification of Human Disease 2012 105-168.
742. Pontzer H, Durazo-Arvizu R, Dugas LR, et al.: Constrained Total Energy Expenditure and Metabolic Adaptation to Physical Activity in Adult Humans. Curr Biol 2016 26:410-417. <https://www.ncbi.nlm.nih.gov/pubmed/26832439>
743. Drenowatz C, Grieve GL, DeMello MM: Change in energy expenditure and physical activity in response to aerobic and resistance exercise programs. Springerplus 2015 4:798. <https://www.ncbi.nlm.nih.gov/pubmed/26702387>

Journal References: 744-754

Obesity Myths (continued)

744. Ainsworth BE: 2011 Compendium of physical activities. *Medicine & Science in Sports & Exercise* 2011 43:1575.
745. Sperandei S, Vieira MC, Reis AC: Adherence to physical activity in an unsupervised setting: Explanatory variables for high attrition rates among fitness center members. *J Sci Med Sport* 2016 19:916-920. <https://www.ncbi.nlm.nih.gov/pubmed/26874647>
746. Yen HY, Chiu HL: The effectiveness of wearable technologies as physical activity interventions in weight control: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2019 20:1485-1493. <https://www.ncbi.nlm.nih.gov/pubmed/31342646>
747. Varkevisser RDM, van Stralen MM, Kroeze W, et al.: Determinants of weight loss maintenance: a systematic review. *Obes Rev* 2019 20:171-211. <https://www.ncbi.nlm.nih.gov/pubmed/30324651>
748. Ramage S, Farmer A, Eccles KA, et al.: Healthy strategies for successful weight loss and weight maintenance: a systematic review. *Appl Physiol Nutr Metab* 2014 39:1-20. <https://www.ncbi.nlm.nih.gov/pubmed/24383502>

Additional references used: [21][22][25][311][312][313][634]

Investigational Anti-obesity Pharmacotherapy

749. Bray G: *Battle of the Bulge*. Dorrance Publishing 2007 59.
750. James WP, Caterson ID, Coutinho W, et al.: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med* 2010 363:905-917. <https://www.ncbi.nlm.nih.gov/pubmed/20818901>
751. Saxena A, Sachin K: A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets. *Curr Genomics* 2018 19:630-666.
752. Srivastava G, Apovian C: Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. *Curr Obes Rep* 2018 7:147-161. <https://www.ncbi.nlm.nih.gov/pubmed/29504049>
753. Xiong Y, Walker K, Min X, et al.: Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys. *Sci Transl Med* 2017 9: <https://www.ncbi.nlm.nih.gov/pubmed/29046435>
754. Pocai A: Action and therapeutic potential of oxyntomodulin. *Mol Metab* 2014 3:241-251. <https://www.ncbi.nlm.nih.gov/pubmed/24749050>

Journal References: 755-766

Investigational Anti-obesity Pharmacotherapy (continued)

755. Khatib MN, Gaidhane S, Gaidhane AM, et al.: Ghrelin O Acyl Transferase (GOAT) as a Novel Metabolic Regulatory Enzyme. *J Clin Diagn Res* 2015 9:Le01-05.
756. Zhang SR, Fan XM: Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. *World J Gastroenterol* 2015 21:3214-3222. <https://www.ncbi.nlm.nih.gov/pubmed/25805927>
757. Pratley RE, Kang J, Trautmann ME, et al.: Body weight management and safety with epeglenatide in adults without diabetes: A phase II randomized study. *Diabetes Obes Metab* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31264757>
758. Chen J, Zhao H, Ma X, et al.: GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis. *Cell Physiol Biochem* 2017 42:1165-1176. <https://www.ncbi.nlm.nih.gov/pubmed/28668964>
759. Liu R, Li N, Lin Y, et al.: Glucagon Like Peptide-1 Promotes Adipocyte Differentiation via the Wnt4 Mediated Sequestering of Beta-Catenin. *PLoS One* 2016 11:e0160212. <https://www.ncbi.nlm.nih.gov/pubmed/27504979>
760. Guo C, Huang T, Chen A, et al.: Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. *Braz J Med Biol Res* 2016 49:e5826. <https://www.ncbi.nlm.nih.gov/pubmed/27878229>
761. Wang A, Li T, An P, et al.: Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. *PLoS One* 2017 12:e0169469. <https://www.ncbi.nlm.nih.gov/pubmed/28122026>
762. Sanchez-Garrido MA, Brandt SJ, Clemmensen C, et al.: GLP-1/glucagon receptor co-agonism for treatment of obesity. *Diabetologia* 2017 60:1851-1861. <https://www.ncbi.nlm.nih.gov/pubmed/28733905>
763. Gantz I, Erondü N, Mallick M, et al.: Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. *J Clin Endocrinol Metab* 2007 92:1754-1757. <https://www.ncbi.nlm.nih.gov/pubmed/17341568>
764. Scott R, Minnion J, Tan T, et al.: Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. *Peptides* 2018 104:70-77. <https://www.ncbi.nlm.nih.gov/pubmed/29680267>
765. Persaud SJ, Bewick GA: Peptide YY: more than just an appetite regulator. *Diabetologia* 2014 57:1762-1769. <https://www.ncbi.nlm.nih.gov/pubmed/24917132>
766. Camilleri M, Acosta A: Combination Therapies for Obesity. *Metab Syndr Relat Disord* 2018 16:390-394. <https://www.ncbi.nlm.nih.gov/pubmed/29993319>

Journal References: 767-778

Investigational Anti-obesity Pharmacotherapy (continued)

767. Frias JP, Nauck MA, Van J, et al.: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. *Lancet* 2018 392:2180-2193.
<https://www.ncbi.nlm.nih.gov/pubmed/30293770>
768. Coskun T, Sloop KW, Loghin C, et al.: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. *Mol Metab* 2018 18:3-14. <https://www.ncbi.nlm.nih.gov/pubmed/30473097>
769. Alexiadou K, Anyiam O, Tan T: Cracking the combination: Gut hormones for the treatment of obesity and diabetes. *J Neuroendocrinol* 2018 e12664. <https://www.ncbi.nlm.nih.gov/pubmed/30466162>
770. Bessesen DH, Van Gaal LF: Progress and challenges in anti-obesity pharmacotherapy. *Lancet Diabetes Endocrinol* 2018 6:237-248.
771. Yashiro H, Hamagami K, Hiyoshi H, et al.: SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. *Diabetes Obes Metab* 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31144422>
772. Bergmann NC, Lund A, Gasbjerg LS, et al.: Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. *Diabetologia* 2019 62:665-675.
<https://www.ncbi.nlm.nih.gov/pubmed/30683945>
773. Jorsal T, Rungby J, Knop FK, et al.: GLP-1 and Amylin in the Treatment of Obesity. *Curr Diab Rep* 2016 16:1.
<https://www.ncbi.nlm.nih.gov/pubmed/26699764>
774. Morton NM, Seckl JR: 11beta-hydroxysteroid dehydrogenase type 1 and obesity. *Front Horm Res* 2008 36:146-164.
<https://www.ncbi.nlm.nih.gov/pubmed/18230901>
775. Duerrschmid C, He Y, Wang C, et al.: Asprosin is a centrally acting orexigenic hormone. *Nat Med* 2017 23:1444-1453.
<https://www.ncbi.nlm.nih.gov/pubmed/29106398>
776. Tassi E, Garman KA, Schmidt MO, et al.: Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. *Sci Rep* 2018 8:15973. <https://www.ncbi.nlm.nih.gov/pubmed/30374109>
777. Sonoda J, Chen MZ, Baruch A: FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. *Horm Mol Biol Clin Investig* 2017 30:<https://www.ncbi.nlm.nih.gov/pubmed/28525362>
778. Achari AE, Jain SK: Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. *Int J Mol Sci* 2017 <https://www.ncbi.nlm.nih.gov/pubmed/28635626>

Journal References: 779-789

Investigational Anti-obesity Pharmacotherapy (continued)

779. Kim SH, Plutzky J: Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. *Diabetes Metab J* 2016 40:12-21. <https://www.ncbi.nlm.nih.gov/pubmed/26912151>
780. Mullican SE, Lin-Schmidt X, Chin CN, et al.: GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. *Nat Med* 2017 23:1150-1157. <https://www.ncbi.nlm.nih.gov/pubmed/28846097>
781. Mullican SE, Rangwala SM: Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond. *Trends Endocrinol Metab* 2018 29:560-570. <https://www.ncbi.nlm.nih.gov/pubmed/29866502>
782. Sramkova V, Koc M, Krauzova E, et al.: Expression of lipogenic markers is decreased in subcutaneous adipose tissue and adipocytes of older women and is negatively linked to GDF15 expression. *J Physiol Biochem* 2019 75:253-262. <https://www.ncbi.nlm.nih.gov/pubmed/30912009>
783. Dludla PV, Nkambule BB, Jack B, et al.: Inflammation and Oxidative Stress in an Obese State and the Protective Effects of Gallic Acid. *Nutrients* 2018 11: <https://www.ncbi.nlm.nih.gov/pubmed/30577684>
784. Scott RV, Bloom SR: Problem or solution: The strange story of glucagon. *Peptides* 2018 100:36-41. <https://www.ncbi.nlm.nih.gov/pubmed/29412829>
785. Muo IM, MacDonald SD, Madan R, et al.: Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study. *Diabetes Metab Syndr Obes* 2019 12:743-759. <https://www.ncbi.nlm.nih.gov/pubmed/31213865>
786. Monteiro MP: Obesity vaccines. *Hum Vaccin Immunother* 2014 10:887-895. <https://www.ncbi.nlm.nih.gov/pubmed/24365968>
787. Pathak V, Flatt PR, Irwin N: Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. *Peptides* 2018 100:229-235. <https://www.ncbi.nlm.nih.gov/pubmed/29412823>
788. Malloy J, Zhuang D, Kim T, et al.: Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial. *Diabetes Obes Metab* 2018 20:1878-1884. <https://www.ncbi.nlm.nih.gov/pubmed/29577550>
789. Tam CS, Lecoultrre V, Ravussin E: Novel strategy for the use of leptin for obesity therapy. *Expert Opin Biol Ther* 2011 11:1677-1685. <https://www.ncbi.nlm.nih.gov/pubmed/21910668>

Journal References: 790-799

Investigational Anti-obesity Pharmacotherapy (continued)

790. Behary P, Tharakan G, Alexiadou K, et al.: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. *Diabetes Care* 2019 42:1446-1453. <https://www.ncbi.nlm.nih.gov/pubmed/31177183>
791. Mosli MM, Elyas M: Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? *Saudi J Gastroenterol* 2017 23:117-122. <https://www.ncbi.nlm.nih.gov/pubmed/28361843>
792. He YL, Haynes W, Meyers CD, et al.: The effects of licoglitflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. *Diabetes Obes Metab* 2019 21:1311-1321. <https://www.ncbi.nlm.nih.gov/pubmed/30724002>
793. Erondou N, Gantz I, Musser B, et al.: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. *Cell Metab* 2006 4:275-282. <https://www.ncbi.nlm.nih.gov/pubmed/17011500>
794. Erondou N, Wadden T, Gantz I, et al.: Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. *Obesity (Silver Spring)* 2007 15:895-905. <https://www.ncbi.nlm.nih.gov/pubmed/17426325>
795. Bays HE, Weinstein R, Law G, et al.: Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. *Obesity (Silver Spring)* 2014 22:1042-1049. <https://www.ncbi.nlm.nih.gov/pubmed/24227660>
796. Yabe D, Iwasaki M, Kuwata H, et al.: Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. *Diabetes Obes Metab* 2017 19:739-743. <https://www.ncbi.nlm.nih.gov/pubmed/27990776>
797. Smith SR, Garvey WT, Greenway FL, et al.: Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. *Obesity (Silver Spring)* 2017 25:857-865. <https://www.ncbi.nlm.nih.gov/pubmed/28440045>
798. Hollander P, Bays HE, Rosenstock J, et al.: Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. *Diabetes Care* 2017 40:632-639. <https://www.ncbi.nlm.nih.gov/pubmed/28289041>
799. Tronieri JS, Wadden TA, Walsh OA, et al.: Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. *Metabolism* 2019 96:83-91. <https://www.ncbi.nlm.nih.gov/pubmed/30902750>

Journal References: 800-811

Investigational Anti-obesity Pharmacotherapy (continued)

800. Rossini AA: Why control blood glucose levels? Arch Surg 1976 111:229-233. <https://www.ncbi.nlm.nih.gov/pubmed/816331>
801. Ryan C: New controversies in hypertension: questions answered, answers questioned. Compr Ther 1992 18:20-24. <https://www.ncbi.nlm.nih.gov/pubmed/1547598>
802. Thompson WG: Cholesterol: myth or reality? South Med J 1990 83:435-440. <https://www.ncbi.nlm.nih.gov/pubmed/2181692>
803. Tobert JA: The cholesterol controversy. BMJ 1992 304:713. <https://www.ncbi.nlm.nih.gov/pubmed/1571657>
804. Bierman EL: The oral antidiabetic agents. Am Fam Physician 1976 13:98-104. <https://www.ncbi.nlm.nih.gov/pubmed/1251792>
805. Rys P, Wojciechowski P, Rogoz-Sitek A, et al.: Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015 52:649-662. <https://www.ncbi.nlm.nih.gov/pubmed/25585592>
806. Mannucci E, Monami M, Masotti G, et al.: All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004 20:44-47. <https://www.ncbi.nlm.nih.gov/pubmed/14737744>
807. Gerber JG, Freed CR, Nies AS: Antihypertensive pharmacology. West J Med 1980 132:430-439. <https://www.ncbi.nlm.nih.gov/pubmed/6992462>
808. Bays HE, Ballantyne C: What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009 20:467-476. <https://www.ncbi.nlm.nih.gov/pubmed/19779335>
809. Maki KC, Bays HE, Dicklin MR: Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 2012 6:413-426. <https://www.ncbi.nlm.nih.gov/pubmed/23009777>
810. Bays HE, Goldberg RB: The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007 14:567-580. <https://www.ncbi.nlm.nih.gov/pubmed/18090882>
811. Muppidi A, Zou H, Yang PY, et al.: Design of Potent and Proteolytically Stable Oxyntomodulin Analogs. ACS Chem Biol 2016 11:324-328. <https://www.ncbi.nlm.nih.gov/pubmed/26727558>

Additional references used: [54][78][280][395][555][567][629]

Journal References: 812-819

Early versus Late Weight Management Intervention

- 812.Jensen MD, Ryan DH, Apovian CM, et al.: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014 63:2985-3023. <https://www.ncbi.nlm.nih.gov/pubmed/24239920>
- 813.Garber AJ, Abrahamson MJ, Barzilay JI, et al.: American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract 2013 19:536-557. <https://www.ncbi.nlm.nih.gov/pubmed/23816937>
- 814.James PA, Oparil S, Carter BL, et al.: 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 311:507-520. <https://www.ncbi.nlm.nih.gov/pubmed/24352797>
- 815.American Diabetes A: 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019 42:S81-S89. <https://www.ncbi.nlm.nih.gov/pubmed/30559234>

Additional references used: [29][63][181][508][645]

Gastrointestinal (GI) Hormones

- 816.Dimitriadis GK, Randeve MS, Miras AD: Potential Hormone Mechanisms of Bariatric Surgery. Curr Obes Rep 2017 6:253-265. <https://www.ncbi.nlm.nih.gov/pubmed/28780756>
- 817.Khalaf KI, Taegtmeier H: Clues from bariatric surgery: reversing insulin resistance to heal the heart. Curr Diab Rep 2013 13:245-251. <https://www.ncbi.nlm.nih.gov/pubmed/23354680>
- 818.Batterham RL, Cummings DE: Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care 2016 39:893-901. <https://www.ncbi.nlm.nih.gov/pubmed/27222547>
- 819.Meek CL, Lewis HB, Reimann F, et al.: The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016 77:28-37. <https://www.ncbi.nlm.nih.gov/pubmed/26344355>

Journal References: 820-827

Gastrointestinal (GI) Hormones

820.Nannipieri M, Baldi S, Mari A, et al.: Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 2013 98:4391-4399. <https://www.ncbi.nlm.nih.gov/pubmed/24057293>

Additional references used: [92][662]

Bariatric Surgery

821.Neff KJ, Olbers T, le Roux CW: Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Med 2013 11:8. <https://www.ncbi.nlm.nih.gov/pubmed/23302153>

822.Dixon JB: Referral for a bariatric surgical consultation: it is time to set a standard of care. Obes Surg 2009 19:641-644. <https://www.ncbi.nlm.nih.gov/pubmed/19005734>

823.Mechanick JI, Youdim A, Jones DB, et al.: Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013 21 Suppl 1:S1-27. <https://www.ncbi.nlm.nih.gov/pubmed/23529939>

824. American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS). Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program <https://www.facs.org/quality-programs/mbsaqip> (Accessed August 21, 2016).

825.Appachi S, Kashyap SR: 'Adiposopathy' and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol 2013 28:540-546. <https://www.ncbi.nlm.nih.gov/pubmed/23928918>

826.Abbatini F, Capoccia D, Casella G, et al.: Long-term remission of type 2 diabetes in morbidly obese patients after sleeve gastrectomy. Surg Obes Relat Dis 2013 9:498-502. <https://www.ncbi.nlm.nih.gov/pubmed/23290187>

827.Choi J, Digiorgi M, Milone L, et al.: Outcomes of laparoscopic adjustable gastric banding in patients with low body mass index. Surg Obes Relat Dis 2010 6:367-371. <https://www.ncbi.nlm.nih.gov/pubmed/20185374>

Journal References: 828-840

Bariatric Surgery (continued)

828. Gianos M, Abdemur A, Fendrich I, et al.: Outcomes of bariatric surgery in patients with body mass index <35 kg/m². Surg Obes Relat Dis 2012 8:25-30. <https://www.ncbi.nlm.nih.gov/pubmed/22019140>
829. Parikh M, Duncombe J, Fielding GA: Laparoscopic adjustable gastric banding for patients with body mass index of ≤ 35 kg/m². Surg Obes Relat Dis 2006 2:518-522. <https://www.ncbi.nlm.nih.gov/pubmed/17015204>
830. Scopinaro N, Adami GF, Papadia FS, et al.: Effects of biliopancreatic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011 253:699-703. <https://www.ncbi.nlm.nih.gov/pubmed/21475009>
831. Scinta W: Measuring Success: A Comparison of Weight Loss Calculations. Bariatric Times 2012 9:18-20.
832. Albaugh VL, Flynn CR, Tamboli RA, et al.: Recent advances in metabolic and bariatric surgery. F1000Res 2016 5: <https://www.ncbi.nlm.nih.gov/pubmed/27239296>
833. O'Brien P: Surgical Treatment of obesity. Endotext 2000 <https://www.ncbi.nlm.nih.gov/pubmed/25905316>
834. Zepeda Mejia IA, Rogula T: Laparoscopic single-incision gastric bypass: initial experience, technique and short-term outcomes. Ann Surg Innov Res 2015 9:7. <https://www.ncbi.nlm.nih.gov/pubmed/26473005>
835. Palermo M, Acquafresca PA, Rogula T, et al.: Late surgical complications after gastric by-pass: a literature review. Arq Bras Cir Dig 2015 28:139-143. <https://www.ncbi.nlm.nih.gov/pubmed/26176254>
836. Weng TC, Chang CH, Dong YH, et al.: Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. BMJ Open 2015 5:e006964. <https://www.ncbi.nlm.nih.gov/pubmed/26185175>
837. Lim R, Beekley A, Johnson DC, et al.: Early and late complications of bariatric operation. Trauma Surg Acute Care Open 2018 3:e000219. <https://www.ncbi.nlm.nih.gov/pubmed/30402562>
838. Stefater MA, Wilson-Perez HE, Chambers AP, et al.: All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 2012 33:595-622. <https://www.ncbi.nlm.nih.gov/pubmed/22550271>
839. Kodner C, Hartman DR: Complications of adjustable gastric banding surgery for obesity. Am Fam Physician 2014 89:813-818. <https://www.ncbi.nlm.nih.gov/pubmed/24866217>
840. Dixon JB, Straznicky NE, Lambert EA, et al.: Laparoscopic adjustable gastric banding and other devices for the management of obesity. Circulation 2012 126:774-785. <https://www.ncbi.nlm.nih.gov/pubmed/22869859>

Journal References: 841-852

Bariatric Surgery (continued)

841. Anderson B, Gill RS, de Gara CJ, et al.: Biliopancreatic diversion: the effectiveness of duodenal switch and its limitations. *Gastroenterol Res Pract* 2013 2013:974762. <https://www.ncbi.nlm.nih.gov/pubmed/24639868>
842. Billeter AT, Fischer L, Wekerle AL, et al.: Malabsorption as a Therapeutic Approach in Bariatric Surgery. *Viszeralmedizin* 2014 30:198-204. <https://www.ncbi.nlm.nih.gov/pubmed/26288594>
843. Sullivan S, Stein R, Jonnalagadda S, et al.: Aspiration therapy leads to weight loss in obese subjects: a pilot study. *Gastroenterology* 2013 145:1245-1252 e1241-1245. <https://www.ncbi.nlm.nih.gov/pubmed/24012983>
844. Sarr MG, Billington CJ, Brancatisano R, et al.: The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. *Obes Surg* 2012 22:1771-1782. <https://www.ncbi.nlm.nih.gov/pubmed/22956251>
845. Kumar N, Sullivan S, Thompson CC: The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. *Diabetes Metab Syndr Obes* 2017 10:311-316. <https://www.ncbi.nlm.nih.gov/pubmed/28740414>
846. Jain D, Bhandari BS, Arora A, et al.: Endoscopic Sleeve Gastroplasty - A New Tool to Manage Obesity. *Clin Endosc* 2017 <https://www.ncbi.nlm.nih.gov/pubmed/28607328>
847. Hill C, Khashab MA, Kalloo AN, et al.: Endoluminal weight loss and metabolic therapies: current and future techniques. *Ann N Y Acad Sci* 2017 <https://www.ncbi.nlm.nih.gov/pubmed/28884820>
848. Celio AC, Pories WJ: A History of Bariatric Surgery: The Maturation of a Medical Discipline. *Surg Clin North Am* 2016 96:655-667. <https://www.ncbi.nlm.nih.gov/pubmed/27473793>
849. Kim SH, Chun HJ, Choi HS, et al.: Current status of intragastric balloon for obesity treatment. *World J Gastroenterol* 2016 22:5495-5504. <https://www.ncbi.nlm.nih.gov/pubmed/27350727>
850. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al.: Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. *Obes Surg* 2008 18:841-846. <https://www.ncbi.nlm.nih.gov/pubmed/18459025>
851. Frattini F, Rausei S, Boni L, et al.: Gastric plication: how to decrease the size of the stomach without transection. *Surg Technol Int* 2013 23:84-87. <https://www.ncbi.nlm.nih.gov/pubmed/24081847>
852. Herron D, Roohipour R: Complications of Roux-en-Y gastric bypass and sleeve gastrectomy. *Abdom Imaging* 2012 37:712-718. <https://www.ncbi.nlm.nih.gov/pubmed/22388668>

Journal References: 853-864

Bariatric Surgery (continued)

853. Rogalski P, Daniluk J, Baniukiewicz A, et al.: Endoscopic management of gastrointestinal perforations, leaks and fistulas. *World J Gastroenterol* 2015 21:10542-10552. <https://www.ncbi.nlm.nih.gov/pubmed/26457014>
854. Chivot C, Robert B, Lafaye N, et al.: Laparoscopic sleeve gastrectomy: imaging of normal anatomic features and postoperative gastrointestinal complications. *Diagn Interv Imaging* 2013 94:823-834. <https://www.ncbi.nlm.nih.gov/pubmed/23707144>
855. Davidson JP, Connelly TM, Libove E, et al.: Gastropericardial fistula: radiologic findings and literature review. *J Surg Res* 2016 203:174-182. <https://www.ncbi.nlm.nih.gov/pubmed/27338548>
856. Pauli EM, Beshir H, Mathew A: Gastrogastric fistulae following gastric bypass surgery-clinical recognition and treatment. *Curr Gastroenterol Rep* 2014 16:405. <https://www.ncbi.nlm.nih.gov/pubmed/25113040>
857. Spivak H, Favretti F: Avoiding postoperative complications with the LAP-BAND system. *Am J Surg* 2002 184:31S-37S. <https://www.ncbi.nlm.nih.gov/pubmed/12527348>
858. Rausa E, Bonavina L, Asti E, et al.: Rate of Death and Complications in Laparoscopic and Open Roux-en-Y Gastric Bypass. A Meta-analysis and Meta-regression Analysis on 69,494 Patients. *Obes Surg* 2016 26:1956-1963. <https://www.ncbi.nlm.nih.gov/pubmed/27189352>
859. Karcz WK, Blazejczyk K, Wellner UF, et al.: [Internal hernias after bariatric surgery]. *Chirurg* 2015 86:855-860. <https://www.ncbi.nlm.nih.gov/pubmed/26319178>
860. Azagury D, Liu RC, Morgan A, et al.: Small bowel obstruction: A practical step-by-step evidence-based approach to evaluation, decision making, and management. *J Trauma Acute Care Surg* 2015 79:661-668. <https://www.ncbi.nlm.nih.gov/pubmed/26402543>
861. Levine MS, Carucci LR: Imaging of bariatric surgery: normal anatomy and postoperative complications. *Radiology* 2014 270:327-341. <https://www.ncbi.nlm.nih.gov/pubmed/24471382>
862. Lewis KD, Takenaka KY, Luber SD: Acute Abdominal Pain in the Bariatric Surgery Patient. *Emerg Med Clin North Am* 2016 34:387-407. <https://www.ncbi.nlm.nih.gov/pubmed/27133251>
863. Merkle EM, Hallowell PT, Crouse C, et al.: Roux-en-Y gastric bypass for clinically severe obesity: normal appearance and spectrum of complications at imaging. *Radiology* 2005 234:674-683. <https://www.ncbi.nlm.nih.gov/pubmed/15650038>
864. Mancini MC: Bariatric surgery--an update for the endocrinologist. *Arq Bras Endocrinol Metabol* 2014 58:875-888. <https://www.ncbi.nlm.nih.gov/pubmed/25627042>

Journal References: 865-872

Bariatric Surgery (continued)

865. Ritz P, Hanaire H: Post-bypass hypoglycaemia: a review of current findings. *Diabetes Metab* 2011 37:274-281.

<https://www.ncbi.nlm.nih.gov/pubmed/21676638>

866. Monkhouse SJ, Morgan JD, Norton SA: Complications of bariatric surgery: presentation and emergency management--a review. *Ann R Coll Surg Engl* 2009 91:280-286. <https://www.ncbi.nlm.nih.gov/pubmed/19344551>

Additional references used: [56][309]

Bariatric Surgery Nutrient Considerations

867. Mechanick JI, Kushner RF, Sugerman HJ, et al.: American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. *Surg Obes Relat Dis* 2008 4:S109-184.

<https://www.ncbi.nlm.nih.gov/pubmed/18848315>

868. Lei Y, Zheng MH, Huang W, et al.: Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: A case report and literature review. *Medicine (Baltimore)* 2018 97:e0010. <https://www.ncbi.nlm.nih.gov/pubmed/29489643>

869. Gregorio VD, Lucchese R, Vera I, et al.: The Alcohol Consumption Is Amended after Bariatric Surgery? An Integrative Review. *Arq Bras Cir Dig* 2018 31:e1378. <https://www.ncbi.nlm.nih.gov/pubmed/29972406>

870. Jans G, Matthys C, Bogaerts A, et al.: Maternal micronutrient deficiencies and related adverse neonatal outcomes after bariatric surgery: a systematic review. *Adv Nutr* 2015 6:420-429. <https://www.ncbi.nlm.nih.gov/pubmed/26178026>

871. Balaji M, Ganjaji MS, Hanuma Kumar GE, et al.: A review on possible therapeutic targets to contain obesity: The role of phytochemicals. *Obes Res Clin Pract* 2016 10:363-380. <https://www.ncbi.nlm.nih.gov/pubmed/26740473>

872. Cilla A, Alegria A, Attanzio A, et al.: Dietary phytochemicals in the protection against oxysterol-induced damage. *Chem Phys Lipids* 2017 207:192-205. <https://www.ncbi.nlm.nih.gov/pubmed/28267434>

Journal References: 873-880

Bariatric Surgery Nutrient Considerations

- 873.Liu RH: Health-promoting components of fruits and vegetables in the diet. *Adv Nutr* 2013 4:384S-392S.
<https://www.ncbi.nlm.nih.gov/pubmed/23674808>
- 874.Berger MM, Pantet O, Schneider A, et al.: Micronutrient Deficiencies in Medical and Surgical Inpatients. *J Clin Med* 2019 8:
<https://www.ncbi.nlm.nih.gov/pubmed/31261695>
- 875.Mechanick JI, Apovian C, Brethauer S, et al.: Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. *Endocr Pract* 2019
<https://www.ncbi.nlm.nih.gov/pubmed/31682518>
- 876.Parrott J, Frank L, Rabena R, et al.: American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. *Surg Obes Relat Dis* 2017 13:727-741.
<https://www.ncbi.nlm.nih.gov/pubmed/28392254>
- 877.Sinha S, Kataria A, Kolla BP, et al.: Wernicke Encephalopathy-Clinical Pearls. *Mayo Clin Proc* 2019 94:1065-1072.
<https://www.ncbi.nlm.nih.gov/pubmed/31171116>
- 878.Nishimoto A, Uesry J, Winton JC, et al.: High-dose Parenteral Thiamine in Treatment of Wernicke's Encephalopathy: Case Series and Review of the Literature. *In Vivo* 2017 31:121-124. <https://www.ncbi.nlm.nih.gov/pubmed/28064230>
- 879.Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R, et al.: Comparison of sublingual vs. intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency. *Drug Deliv Transl Res* 2019 9:625-630.
<https://www.ncbi.nlm.nih.gov/pubmed/30632091>
- 880.Tripkovic L, Wilson LR, Hart K, et al.: Daily supplementation with 15 mug vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial. *Am J Clin Nutr* 2017 106:481-490. <https://www.ncbi.nlm.nih.gov/pubmed/28679555>

Journal References: 881-886

Bariatric Surgery Nutrient Consideration

881. Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004 89:5387-5391. <https://www.ncbi.nlm.nih.gov/pubmed/15531486>
882. Mingrone G, Bornstein S, Le Roux CW: Optimisation of follow-up after metabolic surgery. Lancet Diabetes Endocrinol 2018 6:487-499.
883. Manoguerra AS, Erdman AR, Booze LL, et al.: Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005 43:553-570. <https://www.ncbi.nlm.nih.gov/pubmed/16255338>
884. JI M: Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update. In Press 2019

Additional references used: [182][662]

Microbiome

885. Muscogiuri G, Cantone E, Cassarano S, et al.: Gut microbiota: a new path to treat obesity. Int J Obes Suppl 2019 9:10-19. <https://www.ncbi.nlm.nih.gov/pubmed/31391921>

Additional references used: [92][737]

Executive Summary

886. Sharma AM, Kushner RF: A proposed clinical staging system for obesity. Int J Obes (Lond) 2009 33:289-295. <https://www.ncbi.nlm.nih.gov/pubmed/19188927>

Disclosures

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Disclosures

Harold E. Bays, MD, FOMA, FTOS, FACC, FACE, FNLA, FOMA: Neither Dr. Harold Bays or his affiliated research center / weight management center own pharmaceutical stocks or patents. In the past 12 months, Dr. Harold Bays' research site has received research grants from Alon Medtech/Epitomee, Amgen, Eisai, Arena, Lilly, Janssen, Johnson and Johnson, Novartis, and Novo Nordisk, Inc. In the past 12 months, Dr. Harold Bays has served as a consultant/advisor for Amgen.

William McCarthy, MD, FOMA: Nothing to disclose

Sandra Christensen, MSN, ARNP, FOMA: Novo Nordisk, Inc: Speaker's Bureau

Justin Tondt, MD: Nothing to disclose

Sara Karjoo, MD: Nothing to disclose

Laura Davisson, MD, MPH: Nothing to disclose

Jennifer Ng, MD: Nothing to disclose

Angela Golden, DNP, FNP-C, FAANP: Novo Nordisk, Inc: Speaker's Bureau, Advisory Activities

Karlijn Burridge, PA-C, MMS, FOMA: Novo Nordisk, Inc: Advisory Activities

Rushika Conroy, MD, MS: Nothing to disclose

Sarah Wells, MD: Nothing to disclose

Devika Umashanker, MD, MS, MBA: Nothing to disclose

Samina Afreen, MD: Nothing to disclose

Ramona DeJesus, MD: Nothing to disclose

Debra Salter, MD: Nothing to disclose

Nihar Shah, MD, FACP: Nothing to disclose

Larry A. Richardson, MD, MFOMA: Nothing to disclose

Historic Acknowledgement

obesitymedicine.org

Obesity Algorithm®. © 2020 Obesity Medicine Association



Historic Citation and Authorship

2019

eBook Citation: Bays HE, McCarthy W, Christensen S, Wells S, Long J, Shah NN, Primack C. Obesity Algorithm eBook, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2019. <https://obesitymedicine.org/obesity-algorithm/> (Accessed = Insert date)

Free Slide Citation: Bays HE, McCarthy W, Christensen S, Seger J, Wells S, Long J, Shah NN, Primack C. Obesity Algorithm Slides, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2019. <https://obesitymedicine.org/obesity-algorithm-powerpoint/> (Accessed = Insert date)

Historic Citation and Authorship

2017-2018

Bays HE, Seger, J, Primack C, Long J, Shah NN, Clark TW, McCarthy W. Obesity Algorithm, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2017-2018

2016-2017

Bays HE, Seger JC, Primack C, McCarthy W, Long J, Schmidt SL, Daniel S, Horn DB, Westman EC: Obesity Algorithm, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2016-2017

2015-2016

Seger JC, Horn DB, Westman EC, Primack C, Long J, Clark T, McCarthy W, Bays HE. Obesity Algorithm, presented by the Obesity Medicine Association, 2015-2016.

2014-2015

Seger JC, Horn DB, Westman EC, Primack C, Schmidt SL, Ravasia D, McCarthy W, Ferguson U, Sabowitz BN, Scinta W, Bays HE. Obesity Algorithm, presented by the American Society of Bariatric Physicians, 2014-2015.

2013-2014

Seger JC, Horn DB, Westman EC, Lindquist R, Scinta W, Richardson LA, Primack C, Bryman DA, McCarthy W, Hendricks E, Sabowitz BN, Schmidt SL, Bays HE. Obesity Algorithm, presented by the American Society of Bariatric Physicians, 2013-2014.